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ABSTRACT 
Optimisation of minimally invasive therapy 
 for primary varicose veins 
 
B.J. McAree 
Submitted for degree of M.D. April 2015 
 
Introduction: Primary varicose veins are common with a multitude of non-
optimal treatments. Foam sclerotherapy has seen renewed interest but lacks 
efficacy versus more expensive modalities.  The hypothesis of this thesis is that 
increasing the half-life of foams will improve efficacy as will mechanical 
adjuncts.  
 
Methods: The most efficacious proprietary sclerosants are examined in terms 
of their foam half-life and histopathological effects in-vitro. The best proprietary 
foam has its half-life increased and histopathological effects of the three most 
promising resultant foams similarly assessed. Arterial cutting balloons are 
assessed as an adjunct for foam sclerotherapy in the same in-vitro human GSV 
model. The best foams are tested against each other and with cutting balloon 
adjuncts in an animal vein model with results established after three months.   
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Results: half-life of 3% polidocanol foam is longer than 3% STD. 3% STD 
damages the vein wall more than polidocanol. Longer lasting STD foams do not 
enhance its activity against vein wall in-vitro. Cutting balloons increase depth of 
penetration of foam into vein wall by affording it a deeper starting point in-vitro. 
Cutting balloons damage the structure of the vein wall leaving them varicose in-
vivo. This is likely due to available cutting balloons being too large for tested pig 
veins. Longer lasting 0.15% xanthum and 3% STD foam outperformed 
proprietary 3% STD in causing vein occlusion in a pig model. 
 
Conclusions: The active ingredient in sclerosant foams determine its efficacy 
in-vitro more so than the longevity of the foam however longer lasting 3% STD 
foam shows improved efficacy in-vivo in pigs as opposed to in an in-vitro human 
GSV model. Cutting balloons though promising in-vitro as adjuncts to foam 
sclerotherapy are likely best used as a guide to a more optimal mechanical 
adjunct.   
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1 INTRODUCTION 
Varicose veins are elongated, dilated and tortuous superficial veins.1 2 Although 
varicose veins are common, not all patients are symptomatic and only a 
minority present for treatment.3 Despite this the management of varicose veins 
represents a significant burden on the National Health Service (NHS) in the UK. 
Over 110,000 varicose vein procedures were performed in the NHS in England 
in 1999-2000 with around 40,000 performed in 2009-2010. Notwithstanding this 
evident reduction in the number of procedures, treatment of varicose veins 
remains a significant burden on healthcare resources. The cost of treating 
varicose veins and associated complications has been estimated at 1–3% of the 
total annual health care budget in European countries.4 The treatment of 
complications of varicose veins has been estimated to cost about 2 per cent of 
the total NHS spending in the United Kingdom (UK).5   
Primary varicose veins are those that occur due to superficial venous reflux 
alone. Primary varicose veins far outnumber secondary varicose veins, caused 
by deep venous incompetence. The aetiology and pathogenesis of primary 
varicose veins remains unclear.1 6 The majority (60-70%) of patients with 
varicose veins have an incompetent sapheno-femoral junction (SFJ) and great 
saphenous vein (GSV) reflux.7-10 It is known however that successful treatment 
depends on the abolition of reflux. The majority of patients in the UK are treated 
with surgery.11 However, Hospital Episodes Statistics (HES) data from the NHS 
Information Centre for Health and Social Care display a reduction in varicose 
vein surgery in England from 1999-2000 when 48,587 surgical procedures were 
performed to 36,811 procedures in 2008-2009, a decrease of 24.2%. The 
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department of health state that this may be due to a greater proportion of 
varicose vein treatments performed in an outpatient setting, therefore being 
non-surgical.11 Indeed the past decade has seen an explosion in the 
employment of new minimally invasive techniques to treat varicose veins which 
can be performed in the outpatient setting. Minimally invasive techniques 
include radiofrequency ablation (RFA), endovenous laser ablation (EVLA) and 
ultrasound guided foam sclerotherapy (UGFS). HES data show an increase in 
the employment of sclerotherapy from 2,231 procedures in 1999-2000 to 6,823 
in 2009-2010. Transluminal operations (RFA and EVLA) have only been 
recorded separately in HES data since 2006-2007 and since this time the 
number of transluminal procedures has continually increased from 2,271 
procedures to 10,612 in 2009-2010.11 
In order to improve varicose vein therapy, better treatments should have 
improved efficacy and be more cost effective.  
This thesis examines the potential for improving UGFS to meet these goals. In 
its current form despite disappointing recurrence rates of up to 20% at 3 years, 
this increasingly utilised treatment option compares favourably with other 
minimally invasive treatments especially in terms of procedure costs.12 13 14 Little 
is known about its effect on human vein tissue.15 16 This thesis examines the 
effects of the most commonly used foam sclerotherapy agents, modifications to 
these and potential adjuvant treatments in a human in-vitro vein model, with the 
aim of improving its efficacy.  
The introduction presents an overview of the epidemiology, predisposing 
factors, aetiology, and pathogenesis of varicose veins. The relevant anatomy, 
symptoms and risks of varicose veins are discussed.  A synopsis of the 
evidence base for the current treatment of varicose veins is reviewed, including 
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mode of action of treatments, their efficacy and where possible, their cost. The 
aims of this thesis are subsequently outlined.  
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1.1 EPIDEMIOLOGY OF VARICOSE VEINS 
Varicose veins are often described as a “Western” disease as they seem to 
occur more frequently in industrialised than developing countries.17-19  A number 
of large studies of adult populations of developed countries have shown that 30-
50% have truncal varicose veins.19  Epidemiological studies from disparate 
regions of the world report huge variation in the prevalence of varicose veins 
with variable prevalence with ethnicity within the same regions. Mekky et 
alobserved a more than five-fold greater prevalence of varicose veins in English 
compared to Egyptian women.20 In a community study in Jerusalem the 
prevalence of varicose veins was lower in subjects of North African descent 
compared with those of European, American or Asian descent. 21   
1.2 PREDISPOSING FACTORS TO VARICOSE VEINS 
Several pre-disposing factors are thought to contribute to varicose veins. Age 
and family history are risk factors. Sex and pregnancy are often cited as the 
pre-disposing factors however there is variability between reports of different 
studies.  
1.2.1 AGE 
Prevalence of varicose veins increases with age.3 17 22-25 The Edinburgh Vein 
Study reported a prevalence of 11.5% in those aged 18-24 years and 55.7% in 
those aged 55-64 years (p=0.001).25 The Framingham Study reported a 
prevalence of 1% in men and 10% in women under 30 years and 57% and 77% 
in men and women respectively over the age of  70 years.24  
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1.2.2 FAMILY HISTORY 
In a study of Japanese women, 42% of subjects with varicose veins reported a 
positive family history, compared with 14% in those without varicose veins.26 A 
case-control study in the US reported that patients with varicose veins were 
21.5 times more likely to report a positive family history.27 Carpentier et 
alreported that family history of varicose veins in a first degree relative is the 
most important pre-disposing factor in both sexes.18 Though representing a 
reasonable guide, the methodology of these studies can be questioned on the 
basis of self-reporting and that those with varicose veins are more attuned to 
related family history.   
1.2.3 OTHER POTENTIAL RISK FACTORS 
1.2.3.1 SEX 
The vast majority of studies suggest that varicose veins are more common in 
women.28 29 30 They are often quoted as affecting 10-15% of adult men and 25-
33% of adult women in western countries.31 On the basis of estimates of the 
San Diego epidemiological study, more than 11 million men and 22 million 
women in the United States had varicose veins in 2003.32 However, these 
figures are largely based on studies involving self-reporting where women tend 
to be over-represented as women are more likely to present with varicose veins 
and to request treatment.17 33 The Edinburgh Vein Study which included 1,566 
randomly selected subjects, found a reversal of this gender difference with 32% 
of women and 40% of men having truncal varicosities.25  Clinical series always 
contain an excess of women (usually about 3:1) but age for age, varicose veins 
probably affect men and women equally.34  
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1.2.3.2 PREGNANCY 
Pregnancy is associated with a number of anatomical and physiological 
changes which likely contribute to the development of varicose veins. 19 35-40   
The risk of developing varicose veins increases with parity with Laurikka et 
alreporting a prevalence of 32, 38, 43, 48 and 59 percent in women with no, 
one, two, three and four pregnancies respectively.29  
1.2.3.3 ELEVATED BODY-MASS-INDEX (BMI) 
Most studies have shown that overweight and obese women are more likely to 
develop varicose veins.20 22 24 27 40-45 However, there is no consistent indication 
that this relationship holds true for men.40 46-48 These studies largely derive their 
data from self reporting. The gender difference reported, coupled with the fact 
that average body weight is higher in parous compared with nulliparous women 
cannot exclude the possibility that the observed associations between varicose 
veins development and obesity may be explained by a confounding effect of 
parity. 49 Elevated BMI appears to be an aggravating factor rather than a 
primary cause of varicose veins.17 
1.2.3.4 OCCUPATION 
The ergonomics and physical activity of an occupation may represent a 
contributing factor in the epidemiology of varicose veins. Most studies 20 21 29 50-
53, but not all 54, indicate that working in a position resulting in protracted 
orthostasis may increase the prevalence and severity of disease.  
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1.2.3.5 OTHER POTENTIAL RISK FACTORS 
Studies have examined associations between smoking, female hormone 
therapies, hypertension, diabetes mellitus, lack of dietary fibre, constipation, 
traumatic injury to the extremities, and coagulopathies.17 24 27 28 30 38-40 48 50 55-58 
No direct link has been proven.  
1.3 AETIOLOGY AND PATHOGENESIS OF PRIMARY 
VARICOSE VEINS 
The aetiology and pathogenesis of varicose veins remains unclear.1 6 34 59 A 
normal venous system depends on the integrity of valves, vein wall and the 
haemodynamics of venous blood flow. These components are interdependent 
and disruption of one affects the integrity of the others. Blood flow in varicose 
veins is disrupted, resulting in blood stasis and reflux. The cause and sequence 
of events leading to such inefficient blood flow remain unclear, although the 
main hypotheses are: primary valvular incompetence and primary changes in 
the varicose vein wall causing weakness with venous dilatation. These 
categories are considered by many as primary and secondary valve failure with 
the latter being caused by a developmental weakness of the vein wall resulting 
in secondary widening of valve commissures and resultant valvular 
incompetence. There is increasing evidence that alteration of the vein wall is the 
primary abnormality in varicose veins.58 60 
1.3.1 PRIMARY VALVULAR DYSFUNCTION / PRIMARY VALVE 
FAILURE 
Absence and deformities, including tearing, thinning, thickening and scarring of 
the saphenous vein valves are found more frequently in varicose than non-
varicose veins retrieved from surgery and during angioscopy.61-63 Varicose 
veins also demonstrate hypotrophy of the valves and widening of the valvular 
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annulus compared with non-varicose veins.61 64-66  The valves of varicose veins 
contain less collagen and lose the normal viscoelastic features typical of non-
varices.64 This long-standing hypothesis that a primary valve “lesion” is the 
initial pathological change occurring in varicose veins has been challenged 
more recently by several common ultrasonographic and histological findings in 
varicose veins. Varicosities are often observed below competent valves and not 
uncommonly found to precede valvular incompetence. Venous dilatation is also 
frequently seen distal to a valve rather than proximal, which one would expect if 
valvular dysfunction is the initial event.58 67  
 
1.3.2 PRIMARY CHANGES IN VEIN WALL / SECONDARY VALVE 
FAILURE   
The gravitational load on the vein wall and lack of an active mechanism of blood 
flow return means that elastic vein tissue is subjected to intense biomechanical 
stress, increasing its susceptibility to functional failure. Recent studies of 
varicose vein pathogenesis have focused on the structural and biochemical 
changes in the vein wall.58 60 68 The underlying hypothesis is that the formation 
of varicose veins is secondary to defects in cellular and extracellular matrix 
(ECM) components, causing weakness and altered venous tone.58 60 69 The 
triggers for these changes remain unclear, although several factors are likely to 
be involved, including hypoxia, mechanical stretch and low shear stress.38 70 
Numerous changes in cellular and extracellular matrix components of the vein 
wall have been identified, including intimal hyperplasia, smooth muscle cell 
dysfunction, changes to the collagen and elastin content and imbalances of 
matrix metalloproteinases and their tissue inhibitors. 58 60 71 These changes 
occur randomly rather than continuously or following a particular pattern. They 
are thought to cause an overall weakening and relaxation of vein wall leading to 
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venous dilatation, valve incompetence and reflux. Areas of irregular intimal 
hyperplasia with associated collagen deposits, smooth muscle cell (SMC) 
infiltration and plaques underneath the endothelial lining are common in 
varicose veins.  Changes in the media including SMC proliferation and ECM 
degradation are seen more often in varicose than in non-varicose veins. 
Stereological studies by Travers et alcompared the estimated collagen, elastin 
and smooth muscle content of varicose and control great saphenous veins. 
Varicose vein cross-sections had significantly larger wall areas (p < 0.01) and 
higher amounts of collagen and smooth muscle compared to controls (p < 0.01). 
There was a higher content of smooth muscle and elastin in varicose veins 
proximally compared to distally (p < 0.05). There was no significant difference in 
mean wall thickness or in elastin content between the 2 groups. These findings 
suggest that varicose veins are a dynamic response to venous hypertension 
and that in general they are not thin walled structures as previously thought.72 
Similarly the adventitia of varicose veins demonstrates areas of increased SMC, 
fibroblasts and connective tissue with regions of atrophy and devoid of vasa 
vasorum.38 70 Vein wall hypoxia has been suggested as a contributing factor for 
varicose vein formation  58 60 73 Inadequate oxygen supply from luminal blood or 
vasa vasorum or both could potentially cause vein wall hypoxia. 74 75 Knaapen 
et alexamined whether the changes that occur in varicose veins are associated 
with smooth muscle cell (SMC) hypertrophy, cellular proliferation or apoptosis. 
They concluded that cell death or proliferation of SMC do not, or only rarely, 
occur in varicose veins. However, remodelling of varicose veins can mainly be 
attributed to increased volumes of the SMC of the circular layer and this 
increase correlates with oestrogen receptor (ER) expression.76  
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The findings from duplex ultrasonography on the pattern and progression of 
venous dilatation and reflux strongly support vein wall changes as the primary 
event, although isolated primary valvular dysfunction may sometimes 
contribute.  
1.4 VENOUS ANATOMY OF THE LOWER LIMB 
The venous drainage of the lower limb is divided into the superficial and deep 
systems, the drainage areas of which are separated by the deep fascia. Thus 
the superficial veins, the great and small saphenous veins and tributaries of the 
perforating veins drain the skin and subcutaneous fat (the so-called superficial 
fascia) and the deep veins are responsible for venous return from muscle and 
other structures deep to the deep fascia. The volume of blood passing through 
the deep system far exceeds that through the superficial system, the function of 
the latter being mainly temperature regulation. The superficial veins 
communicate with the deep veins at the saphenopopliteal (SPJ) and 
saphenofemoral (SFJ) junctions and by way of the perforating veins through 
openings in the deep fascia.  
1.4.1 THE SUPERFICIAL VEINS 
The great saphenous (GSV) vein arises from the medial end of the dorsal arch 
of the foot, then passes in front of the medial malleolus and along the medial 
surface of the leg, enclosed in its own fascial sheath, the great saphenous 
canal. The GSV lies posteriorly at knee level, passing more anteriorly as it 
ascends the thigh and through the foramen ovale and the femoral triangle to 
join the common femoral vein, forming the SFJ. A variable number of tributaries 
join the GSV in this region, namely the anterior accessory GSV, posterior 
- 36 - 
accessory GSV, superficial circumflex iliac, superficial epigastric and external 
pudendal veins.  
The small saphenous vein arises at the lateral end of the dorsal venous arch of 
the foot and passes behind the lateral malleolus entering the small saphenous 
canal (fascial sheath) to join the popliteal vein in the popliteal fossa forming the 
SPJ. This termination is variable and non-existent in up to a quarter of legs.77 
The Giacomini vein, is a proximal extension of the small saphenous vein into 
the thigh. It is present in 50-80% of the population and in >50% of those where 
it exists it terminates at the GSV in the thigh.78-80   
Great or small saphenous vein duplication can occur, with a rate of 20 -50% 
being found in early studies.81 82 83  Of late, these bifid trunks have been further 
delineated into “true” (within the saphenous canal) and “false” (within the 
superficial fascia) duplications and consequently a substantial lower rate of true 
GSV duplication has been found at 1% and 9%.84 85 10 Labropoulos et alfound a 
true duplication rate of both GSV and SSV of around 2% for patients with and 
without varicose veins.10 Any superficial veins outside the saphenous canals are 
termed accessory or a tributary veins.86 The majority of varicose veins are 
located in the saphenous vein tributaries or accessory veins. Zamboni et 
aldetected a saphenous tributary as the primary varicosity in 98% of limbs.87 
Labropoulos et alin a prospective study of 739 patients with CVD and CEAP 
classification 2 to 6, found 94% (402/427) of those with CEAP class 2-3 and 
84% (202/254) CEAP class 4-6 had varicosities arising from the accessory 
veins and tributaries.10 Varicosities of the saphenous trunks are infrequent 
however there is a wide range of data on the actual occurrence. Caggiati et 
alreports a prevalence of saphenous trunk varicosities of 62% in a group with a 
mean age of 60 years and 39% in a group with a mean age of 30 years.88 
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However, the majority of other studies of primary varicosities have revealed a 
complete absence of varicosities within the saphenous trunks or at most 
segmental dilatations.67 89 90 In their more contemporary study with bigger 
patient numbers Labropoulos et alfound a prevalence of varicosities in either or 
both the GSV and SSV of <7%.10     
1.4.2 THE PERFORATING VEINS  
The perforating veins are those other than the great and small saphenous which 
penetrate the deep fascia, passing from superficial to deep. Between 50 and 
100 in-direct perforating veins enter the muscles before joining the deep veins.91 
1.4.3 THE DEEP VEINS 
The deep veins of the lower leg are the paired venae comitantes of the anterior 
and posterior tibial and peroneal arteries, the gastrocnemius veins and the 
soleus venous arcades. These all join to form the popliteal vein, which receives 
the small saphenous vein. The popliteal vein becomes the femoral vein in the 
lower thigh. This large vein only contains two or three valves and has few 
tributaries apart from the Hunterian perforator, some muscle veins and the 
profunda femoris vein, which joins it to form the common femoral vein. The 
common femoral vein receives the termination of the GSV and often a deep 
pudendal branch.91 
1.4.4 VALVES 
Valves are present in both venous systems to ensure that blood flows in a 
single direction, from the superficial to the deep system, toward the heart and 
against gravity.1 Valves are present at the junctions between the superficial and 
deep venous systems and within the perforator veins to prevent backflow from 
the deep to superficial systems.91  
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1.4.5 VEIN WALL STRUCTURE 
The normal vein wall is composed of intimal, medial and adventitial layers. The 
content of each layer differs to other blood vessels reflecting the specific 
functions of veins as low pressure capacitance vessels. The intima is formed by 
a layer of endothelial cells which rest on a basal lamina. Beneath this is the thin 
subendothelial layer, which may not always be present, containing connective 
tissue and infrequent smooth muscle cells. Deep to this is the media comprising 
a network of type III collagen, elastin fibres and bundles of smooth muscle cells. 
The final and outermost layer of adventitia consists of longitudinally arranged 
type I collagen fibres. The intermittently placed valves within veins are 
composed of two semi-lunar endothelial lined folds of connective tissue.92   
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Figure 1.1: Anatomy of the Great Saphenous Vein, its accessory veins and 
tributaries, displaying the medial superficial and perforating veins of the 
lower limb. (Mayo Foundation for Medical Education and Research) 
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Figure 1.2: Anatomy of the Small Saphenous Vein, its accessory veins and 
tributaries, displaying the posterior superficial and perforating veins of 
the leg. (Mayo Foundation for Medical Education and Research) 
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1.5 SYMPTOMS OF VARICOSE VEINS 
Varicose veins may cause symptoms of heaviness, swelling, aching, restless 
legs, cramps and itching in the legs.3 93 However correlation between varicose 
veins and symptoms is controversial. The Edinburgh Vein Study reported 
pruritus (itch) as the only symptom significantly associated with the severity of 
truncal varices in men. In women, heaviness/tension, aching and itch all 
correlated with varicose vein occurrence. Not all patients with the condition are 
symptomatic and only a minority present for treatment. The Edinburgh Vein 
Study demonstrated that in the general population there is poor correlation 
between the presence of varicose veins detected on clinical examination and 
lower limb symptoms.3 The presence of reflux on duplex scanning has a weak 
association with symptoms. Asymptomatic superficial venous reflux on duplex 
ultrasound is present in 7-39% of the population.3 8 94 95 Even in the presence of 
trunk varices (varicose veins originating from an incompetent saphenous 
system), lower limb symptoms are likely to have a non-venous cause.3 93 
Symptomatic venous insufficiency (requiring treatment) affects 1-15% of adult 
men and 20-25% of adult women.
31  
1.6 RISKS OF VARICOSE VEINS 
Complications of varicose veins include bleeding, superficial vein thrombosis 
(SVT) and ulceration.96 97-99 100 Varicose vein bleeding and superficial vein 
thrombosis can have life threatening consequences however they are both 
thankfully very rare.97 101 The POST (epidemiological) study and the CALISTO 
(randomised) study state that varicose veins are the main risk factor for SVT 
being involved in 86.5% and 88.6% of cases respectively.102 103 van Langevelde 
- 42 - 
et alfound a 3.9-fold increased risk of pulmonary embolism in clinically 
diagnosed superficial vein thrombosis.101 However, ulceration is by far the most 
common serious complication of varicose veins and that which causes the 
greatest morbidity and has the greatest cost implications to healthcare 
agencies5 97 101 104   Varicose veins are manifestations of chronic venous 
disease (CVD).105 106 CVD includes various medical conditions of long duration, 
all involving morphological and functional abnormalities of the venous system. 
Varicose veins can progress to a more advanced form of chronic venous 
dysfunction such as chronic venous insufficiency (CVI).107 108  In CVI, increased 
ambulatory venous hypertension initiates a series of changes in the 
subcutaneous tissue and the skin with activation of endothelial cells, 
extravasation of macromolecules and red blood cells, diapedesis of leukocytes, 
tissue oedema and chronic inflammatory changes most frequently noted at and 
above the ankles.109 Limb swelling, varicose eczema, haemosiderin deposition, 
lipodermatosclerosis and venous ulceration can develop. Progression of 
primary varicose veins to severe CVI and venous ulceration is not rare as 
indicated by the North American subfascial endoscopic perforator surgery 
(SEPS) registry where more patients with advanced CVI had primary venous 
disease than post-thrombotic syndrome (PTS) (70% vs. 30%)100 Varicose veins 
and associated complications such as ulcers may lead to chronic pain, 
disability, decreased quality of life (QOL), loss of working-days and early 
retirement.104  
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1.7 CLASSIFICATION OF CHRONIC VENOUS DISEASE 
Chronic venous disease (CVD) is classified according to the CEAP 
classification. This scoring system initially created by the American venous 
forum in 1994 and modified in 2004, is used worldwide to descriptively classify 
CVD.110 The fundamentals of the CEAP classification include a description of 
clinical (C) class based upon objective signs, the etiological (E), the anatomical 
(A) distribution of reflux and obstruction in the superficial, deep and perforating 
veins, and the underlying pathophysiology (P), whether due to reflux or 
obstruction. Seven clinical categories are recognised as shown in table 1.1 with 
the remaining breakdown of etiology, anatomical and pathophysiology shown in 
subsequent tables 1.2 to 1.6. Advanced CEAP pathophysiological classification is the 
same as basic with the addition that any of 18 named venous segments can be utilised 
as locators for venous pathology. 
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 CEAP Classification of CVD : 
Clinical 
C0 No visible or palpable signs of 
venous disease 
C1 Telangiectasies or reticular vein; 
veins less than 3 mm 
C2 Varicose veins; veins greater than 3 
mm 
C3 Oedema 
C4a Pigmentation or eczema 
C4b Lipodermatosclerosis or atrophie 
blanche 
C5 Healed venous ulcer 
C6 Active venous ulcer 
S Symptoms including ache, pain, 
tightness, skin irritation, heaviness, 
muscle cramps, as well as other 
complaints attributable to venous 
dysfunction.  
A Asymptomatic 
Table 1.1: CEAP Classification of CVD: Clinical 
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 CEAP Classification of CVD: 
Etiology 
Ec Congenital 
Ep Primary 
Es Secondary 
En No venous cause identified 
Table 1.2: CEAP Classification of CVD: Etiology 
 
 CEAP Classification of CVD: 
Anatomical 
As Superficial veins 
Ap Perforator veins 
Ad Deep veins 
An No location identified 
Table 1.3: CEAP Classification of CVD: Anatomical 
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Basic CEAP CEAP Classification of CVD: 
Pathophysiology 
Pr Reflux 
Po Obstruction 
Pro Reflux and obstruction 
Pn No pathophysiology identified 
Table 1.4: Basic CEAP Classification of CVD: Pathophysiology 
Advanced CEAP CEAP Classification of CVD: 
Pathophysiology 
Superficial veins 1. Telangiectasies/reticular veins  
 2. GSV above knee 
 3. GSV below knee 
 4. GSV 
 5. Non-saphenous veins  
Deep veins 6. IVC  
 7. Common iliac vein.  
 8. Internal iliac vein  
 9. External iliac vein  
 10. Pelvic: gonadal, broad ligament 
veins, other  
 11. Common femoral vein  
 12. Deep femoral vein  
 13. Femoral vein  
 14. Popliteal vein  
 15. Crural: anterior tibial, posterior 
tibial, peroneal veins (all paired)  
 16. Muscular: gastrocnemial, soleal 
veins, other  
 17. Thigh  
 18. Calf 
Table 1.5: Advanced CEAP Classification of CVD: Pathophysiology 
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 CEAP Classification of CVD: Level 
of investigation 
L1 Clinical or doppler 
L2 Non-invasive (duplex 
plethysmography) 
L3 Invasive or complex (venography, 
CT, or MRI) 
Table 1.6: CEAP Classification of CVD: Level of investigation 
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1.8 TREATMENT OPTIONS 
Optimum treatment of varicose veins should aim to abolish venous reflux and 
relieve symptoms.111  
1.8.1 NON - INVASIVE TREATMENT 
1.8.1.1 COMPRESSION HOSIERY 
Graded compression hosiery or graduated elastic compression stockings 
(GECS) apply controlled pressure to the leg. This supports the superficial 
venous system by exerting an external pressure that is greatest at the ankle 
(minimum of 14 mmHg) and decreases up the leg.112 The hypothesis is that by 
reducing venous capacity and increasing venous velocity in the deeper veins, 
venous stasis and reflux are reduced helping to reduce the severity of varicose 
veins and the associated symptoms.113 GECS are often used as a first-line 
treatment for varicose veins in primary care. However despite there being a lot 
of trial data regarding the use of compression hosiery much of this is 
inconclusive except to say that where symptoms were assessed, many studies 
appeared to show a subjective improvement in participants wearing 
stockings.114 115 The lack of published methodology in all of these studies makes 
these conclusions subject to bias.114 There is no good evidence that GECS are 
beneficial in terms of slowing progression or preventing recurrence of varicose 
veins.115 Benefits for symptoms appear restricted to the period during which the 
stocking is worn.116 Palfreyman et al’s systematic review concluded that 
wearing compression improved symptom management, but even this could be 
confounded by the exclusion of a high number of non-compliant patients within 
the trials.  Compliance with compression is variable and difficult to assess. It 
has been reported that only 37-47% of patients continue to wear stockings one 
- 49 - 
year after DVT or for the long-term prevention of venous ulceration.117 118 A 
retrospective patient reported study of compliance with compressions hosiery 
by Raju et alfound that of new patients attending a CVD tertiary referral centre, 
compliance was relatively better at 50% in those giving a prior history of DVT 
(n=675) compared to 35% in those without such a prior history (n=2,437) 
(p<0.001). They found no difference between the compliance of men and 
women (39% vs. 38% respectively) and that compliance increased with 
longevity of symptoms: <1year, 25%; 1-5years, 34%, 6-10years, 40%; 
>10years, 44% (p<0.003).119 They reported that symptoms of CVD persisted in 
about a third (37%) of patients despite apparent compliance with prescribed 
stockings. Ragu et alconcluded that non-compliance with compression hosiery 
in patients with CVD is very high regardless of age, sex, aetiology of CVD, 
duration of symptoms or disease severity. They state the reasons for non-
compliance as being under two interdependent major categories: wear-comfort 
factors and intangible sense of restriction imposed by the stockings.119  
Recently the commonly held opinion that elastic compression stockings should 
have a graduated decrease in pressure application from the ankle upward has 
been questioned. Rather than graduated elastic compression stockings 
(GECS), inversely graduated or “progressive” elastic compression stockings 
(PECS) have been assessed. Beneficial results have been reported in sports 
applications as well as in patients with venous disease.120 121 In a double-blind 
multicentre randomised control trial in patients with mild chronic venous 
insufficiency (CEAP C0-C2), it was demonstrated that PECS are equally 
effective as conventional stockings concerning an improvement of subjective 
symptoms. Additionally, they reported that PECS were easier to put on, were 
more comfortable to wear and had a better compliance compared to GECS.121 
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Mosti et alreport using strain-gauge plethysmography, that the mean increase in 
calf ejection fraction produced by PECS (vs. without stocking) was +75% 
compared to +32% with GECS (vs. without stocking) with a significant 
correlation between calf ejection fraction and the stocking pressure measured at 
calf level during standing and walking. Thereby they concluded that stockings 
exerting a higher pressure on the calf than on the ankle show greater efficacy in 
increasing the venous ejection fraction from the leg. They hypothesise that this 
should translate to benefits for patients with varicose veins.  
A randomised trial comparing surgery and conservative treatment for varicose 
veins showed that surgical treatment produced better results than conservative 
measures in terms of health-related quality of life, symptomatic relief, 
anatomical extent and patient satisfaction.122 The limitations of conservative 
management, relying largely on the use of compression stockings, are further 
confirmed by the large proportion of patients (52%) in this study who had 
crossed over to the surgical arm by three years. 
Compression stockings have not been included in cost-effectiveness analyses 
of varicose vein treatments. An approximate cost to the NHS of two single 
stockings lasting three to six months is £36.95. 123  
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1.8.2 MINIMALLY INVASIVE TREATMENTS FOR VARICOSE VEINS 
Minimally invasive techniques include radiofrequency ablation (RFA), 
endovenous laser therapy (EVLT) and ultrasound-guided foam sclerotherapy 
(UGFS). These procedures are increasingly employed in the treatment of 
varicose veins in the NHS. 
The development of minimally invasive procedures has primarily been led by 
short-term trials that demonstrate equivalence of outcome with conventional 
surgery, with less post-operative discomfort, fewer operative side-effects and a 
speedier return to normal activity.124-126 In addition these new techniques can be 
employed under local anaesthetic, often in an out-patient setting, thereby 
freeing operating theatre time and potentially improving cost-effectiveness.127  
An analysis of the cost-effectiveness of minimally invasive and traditional 
surgical treatments of varicose veins suggests that either RFA or EVLA 
performed in an outpatient or office based setting with staged UGFS for residual 
varicosities, were likely to be as cost-effective as traditional GSV surgery.13 In 
this analysis UGFS alone had the least expensive initial cost, but this advantage 
was partly offset by high expected rates of re-intervention at 3 months for 
residual reflux or varicosities with a corresponding loss in HRQoL (Health 
related quality of life score [EQ-5D™ index (EuroQol Group, Rotterdam, The 
Netherlands)]) for the patient, and the additional cost to the health service. 
However this analysis is based upon non-favourable results which have 
subsequently been highlighted to be disingenuous regarding UGFS.14 128 129    
All treatment modalities fall within the NHS threshold of £20,000 per quality-
adjusted life years (QALY) however there clearly exists a huge range of cost-
implications in deciding upon treatment modality.13  
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Current innovations and developments in minimally invasive varicose 
treatments include the use of endovenous steam, cyanoacrylate adhesive 
(Sapheon®[super-glue]) and mechano-chemical (Clarivein®) devices.130-132  
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1.8.2.1 ULTRASOUND GUIDED FOAM SCLEROTHERPAY (UGFS) 
Sclerotherapy has been used to treat varicose veins from as early as 1835 
according to the records of Massachusetts General Hospital.133 However it was 
not until 1963 that the technique of sclerotherapy was described and 
popularised by Fegan whose name has become synonymous with the 
procedure.134 Although liquid sclerotherapy has been used for treating reticular 
veins or telangiectasia (≤3 mm diameter) for almost a century, foam (1939) and 
mixing the sclerosant with air (1944) are more recent innovations.135 136 137 
However foam has only become more commonly used since the work of 
Cabrera in the early 1990s. Ultrasound guided foam sclerotherapy (UGFS) has 
now become common-place in the management of varicose veins.138 Foam 
displaces blood from the vein and increases the surface area and duration of 
contact between the sclerosant and the vein wall.104 139 In 2000 Tessari 
proposed the method of creating foam that remains the most widely used to 
date.140 
 
The goal of sclerotherapy is to obliterate the lumen of the incompetent varicose 
vein. This requires both intravascular thrombosis and significant damage to the 
vascular endothelium at the very least.133  It is now clear that foam is much 
more effective than traditional liquid sclerosants in achieving sclerosis of the 
saphenous trunk. 141,142 143 Compared with liquid, foam has increased contact 
with the venous endothelium and remains in the vein lumen for a longer period 
of time. This increases the efficacy of the procedure by enhancing contact 
between active agent and vein wall to maximise vein wall damage. The use of 
foam also allows the sclerosant to be visualised with duplex imaging so that the 
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injection can be placed more accurately. UGFS technique has further enabled 
the use of sclerotherapy in the treatment of GSV incompetence. The procedure 
can be carried out using little or no local anaesthetic, takes less than 30 minutes 
and is a true out-patient procedure. Side effects may occur including superficial 
thrombophlebitis (10%) and skin staining (17%).144 Visual disturbance, 
migranous attacks, allergic reactions and deep vein thrombosis occur 
infrequently.12,145 In addition there have been reports of transient ischaemic 
attack and stroke invariably following the entry of foam into the arterial 
circulation via a patent foramen ovale.146-148 In the UK NICE (National Institute 
for Health and Clinical Excellence) has examined the evidence from a large 
number of patient series and concluded that foam is safe for routine use, stating 
that audit of late results is recommended.127 149 
The most commonly used sclerosants worldwide are polidocanol and sodium 
tetradecyl sulphate (STD), the latter being the most common in the UK with the 
former not licenced in the UK.150 151 Polidocanol and STD are detergent agents 
containing a hydrophilic and a hydrophobic pole. They act by altering the 
surface tension around endothelial cells. The hydrophobic pole binds to the cell 
surface, whereas the hydrophilic portion attracts water into the cell, resulting in 
a rapid and intense cell hydration.152 Endothelial damage is enhanced by 
greater concentrations of sclerosant in smaller veins and delivery as foam 
prolongs the time of contact and amplifies the effect of the agent.104 139 It is 
accepted that STD is a more potent sclerosant than polidocanol in the order of 
3:1.153-155 
 
Regarding the practical use of UGFS, once complete obliteration of the 
saphenous trunk has been obtained (which may take more than one treatment), 
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it is likely that the risk of recanalisation of GSV and SSV trunks is up to 10-20% 
within the first year, hence the need for early and on-going follow-up especially 
in the first year.14 129 
 
Using 2007-2008 data, estimated NHS cost of the initial UGFS procedure is 
around £202 with an estimated total cost of £429 over 5 years due to expected 
re-interventions.13 156 Gohel et alstate that the ICER (Incremental cost-
effectiveness ratio) for UGFS being £1400 per QALY (Quality-adjusted life year) 
is the least of all varicose vein therapies, however other treatments may offer 
greater expected benefits for the additional cost and as such may be 
considered better value for money.13 Gohel et alstate that if GSV occlusion 
rates from UGFS could be improved (from those used in their analysis; Wright 
et al)14 it would become a cost-effective treatment and a huge cost saver to 
health services. According to Gohel et al, if the probability of occlusion of the 
GSV 3 months after UGFS was the same as that for surgery, then UGFS would 
be cost-effective with an ICER per QALY of £1,000 versus conservative care. 
Had Gohel et alused other data available on UGFS outcomes128 157 or been able 
to use data from Darvall et alpublished subsequently, showing 97% occlusion 
rates after a single UGFS treatment with 93.7% without recanalisation at 12 
months, they would according to their own hypothesis have found in favour of 
UGFS being cost-effective.129  
 
Beyond this Gohel et aldid not assess the potential societal costs of treatments. 
The different treatments may lead to greatly differing times away from work, 
especially when comparing the most and least invasive treatments. Absence 
from work in the range of 1–4 weeks following surgical treatment has been 
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reported in several studies, whereas minimally invasive treatments usually lead 
to absence from work of a few days, maximally.158 Failure to consider such 
costs does not fully reflect the advantage of less invasive treatments. In a 
recent non-controlled follow-up study, 43·2 per cent of patients had returned to 
work within 24 hours after UGFS, but none after surgery (p < 0·001). 
Respective proportions after 1 week were 77·4 and 23 per cent (p < 0·001).158  
 
A recent Cochrane review of the efficacy of minimally invasive treatment and 
traditional surgery for varicose veins concluded that existing evidence on UGFS 
is insufficient upon which to base an informed decision on its benefits.159 More 
robust randomised controlled trials, for example the CLASS study in the UK 
(Comparison of Laser, Surgery and foam Sclerotherapy), are currently recruiting 
and will hopefully make treatment choice better informed.160 
 
Modifications of sclerotherapy, some listed below, have been attempted with 
varying levels of success.  
1.8.2.1.1 CURRENT UGFS MODIFICATIONS 
1.8.2.1.1.1 CATHETER DIRECTED FOAM SCLEROTHERAPY 
Catheter directed foam sclerotherapy (CDFS) was initially described in 1997.161 
CDFS involves the use of a long catheter to deliver a foam sclerosing agent into 
a target vessel (saphenous trunks or venous malformations) under ultrasound 
guidance.161 Williamsson et alreport 70% occlusion of treated segments at one 
year, in their series of 100 patients, with 15% completely recanalised. They 
performed CDFS using 10mLs of Tessari formed 3% polidocanol foam (2mL 
liquid: 8mL air), delivered along the GSV while the catheter was withdrawn. At 
two weeks and at one year after treatment the patients were evaluated. They 
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report that 84% of the patients were satisfied with the treatment at one year and 
there were no serious side-effects.162 Asciutto et al report that of the 188 
patients who completed the one year follow up examination post CDFS, 67 % 
had a complete and 14 % a near complete obliteration of the treated vessel. 
They report that 92% of patients were satisfied with the results of treatment. 
Tan et alreport on their series of 66 legs treated in 62 patients with CDFS with 
Tessari foam using 3% STD : air (1:3), where they occluded the DUS identified 
SFJ by digital pressure. 62 of the 66 treated veins were completely thrombosed 
at day one, an immediate success rate of 94%. 34 legs were scanned at 12 
months, of which 19 (56%) of legs had an occluded GSV with partial 
recanalisation noted in 8 limbs (24%). 7 (20%) of legs had a patent GSV. 
1.8.2.1.1.2 SFJ OCCLUSION 
Balloon catheters have previously been considered for use as adjuncts to 
UGFS by using them as SFJ occlusion devices. They were used in an attempt 
to prevent the escape of sclerosant into the deep veins theoretically protecting 
the deep veins and enhancing the efficiacy of treatment by increasing the time 
that foam is in contact with the treated vein wall.163  164 Reich-Schupke et 
alreport a pilot study of their use of a triple-lumen, double-balloon catheter again 
born from the hypothesis that in order to minimise the risk of a foam transfer 
beyond the SFJ into the deep venous system the following two techniques are 
of use: when using an angiography-catheter the SFJ is compressed by the 
duplex probe during and some minutes after the foam injection165 166 and using 
a single balloon catheter the balloon at the proximal tip of the catheter is placed 
at the SFJ sealing the junction.163 164 However Reich-Schupke et alhypothesised 
that in both the methods foam escape into the distal part of the vein treated is 
possible. This they felt would reduce the foam volume required to treat the 
- 58 - 
desired area provoking incomplete filling of the vessel resulting in the contact 
time of the foam with vessel wall being shortened inhibiting a successful 
occlusion of the GSV. Reich-Schupke et altherefore initiated a pilot study to 
survey the safety and efficacy of a triple-lumen double-balloon catheter 
(Stopflow-catheter Systems, Clinical Plastic Products SA, La Chaux-de-Fonds, 
Swiss), aiming to diminish the transfer of the foam to the distal part of the vein 
and hopefully improve the efficacy of the sclerotherapy of the varicose GSV.166 
They used Tessari foam (2 mL 3% polidocanol: 8 mL air) applied via the third 
lumen of the catheter exiting via nine small holes in the catheter between the 
proximal and distal balloons. After three minutes the foam was aspirated then 
first the distal, then the proximal balloon deflated and the catheter removed. 1 
day, 1 week and 6 weeks after the treatment, 95% (19/20) of the GSV had a 
complete occlusion of the treated vein segment. Only eight of the patients 
treated attended after six months of which 75% (6/8) had a successful occlusion 
and after 12 months only 50% (4/8) had an occlusion of the treated GSV. Ten 
patients (50%) complained about a feeling of pressure at the site of the two 
filled balloons during the treatment. In 10% of the patients (2/20), the retraction 
of the catheter in the vasospastic vessel was painful. Limitations of this 
treatment include: the length of the vessel that can be treated is limited by the 
fixed distance between the two balloons; the time for the treatment with the 
double-balloon catheter is higher than that compared with the use of an 
angiography catheter; the double-balloon catheter has possible specific 
additional side-effects compared with a simple angiography catheter (e.g. 
rupture of the balloons). Subsequently it appears that attempts to occlude the 
SFJ during UGFS may in fact increase the leakage of foam into the deep veins 
by opening the SFJ which in the majority of those with truncal varices is not 
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actually incompetent. At the very least balloon occlusion, manual compression 
of the SFJ and even ligation of the SFJ prior to UGFS have been found not to 
prevent leakage of foam into the deep veins, hence these techniques have 
been largely abandoned.167 168 
1.8.2.1.1.3 DENUDATION 
1.8.2.1.1.3.1 MECHANOCHEMICAL 
Endovenous mechanochemical ablation is a new technique with minimal data 
thus far. Its mechanism of action is stated to be a combination of mechanical 
damage of the endothelium and scarring of the vein due to liquid sclerosant. 
One qualitative histological in-vitro study of five 8-10cm lengths of GSV 
removed at SJF ligation and subsequently treated with ClariVein® only, revealed 
a qualitative result of >50% but <100% endothelium remaining intact in test 
samples with 100% endothelium remaining in control segments p=0.004 (as per 
publication).169 Mechanochemical ablation does appear to have the advantage 
that it does not involve thermal damage and thus does not require tumescent 
anaesthesia. Two pilot studies have been published, one using 1.5% STD and 
the other 1.5% polidocanol, both using the only commercially available device, 
ClariVein® endovenous mechanochemical ablation.170 171 The single-use, 
disposable ClariVein® infusion catheter contains a rotating dispersion wire that 
extends through its lumen. At the end of the wire is an angled tip that protrudes 
2 cm. A small ball attached to the tip enhances ultrasonographic visibility and is 
stated to mechanically damage the endothelial layer as it rotates at 3500 
revolutions per minute and disperses sclerosant into the bloodstream and onto 
the vessel wall. The catheter is connected to a 9 volt battery motorised handle 
unit that controls wire rotation. A 5 mL syringe mounted on the handle delivers 
sclerosant. The catheter is inserted through a 4-6-Fr micropuncture set inserted 
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into the truncal vein under ultrasound guidance via an 18 gauge intravenous 
access needle. One study reports that 6 weeks following polidocanol in 
combination with Clarivein®, starting 2 cm distal from the SFJ, with a mean 
treatment length of 40cm, a mean sclerosant volume of 6.8mLs sclerosant, the 
GSV was completely obliterated in 26 (87%) of 30 veins. Two patients had 
partial recanalisation of the proximal GSV, 15 and 18 cm respectively from the 
SFJ whilst another had partial recanalisation of the distal GSV. One total 
recanalisation of the GSV was successfully treated in a redo procedure 7 weeks 
after initial treatment. The STD study reports a longer follow-up of six months 
with a mean treatment length of 37.5cm. All patients received 12mLs of liquid 
1.5% STD. DUS findings were similar at one and six months with only one 
recanalisation in 30 GSVs, a primary closure rate of 97.6%.132 170 171 It would 
appear likely that this treatment modality offers similar recanalisation rates to 
more recently reported UGFS follow-up. 129 
 
1.8.2.1.1.3.2 BALLOON DENUDATION 
Fogarty balloons have previously been assessed at Leeds Vascular Institute for 
their potential as adjunctive treatment in UGFS. This work was based on the 
hypothesis that “trawling” an inflated Fogarty balloon through the GSV prior to 
UGFS may potentiate its effects by denuding the endothelium, thus enhancing 
the penetration of foam into the subendothelial layer. Unfortunately, though 
balloon denudation did increase the overall endothelial cell loss, it did not 
increase the depth of injury caused by the foam.16  
This thesis examines the potential for cutting balloons to act as adjuncts to 
UGFS. The cutting balloon was first designed by Barath et al.172 Cutting 
balloons are designed for arterial atherosclerotic stenoses that are unlikely to 
- 61 - 
respond to balloon angioplasty. Cutting balloons feature three or four 
atherotomes (microsurgical blades), which are 3-5 times sharper than 
conventional surgical blades.173 The atherotomes, which are fixed longitudinally 
to the outer surface of a non-complaint balloon, expand radially and deliver 
longitudinal incisions in the vessel, designed to relieve the radial stress of an 
atherosclerotic stenosis. The atherotomes are mounted along the length of the 
cutting balloon. The unique design of the cutting balloon is engineered to 
protect the vessel from the edges of the atherotomes when it is deflated. This 
minimises the risk of trauma to the artery as the balloon is passed to and from a 
target lesion. We hypothesise that cutting balloon atherotomes (used 
immediately prior to UGFS) will cut the GVS media in up to four places 
(depending on the balloon design) allowing influx of foam sclerosant deeper into 
the vein media, thereby increasing the efficacy of UGFS. 
1.8.2.2 THERMAL ABLATION TECHNIQUES 
RFA and EVLA are thermal ablation techniques which use heat to damage the 
vein causing non-thrombotic venous occlusion by inducing endothelial damage, 
collagen denaturation and focal coagulative necrosis.174,175 These techniques 
usually access the GSV at the level of the knee thus avoiding a groin incision 
and the potential morbidity associated with this component of a surgical 
procedure. Controlled trials show that the GSV is obliterated in over 90% of 
patients.174,175 Although the early GSV occlusion rates with thermal ablation 
techniques are encouraging, long term recurrence rates have not been 
established.176,177 Thermal ablation is usually possible only in long, straight 
veins, meaning that typically it is only the truncal vein that is treated thermally. 
An alternative method is often used to obliterate residual varices, although 
many patients obtain symptomatic improvement without this additional step. 
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Thermal ablation is usually carried out under tumescent local anaesthesia, in 
which the local anaesthetic agent injected not only provides pain relief but also 
via volume effect, moves the vein away from the nerve and skin to reduce the 
chance of thermal damage to these structures.  Thermal ablation techniques 
require additional skills namely duplex ultrasonography and duplex-guided 
venous cannulation. There are several different laser and RFA devices and 
specific training and experience are required with each for their use.127   
1.8.2.2.1 ENDOVENOUS LASER ABLATION (EVLA) 
A relatively novel technique, EVLA was invented by Dr. Robert Min at Cornell 
University, New York.178 It involved placement under ultrasound guidance of an 
intravenous catheter into the GSV at knee level, with a sterile bare-tipped laser 
fibre inserted via the catheter up to the SFJ. Delivery of continuous wave laser 
energy commences 1-2cm distal to the SFJ. The laser fibre tip is withdrawn at a 
rate of 3mm/second distributing approximately 70J/cm along the length of the 
GSV. Corcos et alundertook a study assessing the effects of application of an 
808nm diode laser. Specimens were stained with haematoxylin and eosin and 
with Weigert for elastic fibres. The depth of tissue penetration in terms of 
thermal damage was evaluated in 29 vein specimens. Full thickness penetration 
was found in the intimal layer, partial to full thickness in the media in the 
majority of specimens and minimal effects in the adventitia. The thermal 
alterations in tissue were described as necrosis, vacuolation, delamination, 
coagulation and tissue loss. The detection of vaporised, coagulated blood 
further supports the theory of heat transfer to the vein wall via the production of 
steam and subsequent thrombus development as postulated by Proebstle et 
al.179,180 Contemporary EVLA commonly involves the use of higher wavelength 
lasers e.g. 1470nm diode laser directing thermal energy at the water within the 
cells of the veins wall. This results in decreased perforations and bruising seen 
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with earlier lasers. Treatment now also involves ablating from the lowest point of 
reflux which provides maximum improvement in symptom severity scores 
(Aberdeen varicose vein symptom score) and maximum spontaneous resolution 
of varicosities with only 17% have residual varicosities after GSV EVLA 
alone.181 van den Bos et al report in their 2009 meta-analysis that EVLA was 
significantly more effective compared with surgery (AOR, 1.13; 95% CI, 0.40-
1.87), foam sclerotherapy (AOR, 1.02; 95% CI, 0.28-1.75), and radiofrequency 
ablation (AOR, 0.71; 95% CI, 0.15-1.27).125 After 3 years, the estimated pooled 
success rates (with 95% confidence intervals [CI]) for stripping, foam 
sclerotherapy, radiofrequency ablation, and laser therapy were about 78% 
(70%-84%), 77% (69%-84%), 84% (75%-90%), and 94% (87%-98%), 
respectively.  
When offered as an out-patient/office based procedure, the cost of initial EVLA 
is estimated at around £698 with total cost at 5 years, accounting for expected 
re-interventions being £1,021 with an ICER per QALY of around £5,800.13  
1.8.2.2.2 RADIOFREQUENCY ABLATION (RFA) 
RFA was introduced in Europe in 1998 and first described in clinical practice by 
Goldman in 2000.182,183 RFA involves heating the GSV wall to 85C with 
radiofrequency delivered via catheter electrodes with a temperature feedback 
loop. The catheter is placed percutaneously into the GSV at knee level and 
advanced to the SFJ under duplex ultrasound guidance. The catheter is then 
withdrawn treating sequential sections (c.7cm with VNUS ClosureFAST™) with 
a microprocessor radiofrequency generator ensuring delivery of the minimum 
power needed to maintain the target temperature at the treatment site. RFA is 
thought to achieve fibrotic occlusion by direct heating of the vein wall inducing 
collagen denaturation.184 185   The most popular RFA system is the VNUS® 
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ClosureFAST™ (VNUS Medical technologies, San Jose, California, USA) 
segmental ablation catheter, which has superseded earlier continuous 
withdrawal catheters.126   van den Bos et alreported in their meta-analysis that 
RFA was as effective as surgery and foam sclerotherapy, however less-so than 
EVLA.125  
When offered as an out-patient/office based procedure, the cost of initial RFA is 
estimated at around £776 with total cost at 5 years, accounting for expected re-
interventions being £1,110 with an ICER per QALY of around £17,350.13 
1.8.2.3 CURRENT ENDOVENOUS INNOVATIONS 
1.8.2.3.1 ENDOVENOUS STEAM 
The exact mechanism of action of endovenous laser is not fully understood 
however several theories exist such as the “steam bubble theory,” the “direct 
contact theory,” the “heat pipe,” and “direct light energy absorption” 
hypotheses.186 Obviously several factors play an important role in the 
mechanism of endovenous laser ablation. Direct energy absorption by the vein 
wall appears the most efficient mechanism.186 With a view to extrapolating the 
potential ablative action of intravascular “steam bubbles”, steam itself has been 
used as an ablatant in a new method of thermal vein ablation. Its objective is to 
achieve a potentially safer and easier method of thermal ablation that has fewer 
side effects. Only one study has been reported thus far with histological reports 
from animal studies on sheep and a pilot study in humans. The Steam Vein 
Sclerosis (SVS) system (CERMA SA, Archamps France) was used. The SVS 
system consists of a steam generator and a hand-piece that injects micropulses 
of steam into a catheter that delivers the steam into the vein to be treated.  They 
calculated that approximately 2258 J is released when 1 gram of steam 
condenses. In EVLA, it is considered consensus to apply about 50 to 60 
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Joules/cm. To occlude 30 cm of vein with steam ablation, theoretically, 1 to 1.5 
mL of water is needed. In practice, 2 to 5mLof water is likely to be required, 
because not all steam condenses at the vein wall. The steam is produced by 
means of piston pressing a fixed amount of water (76µL=diameter piston x 
stroke) through a heated element located just before the catheter. By keeping 
the lumen diameters very small and the exit holes even smaller, pressure is 
maintained and loss of energy is limited. The volume of the steam depends on 
the pressure and temperature. As the energy is transferred to the vein, the 
steam cools and condenses to the same volume of water used to produce the 
steam. The steam starts to cool and condense when it leaves the catheter due 
to the drop in pressure and the exchange of energy with the surroundings. This 
process is dynamic. The theoretic amount of energy of one pulse of steam is 
174 J. The measured amount released at the tip of the catheter is 60 J per 
pulse. Results in sheep veins treated with steam ablation displayed fibrosis and 
destruction of the vein was confirmed by histology, and ongoing fibrotic 
contraction was confirmed by shrinking of vein diameter on US imaging. The 
similar histological changes found after heating using the RFA technique are 
stated by the authors to show that their study design was valid and in line with 
other minimally invasive thermal ablation modalities. The human pilot study 
comprised 19 patients treating 20 veins. The mean treated length of the veins 
was 25 cm, with an average of 50 pulses of steam were administered per 
treated vein. All treated veins were occluded on US examination at 1 week. At 3 
months, 1 of the 20 treated varicose veins showed a small segment of several 
centimetres with minimal blood flow. At 6 months, flow was observed on US 
examination in 7 of 20 treated saphenous veins, but this was segmental (<10 
cm). Subsequent work by this team has led them to recommend an increase 
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dose of steam to induce veins i.e. 2 instead of 1 steam pulse/cm.187 Though this 
potential treatment modality is very much in its infancy, it appears to show 
promise. 
1.8.2.3.2 CYANOACRYLATE  
Cyanoacrylate (CA), commonly referred to as ‘‘superglue,’’ has gained 
momentum in recent years for intravascular use to treat conditions such as 
arteriovenous malformations (AVMs), 
varicoceles among other pathologies.188 189-191 Although its use is off patent for 
peripheral applications, the properties of CA make it potentially useful for a 
number of vascular occlusion procedures. When used intravascularly, CA 
triggers a robust inflammatory reaction in the vessel wall. Anionic substances 
such as plasma, blood, or saline stimulate polymerisation of the CA adhesive 
upon contact, leading to occlusion. The resultant polymerisation damages the 
vascular intima and induces an acute immunological response.192 After 
polymerisation is complete, gradual resorption of the occlusive polymer takes 
place. Within approximately one month, the response progresses to granuloma 
formation with giant cells and eventually fibrosis.193 194 Preliminary studies have 
been carried out in animal models and a small number of human subjects 
though the later has not yet been reported. These studies have employed the 
Sapheon® CA adhesive delivery catheter (Sapheon, Santa Rosa, California). 
The dispenser gun delivers a fixed volume (0.16mL) of glue per trigger pull, 
which is repeated every 3cm. Animal studies using a porcine model report 
endpoints of histological findings at 30 and 60 days as being, venous closure, 
segmental wall thickening and fibrosis. They state that intravascular injection of 
CA is feasible for closure of superficial veins in animal models and clarify that 
these findings warrant further animal studies of this proprietary CA to assess 
efficacy, safety and its effects on perivenous structures. They have already 
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conducted human trials on eight subjects with incompetent GSVs and signs or 
symptoms of chronic venous disease. They report that the mean treatment time 
was 17 minutes, the mean treatment length was 31 cm, and the mean CA 
injected volume was 1.58 mL. Results declared are that all veins were closed at 
1 month and there were apparently no serious adverse events. The authors 
conclude that CA adhesive is a feasible alternative treatment for incompetent 
saphenous veins and state that a more robust study began in March 2011.195 
Human studies have begun in other units.196 
 
1.8.3 SURGICAL TREATMENT 
1.8.3.1 SFJ LIGATION (CROSSECTOMY), GSV STRIPPING, 
PHLEBECTOMIES 
The most common method of treatment of varicose veins in the UK remains 
surgical ligation of the saphenofemoral junction (SFJ) with subsequent stripping 
of the great saphenous vein (GSV).11 Conventional varicose vein operations are 
high volume and low risk and are typically carried out under general 
anaesthesia. These operations have changed little over decades. Although 
surgery is highly effective in the short term, the 5-year recurrence rates are 
approximately 30% for GSVs and 50% for SSVs, which may be due to 
neovascularisation.197 Campbell et alreport a 10 year recurrence rate post-
surgery of 70% and Winterborn et alreport recurrence at 11 years in the order of 
60%.198 199 The Randomised and Economic Assessment of Conservative and 
Therapeutic interventions for Varicose Veins (REACTIV) trial suggests that the 
cost of varicose vein surgery in the UK is within National Institute of Health and 
Clinical Excellence (NICE) guidelines for quality-adjusted life years.122 127 When 
offered as a day case procedure, the cost of initial surgery is estimated at 
around £980 with total cost at 5 years, accounting for expected re-interventions 
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being £1,242 with an ICER per QALY of around £19,012.13 Costs are greatly 
increased by inpatient status and according to the review of cost-effectiveness 
of varicose vein treatments by Gohel et alnegate the probability that the 
treatment is cost-effective at the NHS threshold of £20,000 per QALY. 
1.8.3.2 MODIFICATIONS TO STANDARD SURGICAL TREATMENT 
Over more than 20 years a number of attempts at conservative surgery for 
saphenous truncal incompetence have been reported.200 201 202 A technique 
which has fallen from favour is flush sapheno-femoral ligation combined with 
multiple phlebectomies without stripping of the GSV. Some short term reports 
suggested that this resulted in similar outcomes to stripping operations.202 The 
evidence in favour of stripping is suggestive but not overwhelming. Stripping of 
the GSV is postulated to reduce recurrence by preventing neovascularisation in 
the groin joining up with the residual trunk of the GSV in the upper thigh and 
producing significant GSV reflux in the lower limb. Neovascularisation has been 
shown to be the cause of recurrence in up to two-thirds of patients198 but this 
same trial showed no difference in rates of recurrence between legs that had 
undergone stripping and those that had undergone simple SFJ ligation. Despite 
this finding of equal rates of recurrent varicosities, those patients in the stripping 
group had fewer re-do operations for recurrent varicose veins, a finding that is 
not explained.198 203  
SFJ ligation without GSV stripping is often confused with the Haemodynamic 
Correction procedure (CHIVA, Cure Conservatrice et He´modynamique de 
l’Insuffisance Veineuse en Ambulatoire, Ambulatory Conservative 
Haemodynamic Management of Varicose Veins).  
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1.8.3.2.1 CURE CONSERVATRICE ET HEMODYNAMIQUE DE 
L´INSUFFICIENCE VEINEUSE EN AMBULATOIRE (CHIVA) / 
CONSERVATIVE HAEMODYNAMIC CURE OF VENOUS 
INSUFFICIENCY. 
 In 1988, Franceschi described conservative haemodynamic cure of venous 
insufficiency, known by the French acronym “CHIVA”.204 CHIVA was designed 
to allow treatment of varicose veins without sacrificing the superficial vein 
network, and consists of minimally invasive surgical procedures under local 
anaesthesia that are based on findings of careful haemodynamic analysis of the 
venous network of the lower limb using duplex imaging. CHIVA is based on the 
fact that, even though varicose disease is associated with weakness of the vein 
wall, clinical manifestations occur only under certain orthostatic haemodynamic 
conditions.204-206 If these haemodynamic abnormalities are corrected by 
breaking the pressure column and suppressing veno-venous shunting, 
manifestations disappear while preserving runoff from superficial tissue via the 
superficial vein network. Therefore, the goal of CHIVA for superficial venous 
insufficiency is to relieve the hydrostatic pressure column by stopping veno-
venous shunts of the saphenous vein or disruption of drainage of superficial 
tissue.207 The aim of CHIVA is not only to preserve the GSV for use as a future 
vascular graft, but also to maintain its drainage eliminating reflux points with 
change of compartments.204 206 208 209 CHIVA aims to treat the varicose vein 
disease by creating a draining saphenous system. A single randomised trial 
comparing the outcome of CHIVA with saphenous stripping operations has 
been reported.  In those treated with surgery their treatment involved: flush 
sapheno-femoral ligation, GSV stripping from groin to knee, multiple 
phlebectomies of the tributaries and subfascial ligation of thigh perforating veins 
under general or spinal anaesthesia. Haemodynamic correction (CHIVA) in 
keeping with the philosophy of CHIVA treatment was performed using what is 
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termed a minimally invasive technique Haemodynamic Correction type 1 
(CHIVA 1).202 This consists of flush SFJ ligation, disconnection from the GSV of 
the varicose tributaries and their avulsion through cosmetic incisions. Reverse 
drainage of both the GSV and competent tributaries toward the re-entry 
perforating vein is produced. Incompetent tributaries were disconnected from 
the GSV and partially removed, the residual distal segments of these tributaries 
drain separately though their own re-entry perforating vein. All CHIVA 
operations were performed as day surgery cases and under local anaesthesia. 
The rate of ultrasound confirmed recurrence was significantly higher in the 
stripping group, 35% compared to 18% in the CHIVA group, respectively (p = 
0.038, Fisher’s exact test). The relative risk of recurrence in the stripping group 
is doubled at 10 years compared to CHIVA (OR 2.2; 95% CI 1-5, p = 0.04, 
Fisher’s exact test). The main difference between the two groups after 10 years 
is the 22% of newly formed varicose veins found in the stripping group, without 
any detectable reflux point. The authors believe that this type of recurrence is 
attributable to the lack of a draining saphenous system encouraging 
neovascularisation. The maintenance of drainage seems to be a decisive factor 
in avoiding neovascularisation after varicose vein surgery.210 This observation is 
confirmed when CHIVA treatment is not correctly performed leading to post-
operative GSV thrombosis and occlusion. A non-draining GSV, despite 
conservative surgery, increases the number of recurrences in comparison to 
draining GSV systems.209 CHIVA presents difficulties as the operating surgeon 
must also be competent at duplex ultrasonography and capable of analysing 
patterns of varicose veins by duplex ultrasonography undertaken before the 
operation. In countries where surgeons usually perform their own duplex 
ultrasound examinations such as in Italy and Spain, the CHIVA technique is 
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more commonly used. In Spain, a national survey demonstrates this technique 
is used in about 50 % of cases.207 In contrast, in France the same kind of 
evaluation assessed CHIVA performed in less than 5 % of cases.211  
1.8.3.2.2 AMBULATORY SELECTIVE VARICES ABLATION UNDER 
LOCAL ANESTHESIA (ASVAL) 
As discussed previously numerous biochemical, anatomical and pathological 
studies suggest a parietal or secondary valve failure, rather than primary 
valvular failure hypothesis as the origin of varicose veins.58 60 212-214 According to 
this hypothesis, valvular insufficiency is caused by the dilatation of the vein. 
Anatomical and clinical studies indicate that in the presence of varices, not only 
is the SFJ competent in >50% of cases,215 216 but moreover the GSV is often 
partially or wholly competent.9 217 All of these observations collectively challenge 
the sole culpability of the GSV in the initial development of saphenous vein 
disease. The correlation between the extent of the saphenous reflux, age, and 
clinical stage is described in the literature9 79 88 and supports the theory of the 
development of superficial venous insufficiency starting from the suprafascial / 
superficial venous network in an ascending or multifocal fashion.9 67 88 217-220 
Pittaluga et alhypothesised that it appeared logical therefore to treat the 
superficial varicosities alone in an attempt to reverse the changes in leading to 
further and worsening varicose veins.220 They report a 4 year follow-up on a 
cohort of patients treated by ASVAL. ASVAL was done with phlebectomies 
(reducing the varicose reservoir  number of zones to be treated [NZT; of 32 
potential zones per leg]) through staged incisions under tumescent local 
anaesthesia. They treated one cohort with ASVAL and another with high (SFJ) 
ligation and GSV stripping (High ligation and strip; HLS). Retrospective 
comparison of the two cohorts confirmed that they had as planned been 
selective in choosing patients for ASVAL. They reserved this more limited 
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surgical treatment for the least evolved stage of the varicose disease hoping to 
obtain clinical and hemodynamic reversibility. The comparison of the cohorts 
undergoing ASVAL and HLS revealed significant differences: In the ASVAL 
group the mean age was younger, the proportion of women was greater, the 
mean body mass index (BMI) was lower, the CEAP C4 to C6 class was less 
frequent (33% asymptomatic and 91% had no skin changes), the mean 
varicose reservoir was smaller (the mean number of zones to be treated [NZT] 
was lower) and the incidence of asymptomatic lower limbs was higher. The 
hemodynamic status of the lower limbs undergoing ASVAL also revealed 
significant differences: the SFJ was competent more often, its diameter was 
smaller, and the saphenous reflux was less often complete from the SFJ to the 
malleolus. They report a recurrence of 11.5% at 4 years with 78% having 
symptom improvement. They state that this is favourable when compared to 
recurrence rates observed after HLS 221 222 (15% to 30%) or after RFA 223 224 
(22% to 23%) after 3 or 4 years of follow-up. They highlight that it in their 
ASVAL cohort, recurrences were accompanied by an absence of saphenous 
reflux in 17 of 24 cases, and that the reflux was unchanged compared with the 
preoperative situation in only three limbs, stating that this outcome is 
comparable with the midterm results of RFA in which approximately half of the 
recurrences appeared despite permanent obliteration of the GSV.223 224 They 
surmise that this finding further suggests an evolution of the varicose 
recurrence from the suprafascial venous network, unrelated to any persistent or 
recurrent GSV reflux, but further reflecting the secondary valvular/primitive 
ascending/ multifocal evolution of varicose veins. They conclude that the 
performance of isolated phlebectomy with the conservation of a refluxing GSV 
may be effective over the mid-term against the symptoms of superficial venous 
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insufficiency, for the disappearance of the varices, and for saphenous 
haemodynamics, with attainment of non-significant postoperative reflux in two-
thirds of ASVAL treated limbs. The magnitude of the volume of the varicose 
reservoir appears to be the determining factor for the clinical and hemodynamic 
efficacy of this more limited surgical approach. They highlight that further long-
term prospective studies will be necessary to delineate the indications for this 
therapeutic approach. Pittaluga et alcalculated the cost of the procedures from 
insurance company reimbursement. The mean cost for each procedure was 
€758.88 ± 10.20 for ASVAL vs. €1143.96 ± 12.42 for HLS (p < 0.05), yielding a 
mean saving of €387.08 ± 14.35 per procedure for the ASVAL group. This 
treatment modality shows promise but is likely only useful in the treatment of 
minor to moderate varicose veins.  
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1.9 SUMMARY OF TREATMENTS AT OUTSET OF THIS 
THESIS 
In 2008 Luebke et alperformed a systematic review and meta-analysis of 
endovenous radiofrequency obliteration, endovenous laser therapy, and foam 
sclerotherapy for primary varicose veins. Twenty-nine EVLA studies, 32 RFA 
studies and 22 foam sclerotherapy trials were included. They reported RFA was 
associated with the worst short and long-term safety and efficacy results 
compared to EVLA and foam sclerotherapy regarding complete occlusion at the 
end of follow-up, phlebitis, deep vein thrombosis, and paraesthesia. EVLA had 
the best results concerning the long-term effectiveness parameters for 
occlusion at the end of follow-up and recanalisation, recurrence or development 
of new veins, compared to RFA and foam sclerotherapy. They reported that 
foam sclerotherapy of varicose veins is associated with a higher recurrence rate 
in patients with SFJ incompetence compared to the rates after EVLA or RFA 
treatment.225 
A 2009 meta-analysis by van den Bos et alcomparing minimally invasive 
varicose vein treatments with surgery reported on 64 eligible studies including 
12,320 limbs, with a mean follow-up of 32.2 months compiles the majority of 
data available to guide treatment of varicose veins in the UK during the time 
period of this research.  They report estimated pooled success rates (with 95% 
confidence intervals [CI]) for stripping, UGFS, RFA and EVLT were 78% (70%-
84%), 77% (69%-84%), 84% (75%-90%) and 94% (87%-98%) respectively. 
After adjusting for follow-up, UGFS and RFA were as effective as surgical 
stripping (adjusted odds ratio [AOR], 0.12 [95% CI, -0.61 to 0.85] and 0.43 [95% 
CI, -0.19 to 1.04] respectively). EVLT was significantly more effective compared 
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with stripping (AOR, 1.13; 95% CI, 0.40-1.87), UGFS (AOR, 1,02; 955 CI, 0,28-
1.75) and RFA (AOR, 0.71; 955 CI, 0.15-1.27).125 van den Bos et 
alacknowledge that  large, long-term comparative randomised controlled trials 
(RCTs) that include patient-reported outcomes, cost-effectiveness analyses and 
safety assessment are need to achieve level 1 medical evidence for the 
treatment of varicose veins. 
1.10 SUMMARY OF MORE RECENT EVIDENCE 
The CLASS trial was designed to compare the clinical effectiveness and cost-
effectiveness of foam sclerotherapy, endovenous laser ablation (EVLA) and 
surgery for the treatment of patients with varicose veins.226 The study was 
designed as a parallel-group randomised controlled trial (RCT) without blinding. 
Eleven UK specialist vascular centres were included. In total seven hundred 
and ninety-eight patients with primary varicose veins were included (foam, 
n = 292; surgery, n = 294; EVLA, n = 212). Patients were randomised between 
all three treatment options (eight centres) or between foam and surgery (three 
centres). Primary outcome measures being disease-specific [Aberdeen 
Varicose Vein Questionnaire (AVVQ)] and generic [European Quality of Life-5 
Dimensions (EQ-5D), Short Form questionnaire-36 items (SF-36) physical and 
mental component scores] quality of life (QoL) were assessed at 6 months. 
Cost-effectiveness was examined as cost per quality-adjusted life-year (QALY) 
gained. Secondary outcome measures were quality of life at 6 weeks; residual 
varicose veins; Venous Clinical Severity Score (VCSS); complication rates; 
return to normal activity; truncal vein ablation rates; and costs. Considerations 
of both the 6-month clinical outcomes and the estimated 5-year cost-
effectiveness suggest that EVLA should be considered as the treatment of 
choice for suitable patients. 
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Current NICE guidelines (2013)227 on the treatment of varicose veins are that 
for people with confirmed varicose veins and truncal reflux: 
 Offer endothermal ablation (radiofrequency ablation or endovenous laser 
treatment of the long saphenous vein).  
 If endothermal ablation is unsuitable, offer ultrasound-guided foam 
sclerotherapy.  
 If ultrasound-guided foam sclerotherapy is unsuitable, offer surgery. 
 If incompetent varicose tributaries are to be treated, consider treating 
them at the same time.  
1.11 COMPARISON OF HISTOLOGICAL CHANGES INDUCED 
BY MINIMALLY INVASIVE TREATMENTS 
Duplex ultrasound follow-up after truncal vein foam sclerotherapy demonstrates 
recanalisation and recurrent reflux in 20-32% of limbs at 1-3 years, compared to 
a rate of 1-16% following RFA and EVLA.228 229 230 14 125 It is likely that the more 
favourable early and mid-term occlusion rates offered by these techniques are 
the result of a greater damage inflicted upon the vessel wall. What remains 
unclear is whether the vessel damage produced by UGFS is likely to be 
sufficient to produce similar results to other minimally invasive varicose vein 
treatments. The above recanalisation rates suggest that the principle mode of 
action of UGFS is to promote thrombotic occlusion rather than permanent vein 
wall injury.  
EVLA and RFA inflict tissue injury by thermal-dependent changes in collagen in 
the vein wall with loss of periodicity, dissolution and fusion of fibres, coagulation 
of collagen bundles and shrinking of smooth muscle, resulting in vessel 
contraction.179 184 185 It therefore appears that denaturing collagen is necessary 
for sustainable vessel closure.231 Whilst this has been demonstrated with EVLA 
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and RFA, associated with high ablation rates, little is known about the ability of 
either STD or polidocanol to achieve this.232 233 
Effective sclerosis (fibrosis) of a vein requires endothelial destruction and 
exposure of subendothelial collagen fibres to the sclerosant. This initiates the 
intrinsic pathway of blood coagulation by activating factor XII. Nevertheless the 
aim of sclerotherapy is not to merely achieve vein thrombosis, which may be 
amenable to recanalisation, but to achieve transformation into a fibrous cord.104 
234 The latter is more likely to occur where the damage inflicted upon the vein 
wall involves both the endothelium and the subendothelial, medial layer. 
Although sodium tetradecyl sulphate (STD) and polidocanol are the two most 
widely used sclerosant foams for treating varicose veins150 151 minimal data is 
available displaying the damage that they inflict upon the vein wall. Endothelial 
damage is enhanced by greater concentrations of sclerosant in smaller veins 
and delivery as foam prolongs the time of contact and amplifies the effect of the 
agent.104 Longevity of the foam could therefore be a factor in determining the 
efficacy of these treatments. Differences between the longevity of the respective 
proprietary foams have been found by others using different strengths of these 
sclerosants.235 STD foam is more stable (longer-lasting) than polidocanol at 
lower comparable concentrations and this finding is reversed with increasing 
concentrations of each. This may be related to the larger molecular size of 
polidocanol thus enhancing its surfactant and foaming properties at higher 
concentrations. Most literature (including product information) recommends a 
concentration of 3% for both sclerosants in the treatment of large superficial 
varicose or incompetent truncal veins.139 236 237 Their relative stabilities at the 
3% concentrations have not been compared though should this hold true it 
ought to be beneficial to the efficacy of polidocanol because of a longer contact 
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time between the sclerosant and the endothelial cells.104 On the other hand in 
the treatment of varicose veins and telangiectasia with sclerotherapy there is 
some evidence that STD may be more effective than polidocanol.153-155 
Nevertheless the EASI study (using liquids not foams) showed that polidocanol 
0.5% and 1% were as effective as STD in the treatment of patients with reticular 
and spider veins, and that more patients were satisfied with the effect of 
polidocanol because of more adverse events with STD.234 Similarly, Goldman 
treated patients with varicose and telangiectatic veins (none with truncal vein 
incompetence) with either polidocanol liquid (0.5%, 1%) or STD liquid (0.25%, 
0.5%) and observed that polidocanol and STD were equally effective although 
tissue necrosis and swelling was less common in the polidocanol group.154  Rao 
et al, in the only study using foam also found that the two sclerosants had 
similar efficacy, tolerability and patient satisfaction.155  
STD is invariably described as more potent than polidocanol in the order of 3:1, 
however most literature (including product information) recommends a 
concentration of 3% for both sclerosants in the treatment of large superficial 
varicose or incompetent truncal veins.139 236 237  This was confirmed as common 
practice in a survey of members of the Vascular Society of Great Britain and 
Ireland in 2007.238 Therefore this research compares STD with polidocanol each 
at a concentration of 3% as this is what is used and recommended in the 
majority of clinical practice.  
Although there is much work describing the in-vitro effects of sclerosants on 
coagulation and cultured cell lines using normal arterial or superficial venous 
tissue there is minimal data on their effect on the superficial veins of patients 
with varicose veins.239 16 240 241 Further there is no literature comparing the 
effects of STD and polidocanol on human veins. 
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Orsini et aldescribed changes in the vein wall of GSV treated with 3% STD (in-
vivo), reporting complete loss of endothelium after 2 minutes with 
subendothelial oedema developing after 15 minutes exposure to STD.15 
Ikponmwosa et alfound almost complete endothelial cell loss after exposure to 
1% and 3% STD after two minutes but with minimal subendothelial damage and 
no collagen disruption.16  
At the very least a sclerosant which causes maximal endothelial destruction is 
likely to have a longer lasting therapeutic effect. Nevertheless even when 
complete endothelial loss is achieved re-endothelialisation may still occur via 
circulating endothelial progenitor cells.242 243 Early treatment failure following 
sclerotherapy is associated with recanalisation of the treated vein. For long-term 
success it is probable that denaturation of the cells in this layer (which results in 
contraction and fibrosis of the treated vein) is required (as per EVLT and RFA). 
It is possible that if the foam was in contact with the vein for longer that greater 
vessel injury may occur. To that end research preceding this, performed at 
Leeds Vascular Institute resulted in the development of a technique that 
increases the half-life of foam from around 160 seconds to greater than 15 
minutes. Balloon mechanical denudation was also formerly assessed as a 
potential adjunct to foam sclerotherapy to enhance damage to both endothelium 
and media. 16 
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1.12 RESEARCH QUESTIONS 
Below are the main research questions to be examined in this thesis with a 
discussion as to how these questions have arisen and how the research aims to 
answer them. 
The aims of this research to improve the efficacy of UGFS are: 
 assess the half-lives of the two most commonly used sclerotherapy 
foams worldwide   
 assess in-vitro (using sections of GSV excised from patients undergoing 
varicose vein surgery) the histological effects of proprietary (STD and 
Polidocanol) foam sclerosants on vein wall integrity, to ascertain the 
optimal proprietary sclerosant  
 assess in-vitro the histological effects of constituent parts of the 
proprietary sclerosant foams on vein wall integrity, to ascertain the most 
active ingredient 
 assess in-vitro the histological effects of ‘longer-lasting’ foam sclerosants 
on vein wall integrity, to ascertain that producing maximal effect on the 
vein wall  
 assess in-vitro the histological effects of cutting balloons upon vein wall 
integrity, to assess their possibility as mono-therapy for varicose veins or 
as adjuvant to enhance foam sclerotherapy. 
 Identify the most promising treatment(s) from the above and apply this in 
an animal model 
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1.12.1 WHAT IS THE HALF-LIFE OF FOAMS CURRENTLY USED 
FOR UGFS AND DOES THIS AFFECT EFFICIACY? 
This research focuses on the use of foams for treating truncal varicosities of the 
great or small saphenous systems. As stated previously STD is widely regarded 
as more potent than polidocanol, in the order of 1:3 respectively.152-155 Despite 
the acknowledged difference in potency, the majority of world literature 
(including product literature) recommends a concentration of 3% for both 
sclerosants in the treatment of truncal varicosities.139 236 237 244-246 In a survey of 
members of the Vascular Society of Great Britain and Ireland in 2007, the 
majority of those who responded used 3% (STD or polidocanol) for the 
treatment of truncal varicosities.238   3% is therefore the concentration of each 
sclerosant that were used for studies comparing their relative half-lives.   
Sodium tetradecyl sulphate (STD; Molecular Formula C14H30O4S) is listed on 
PubChem (National Centre for Biotechnology Information; USA) as a sclerosing 
solution.247 PubChem describes STD as an anionic surface-active agent used 
for its wetting properties in industry and used in medicine as an irritant and 
sclerosing agent for haemorrhoids and varicose veins as well as gastric varices, 
oesophageal varices and in peptic ulcer haemorrhage.247 It is made by a 
number of manufacturers most commonly marketed in the UK as Fibro-vein™ 
(STD Pharmaceutical products Ltd, Hereford, UK). 
Polidocanol (Molecular Formula C14H30O2) is listed on PubChem as a detergent 
and sclerosing solution, the former described as purifying or cleansing agents, 
usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-
dissolving) and antimicrobial effects through a surface action that depends on 
possessing both hydrophilic and hydrophobic properties. Polidocanol was first 
synthesised in 1936 and marketed as a topical and local anaesthetic.150 This 
urethane local anaesthetic differs from classic ester and amide anaesthetics 
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agents as it lacks an aromatic ring. The ability of polidocanol to sclerose blood 
vessels without significant damage to surrounding tissues led to its use as a 
sclerosant in the 1960s. In 1967 it was registered in the Federal Republic of 
Germany as aethoxysklerol (Kreussler & Co. GmbH) and is now the only 
sclerosant registered for use in Germany.150 Polidocanol (Asclera injection, 
Bioform Medical Inc, San Mateo, Calif) was approved for use in the USA in 
2010.104 Though currently unlicensed in this country, polidocanol is certainly 
used by a number of practitioners in the UK.238   
A comparison of the chemical structure of polidocanol and STD in Figures 1-1, 
1-2 and 1-3 shows that the polymer backbone of polidocanol is longer than 
STD. This tends to provide greater stabilisation of polidocanol foam through 
steric and electric repulsion at the gas-liquid interface, reducing coalescence 
and disproportionation. 
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Figure 1.3: Chemical structures of polidocanol and sodium tetradecyl 
sulphate.  
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Figure 1.4: Pubchem images of STD in 2D and 3D 
 
 
Figure 1.5: Pubchem images of polidocanol in 2D and 3D 
 
UGFS as the name implies utilises sclerotherapy in the form of foam to enhance 
the efficacy of sclerotherapy by increasing the surface area of the treated vein 
contacted by the sclerosant. A question previously unanswered in the literature 
is how the half-lives of the two most commonly used sclerosants world-wide 
compare and similarly how they compare in in-vitro testing regarding damage to 
the vein wall.  The first of these questions is answered in chapter three and the 
second in chapter four with the method of experimentation presented below.  
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Foam is commonly made from gas and liquid in a ratio of four parts of gas and 
one of liquid sclerosant. This is based on physical characteristics produced by 
different ratios of foam.  
The most commonly used technique for preparation of sclerosant foams was 
developed by Tessari et alusing a three-way-tap with ratios from 1:3 to 1:5, 
sclerosant to air (or using physiological gas e.g. CO2 & O2 mixture).
104 139 248 The 
most commonly used gas in clinical practice is room air.249 At the 2003 
European Consensus Meeting on Foam Sclerotherapy, sclerosing foam was 
defined as a dispersion of gas in a liquid sclerosing solution where the gas is 
physiologically tolerated at therapeutic doses.250 The 2nd European Consensus 
Meeting on Foam Sclerotherapy 2006 stated that “The preferred ratio of liquid to 
gas for preparing sclerosant foam for all indications is 1:4 (1 part liquid : 4 parts 
gas).”139 However, much of the evidence upon which they based this decision 
was research done using polidocanol and a modification of Tessari’s, Tourbillion 
technique.139 251 252 They also state that for large truncal vessels a viscous foam 
should be utilised.139 Previous research at Leeds Vascular Institute has tested 
ratios of 1:3 and 1:4 liquid (1% and 3%) STD:air and found for both 
concentrations of STD, 1:3 forms more stable foam than 1:4. 3% STD or 
polidocanol foams have a longer half-life than their respective 1% foams. This is 
expected due to the intrinsic surfactant properties of these detergents.253 Hence 
for the purposes of the foam stability studies in this research, foam was 
prepared using Tessari’s technique (1:3 ratio of sclerosant : air) with 20 passes 
through a double syringe system (Figure 2.4) and immediately transferred to a 
preheated (37°C) 15 ml graduated polyester tube (Figure 2.5). 
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Previous research on foam stability and degradation was performed at Leeds 
Vascular Institute in conjunction with The Institute for Pharmaceutical Innovation 
at Bradford University. This confirmed that the rate of destabilisation of these 
foams is non-linear displaying periods of apparent stability before sudden 
decreases in the volume of foam as demonstrated by the experimental data in 
Figure 2.6 showing the degradation of three runs of STD 1% foam. McMaster 
describes this from the perspective of liquid reformation, which though stated to 
be predictable, does not progress at a constant rate.254  
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Figure 1.6: Volume vs. Time for fibro-vein™ (STD) 1% (1:3), results 
demonstrate the foam destabilisation is non-linear 
 
Further complications arise because the initial volumes of foam often vary 
between experiments. The rate of change (in the foam volume) cannot therefore 
be used as a measure of foam stability.  Instead the experimental data was 
converted to percentage (of foam remaining) as a function of time with the time 
taken for a 10% decrease in the overall volume (T90) and for a 50% decrease in 
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the overall  volume of the foam / liquid (T50) used as a measure of the foam 
stability, with higher values meaning a more stable foam.  A high foam fraction 
is however essential for maximum effectiveness of Fibro-Vein™ (STD), in order 
to maintain contact with the vein walls. This is not necessarily indicated by a 
high value for T50. T90 was therefore also calculated as an additional indicator of 
foam stability.   
We determined the T90 and T50 values for STD (Fibro-Vein™) and polidocanol 
(Sclerovein®) 3% solution for comparison. The raw experimental data does not 
allow comparison of the results. All experimental data was therefore converted 
to percentage (of foam) vs. time data. The time taken for the volume of foam to 
drop by 10% (T90) and 50% (T50) were then calculated from the converted 
experimental data. These are similar values sought in other research into foam 
degradation. The T50 should not be confused with the term “Foam half time” 
(FHT) which is the time (in seconds) it takes to form a liquid layer at the bottom 
of the foam column that is half the volume of the original liquid.253   
A hypothetical plot of the percentage volume of the foam (X) against time (T) is 
shown in Figure 1.7. The value z is the cut off value for the percentage of the 
foam, i.e. 50% or 90% and Tz is the time taken for the volume of the foam to 
reach this percentage. It is this value which is used for evaluation of the stability 
of the foam where z equals 90% and 50% of foam volume at 30 seconds. 
(Volume at 0 seconds is not used as the foam takes time to settle). 
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Figure 1.7: A hypothetical plot of the percentage volume of the foam (x) 
against time (t).  
X>z,X≤z  and T>z,T≤z are known experimental points whose values are closest to 
z (and Tz) (z must fall between these values). X>z is the percentage of foam 
greater than Z and T>z is the corresponding time as shown in Figure 2.7, while 
X≤z is the percentage of foam lower or equal to Z and T≤z is the corresponding 
time i.e. the time taken for the volume of the foam to drop before Z. From these 
values the gradient of the graph between point A and point B can be calculated 
using equation 1. 
EQUATION 1 
 
From the gradient of the graph the time taken (∆t) for the volume of the foam to 
drop from Z (90%) to X≤z (86.36%) can be calculated using equation 2. 
EQUATION 2 
 
This value can then be used to calculate Tz using EQUATION 3.  In terms of 
experimental data, an excel spread sheet template was used to perform the 
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necessary calculations, however X>z, X≤z and T>z, T≤z still had to be identified for 
each experimental run as this function is not available with excel. 
EQUATION 3 
 
 
Figure 2.8 shows a cross section of a results template, the experimental values 
for calculating Tz where z equals 90% are shown. As can be seen from the table 
these values are selected because z falls within the associated range for the 
percentage volume. The values for T>z and T≤z are the corresponding values for 
time.  An example of the calculations using the values from Figure 2.8 is given 
below: 
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Figure 1.8: Section of results spread sheet showing values used to 
calculate Tz where z is 90%. 
As Tz is a calculated value it should be noted that this value is an approximation 
and that the experimental value may differ slightly.   
This method was used to calculate T90 and T50 for both sclerosants via 10 runs 
used per foam.  Median values (with inter-quartile ranges) were used for 
statistical analysis.  
In summary, the rate of destabilisation of foam is non-linear with periods of 
apparent stability before sudden decreases in the volume of foam.254 Further, 
the initial volume of the foam varied slightly between experiments. Thus, rate of 
change in foam volume cannot be used as a measure of foam stability.  Instead 
the experimental data was converted to percentage of foam remaining against 
time with the time taken for a 10% (T90) and 50% (T50) decrease in volume used 
as a measure of foam stability.  
Hence the methods details experiments undertaken to compare the half-lives of 
the two foams.  
1.12.2 DOES INCREASING THE HALF-LIFE OF FOAM IMPROVE 
ITS EFFICACY? 
We hypothesize that foam sclerosants with a longer foam half-life are more 
active against the vein wall and therefore potentially more efficacious. Longer-
lasting foams were previously developed through Leeds Vascular Institute in 
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conjunction with the Institute for Pharmaceutical Innovation at Bradford 
University. These included STD 3%/pluronic 5%, STD 3%/carbomer 0.45%, and 
STD 3%/xanthum 0.15%. Polymers such as pluronic cause stabilisation of 
foams through electric and steric repulsion.255 Xanthan gum and carbomer are 
viscosity enhancing agents which aid foam stabilisation by increasing the 
viscosity of the continuous phase which inhibits the key mechanisms of 
destabilisation – drainage, coalescence and disproportionation.256 These 
products were the most promising of many longer-lasting sclerosant foams 
tested at Bradford University and the strengths used were those which provided 
the longest lasting foams.  
These foams were used in experiments detailed in chapter two to test the 
hypothesis that longer-lasting foams would be more efficacious in the treatment 
of varicose veins.  
1.12.3 DO CUTTING BALLOONS INCREASE THE EFFICACY OF 
UGFS? 
Previous research at Leeds Vascular Institute demonstrated that despite 
Fogarty balloon denudation increasing the overall endothelial cell loss when 
used as an adjunct to foam sclerotherapy, it did not increase the depth of injury 
caused by the foam.16 Those experiments used 5 Fr LeMaitre® embolectomy 
catheters with a balloon diameter 13.0 mm.  
This thesis examines the potential for cutting balloons, those licensed for 
arterial work, to act as adjuncts to UGFS.  Cutting balloons have three or four 
atherotomes (microsurgical blades) mounted along the length of a non-
complaint balloon, which expand radially and deliver longitudinal incisions to the 
vessel, designed to relieve the radial stress of arterial atherosclerotic stenoses. 
The cutting balloon is designed to protect the vessel from the edges of the 
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atherotomes when it is deflated minimising the risk of trauma to the vessel as 
the balloon is passed to and from a target lesion. We hypothesise that cutting 
balloon atherotomes used immediately prior to foam sclerotherapy will cut the 
GVS media in up to four places (depending on the balloon design) allowing 
influx of foam sclerosant deeper into the vein media, thereby increasing the 
damage caused by the foam sclerosant and thereby enhance its efficacy. 
1.12.4 HUMAN VARICOSE VEIN MODEL 
It is widely believed that to effectively sclerose (fibrose) venous tissue, 
sclerosants must produce total endothelial destruction resulting in the exposure 
of subendothelial collagen fibres (an obligate step in thrombogenesis) to 
sclerosants, which initiates the intrinsic pathway of blood coagulation by 
activating factor XII.257 The purpose of sclerotherapy is not merely to achieve 
thrombosis of the vessel, which per se may be amenable to recanalisation, but 
definitive transformation into a fibrous cord.234 The latter is more likely to occur 
where damage inflicted upon the vein wall initially occurs not only to the 
endothelium but to the subendothelial medial layer of vein wall. This is the case 
with other minimally invasive treatments including endovenous laser ablation 
(EVLA) and radiofrequency ablation (RFA).232 233 258-260 Foam sclerotherapy has 
early recanalisation rates of up to 32% as well as poor medium to long-term 
occlusion rates compared to these other minimally invasive treatments.261-263 
Therefore one might expect that the more localised superficial venous damage 
caused by detergent foam, the more likely it is have better early and durable 
occlusion rates. Obviously a dose response curve is also likely whereby this 
benefit is limited by production of side-effects. Much work has been published 
on the in-vitro effects of detergent sclerotherapy agents on coagulation, cultured 
cell lines or animal studies or using normal arterial or superficial venous 
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tissue.239-241 264-266 However there is minimal data on the effect on human 
varicose vein tissue.15 16 There is no literature comparing the effects of STD to 
polidocanol, the two most widely used sclerosants worldwide, in human 
varicose vein tissue in-vitro.   
The majority of experimentation for testing treatments for varicose veins is 
performed on in-vitro cell lines or in-vivo in animal models.131 232 233 239 240 In-vivo 
animal models are expensive and ideally reserved until preliminary research in 
other models directs the most useful animal studies, for monetary and ethical 
reasons. There is remarkably little published research using human vein in-vitro 
models for assessing varicose vein treatments.185 Rotter et aldescribed a model 
using vein left over from cardiac bypass surgery.241  This has the disadvantage 
of having a different make up to GSV in patients with varicose veins as it is 
recognised that such veins have different medial collagen type and deposition. 
A model for varicose vein experimentation was developed in recent years at 
Leeds Vascular Institute which uses sections of proximal GSV dissected out 
pre-stripping at varicose vein surgery. This model has the advantage of using 
GSV tissue from patients with proven varicose veins on clinical and duplex 
examination with all having documented significant SFJ incompetence.16  
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1.10.5 ANIMAL VEIN MODEL 
Upon obtaining results from the above experimentation the aim is to test any 
promising modifications of UFGS and related adjuncts in an animal model. The 
objective of this research section will be to ascertain the haemodynamic, 
ultrasonographic and histopathological changes of superficial veins treated with 
licensed foam sclerotherapy, “long-lasting” (unlicensed for human use) foam 
sclerotherapy and endovenous catheter balloon (fogarty and cutting) therapy 
(unlicensed for human use), versus control. The study endpoints were ideally to 
be: 
1. Haemodynamic changes: patency, reflux and ultrasonographic changes 
2. Histopathological analysis: degree and  extent of tunica intima and media 
damage  
 
This research focuses on the treatment of GSV truncal varicosities therefore 
directing treatment at the GSV. An animal model was sought that would mimic 
human GSV. It is well documented that varicose veins are a disease of homo-
sapiens and do not naturally occur in other animals.267 Anatomical and clinical 
studies in humans indicate that in the presence of varices, not only is the SFJ 
competent in >50% of cases,215 216 but moreover the GSV is often partially or 
wholly competent.9 217 The majority of studies of patients with primary 
varicosities have revealed a complete absence of varicosities within the 
saphenous trunks or at most segmental dilatations.67 89 90 Labropoulos et 
alfound a prevalence of varicosities in either or both the GSV and SSV of 
<7%.10 Hence for the purposes of this research it was decided not to attempt to 
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create an incompetent animal model as has been previously used in other 
related research.267  
A suitable animal model required a superficial truncal vein which entered the 
deep venous system in a similar fashion to the SFJ in humans. It requires a 
similar structure and dimension to human superficial truncal veins. It also 
requires to be affected by gravity i.e. vertical leg vein as opposed to veins that 
have been used in some animal models, e.g. superficial epigastric veins, which 
are horizontal to the ground and would not be subject to the same gravitational 
forces or those of compression etc caused by movements of the leg and calf 
and thigh muscle groups.131  Animal models previously used for varicose vein 
treatment research include pigs, sheep and goats.131 267 130 233 268 Overarching 
many of the requirements of the animal vein model necessary were the fact the 
animal needed to be amenable to having procedures performed whether they 
were under sedation or general anaesthetic and therefore that the animal would 
withstand these procedures. As well as requiring the veins and animal to be of a 
suitable size at initial treatment, it was also necessary that the animal be of an 
appropriate size after an adequate time to allow response to treatment. An 
interval of 12 weeks / 3 months was chosen as the time interval before treated 
vein segments were to be harvested.  
The assessment of suitable models involved practical experimentation and is 
included in chapter two. 
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1.13 RESEARCH QUESTION; AIMS AND OBJECTIVES 
Despite 150 years of unregulated human experimentation encompassing a 
range of more or less toxic agents, the “perfect sclerosant,” free from 
complications and causing permanent vein occlusion has not been found. All 
sclerosants represent a compromise between efficacy and toxicity.150 UGFS has 
vastly improved the efficacy of this treatment and shows much promise and 
versatility in the treatment of varicose veins. It can be used to treat thread veins 
and superficial as well as truncal related varicose veins. It is cheap, quick, 
relatively easily performed and easily repeatable. It remains to be seen whether 
clinicians and health services as well as patients, deem the current requirement 
for some patients to require repeat treatments as being preferable to other 
treatments that at least currently appear to need fewer treatments to achieve 
“completion”. If it is possible to improve the longevity of results achieved with 
UGFS it would surely represent a much more favourable treatment option for 
patients, clinicians and health services alike.  
This thesis examines the hypothesis that if the foam itself can be made to last 
longer or an additional synergistic treatment be performed in the treated vein 
segment this should allow increased time for delivery or penetration of the 
active ingredient into the vein wall thereby hopefully improving the efficacy of 
UGFS.  
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We hypothesise that it may be possible to improve its efficacy by: 
 
1. increasing the half-life of the foam 
2. using adjuncts to synergistically assist the activity of the foam 
 
Modified longer lasting foams have been developed at Leeds Vascular Institute 
and this thesis tests each of these longer lasting foams in an in-vitro human 
model with the aim to test the best performing in an in-vivo animal model. 
Similarly balloon denudation has been assessed at Leeds Vascular Institute as 
an adjunct to UGFS, and this work shall be continued with cutting balloons and 
again tested in an in-vitro human model and in an in-vivo animal model. 
Before performing these tasks it is necessary to review our current knowledge 
about sclerosants foams with respect to: 
1. their longevity 
2. what injury do they inflict upon the veins 
3. which sclerosant appears to inflict the most damage   
This study is designed to complete the aforementioned research at Leeds 
Vascular Institute providing information on the activity of proprietary foams on 
the vein wall, as well as that of Longer lasting sclerosant foams and that of 
balloons including cutting balloon adjuncts. 
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CHAPTER II 
METHODS 
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2 METHODS 
This chapter presents the methods used in all experiments conducted as part of 
this research.  
2.1 IN-VITRO FOAM HALF-LIFE STUDIES 
This research focuses on the use of foams for treating truncal varicosities of the 
great or small saphenous systems. Despite the acknowledged difference in 
potency, the majority of world literature (including product literature) 
recommends a concentration of 3% for both sclerosants in the treatment of 
truncal varicosities.139 236 237 244-246 3% is therefore the concentration of each 
sclerosant that were used for studies comparing their relative half-lives.   
Previous research on foam stability and degradation was performed at Leeds 
Vascular Institute in conjunction with The Institute for Pharmaceutical Innovation 
at Bradford University. This confirmed that the rate of destabilisation of these 
foams is non-linear displaying periods of apparent stability before sudden 
decreases in the volume of foam. A problem with these experiments was that 
the initial volume of foam often varied between experiments. The rate of change 
(in the foam volume) cannot therefore be used as a measure of foam stability.  
Instead the experimental data was converted to percentage (of foam remaining) 
as a function of time with the time taken for a 10% (T90) or 50% decrease in the 
overall volume of the foam / liquid (T50) used as a measure of the foam stability, 
with higher values meaning a more stable foam.  A high foam fraction is 
considered essential for maximum effectiveness of Fibro-Vein™ (STD), in order 
to maintain contact with the vein walls. This is not necessarily indicated by a 
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high value for T50. T90 was therefore also calculated as an additional indicator of 
foam stability.   
We determined the T90 and T50 values for STD (Fibro-Vein™) and Polidocanol 
(Sclerovein®) 3% solution for comparison. The experimental data was converted 
to the percentage (of foam) vs. time data, as indicated above. The time taken 
for the volume of foam to drop by 10% (T90) and 50% (T50) were then calculated 
from the converted experimental data. These are similar parameters to those 
measured in other research into foam degradation. The T50 should not be 
confused with the term “Foam half time” (FHT) which is the time (in seconds) it 
takes to form a liquid layer at the bottom of the foam column that is half the 
volume of the original liquid.253   
Thus the initial foam volume was recorded and subsequent readings were taken 
every 30 seconds until the volume of the foam fell below 25% of its original 
volume. Experiments were conducted at 37oC (Stuart Incubator S16D, Bibby 
Scientific Ltd, Staffordshire, UK), (Figure 2.1). 10 runs were performed for both 
3% STD and 3% polidocanol foams.  
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2.1.1 FOAM HALF-LIFE EXPERIMENTAL METHOD  
3% STD and 3% polidocanol foams were produced using the Tessari technique 
with a ratio of 1:3 (1 part liquid to 3 parts air) (Tessari 2000): 
 2mL of liquid 3% STD (Fibro-vein®, STD Pharmaceutical Products Ltd, 
England) or polidocanol (Sclerovein, Resinag Pharmaceutical and Health 
Care Products, Switzerland) drawn into the first of two 10mL syringes 
(BD Elastipac, Becton Dickinson Infusion Therapy, Helsingborg, 
Sweden) using an 18 gauge drawing up needle (Terumo Medical 
Products, USA). 
 6mLs of air drawn into the second syringe. 
 Syringes connected at 90o three-way tap (BD connecta™, Becton 
Dickinson Infusion Therapy, Helsingborg, Sweden)  
 Contents mixed to produce foam by 20 passes of each syringe plunger. 
(Figure 2.2) 
 
2mL of liquid was used to produce foam in 10mL syringes. This volume was 
selected in order to facilitate recording of foam volumes during the experiments. 
On completion the foam was transferred to a preheated 15mL graduated 
polyester tube. The initial foam volume was recorded and subsequent readings 
were taken every 30 seconds until the remaining volume of the foam fell below 
25% of its original volume. (Figure 2.3) All experiments were conducted at 37 oC 
using a Stuart Incubator (Bibby Scientific Ltd, Staffordshire UK). 
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Figure 2.1: Stuart Incubator S16D (Bibby Scientific Ltd, Staffordshire, UK), 
At 37oC 
 
 
Figure 2.2: Foam preparation for stability studies; Tessari’s  technique 1:3 
sclerosant: air, 20 passes via fully open three way tap without filter. 
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Figure 2.3:pre-heated graduated polyester tube (incubator at 37°c) 
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2.2 IN-VITRO HUMAN GSV EXPERIMENTS 
Very little literature exists examining the effects of sclerotherapy in-vitro, foam 
or liquid, on human vein wall. Beyond this the basis of this thesis was to 
examine whether foam sclerosants with a longer foam half-life inflicted a greater 
injury on the vein wall and thus be potentially more efficacious. The experiments 
detailed below display the method used to obtain human GSV to allow in-vitro 
experimentation. Foam sclerosants including the two proprietary agents most 
commonly used world-wide were tested using our in-vitro experimental model.  
Longer-lasting foams developed through Leeds Vascular Institute in conjunction 
with the Institute for Pharmaceutical Innovation at Bradford University were 
developed using the experimental model described. These included 3% STD 
and 5% pluronic, 3% STD and 0.45% carbomer and 3% STD and 0.15% 
xanthum, each of which was tested for 5 and 15 minutes as per section 2.2.2. 
Polymers such as pluronic cause stabilisation of foams through electric and 
steric repulsion.255 Xanthan gum and carbomer are viscosity enhancing agents 
which aid foam stabilisation by increasing the viscosity of the continuous phase 
which inhibits the key mechanisms of destabilisation – drainage, coalescence 
and disproportionation.256 These products were the most promising regarding 
their longevity, of many longer-lasting sclerosant foams tested at Bradford 
University and the strengths used were those which provided the longest lasting 
foams. It should be noted that addition of stabilising agents reduces the strength 
of the sclerosant. The proportions are detailed in Table 2.1. Hence the actual 
strength of STD in each of the products is 2.857% STD and 5% Pluronic, 
2.988% STD and 0.4% Carbomer and 2.995% STD and 0.15% xanthum. 
Experiments were carried out for 5 and 15 minutes each as per section 2.2.2. 
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Table 2.1: Relative strength of “3%” STD in longer-lasting foams produced 
at Bradford institute for pharmaceutical innovation  
 
2.2.1 PATIENT RECRUITMENT 
Patients with primary varicose veins with documented ultrasound evidence of 
SFJ incompetence and GSV reflux, listed for surgery (SFJ ligation and GSV 
stripping) were approached prior to surgery. All participants were provided with 
an information sheet and written informed consent was obtained to allow 
laboratory analysis on a segment of GSV removed at surgery and for a blood 
 % additive Dosage of STD in 3% solution after additive 
 0.1 2.997 
Xanthum 0.15 2.995 
 0.2 2.996 
 0.3 2.991 
Carbomer 0.4 2.988 
 0.5 2.985 
 1 2.970 
 2 2.941 
 3 2.912 
 4 2.884 
Pluronic 5 2.857 
 6 2.830 
 7 2.803 
 8 2.777 
 9 2.752 
 10 2.727 
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sample to be taken for use during experiments (Appendix I). Ethical approval 
was granted by the local research and ethics committee. 
2.2.2 HARVESTING OF HUMAN GSV FOR IN-VITRO EXPERIMENTS 
In summary a groin skin crease incision was made medial to the femoral pulse, 
the superficial fascia incised and the GSV identified. After ligation and division 
of minor tributaries, the SFJ was identified and standard SFJ ligation was 
performed.  In-vitro experiments required a 3-5cm length of proximal GSV to act 
both as test and control section. Upon disconnection of the SFJ this proximal 
section of the GSV was excised with minimal trauma and instrumentation during 
SFJ ligation prior to placement of the pin stripper in order to minimise the risk of 
mechanical injury (Figure 2.4). The use of diathermy was avoided. Once 
harvested, (Figure 2.5) the section was divided into two; one half test, the other 
half control segment.  
A heparinised syringe with 22Gauge needle was used to extract blood from the 
distal GSV prior to stripping. This was used to control for pressure effects in 
controls and for tissue preservation (Figure 2.6). 
Experiments were performed on the vein segment in a side-room off the 
operating theatre in order to minimise the time between excision and 
experimentation. 
 
Figure 2.4: Dissection of the proximal gsv using minimal instrumentation 
to obtain a 3-5cm segment  
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Figure 2.5: 3-5cm segment of proximal GSV to be divided into test and 
control segment 
 
 
Figure 2.6: Heparinised syringe used to extract blood (for controls and 
tissue preservation) from distal GSV prior to stripping  
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2.2.3 PROTOCOL FOR IN-VITRO EXPERIMENT TECHNIQUE FOR 
COMPARISON OF TESTS CHEMICALS WITH CONTROLS 
 Vascutek® clip or small artery clip placed at one end of the test specimen 
to occlude it.  
 Foam produced using the Tessari technique (Figure 2.7). 
 0.5mL of liquid sclerosant drawn into the first of two 2mL syringes (BD 
Elastipac, Becton Dickinson Infusion Therapy, Helsingborg, Sweden) 
using an 18 gauge drawing up needle (Terumo Medical Products, USA). 
 1.5mLs of air drawn into the second syringe. 
 Syringes connected at 90o three-way tap (BD connecta™, Becton 
Dickinson Infusion Therapy, Helsingborg, Sweden)  
 Contents mixed to produce foam by 20 passes of each syringe plunger. 
 Foam placed in the lumen of the vein specimen via a foreshortened 20 
Gauge IV cannulae (B Braun) with finger versus thumb pressure 
occluding the open end of the vein around the cannula (Figure 2.8).  
 A second clip is placed to occlude the opposite end of the vein specimen 
(Figure 2.9). Foam (or other test substance depending on the 
experiment; all test liquids were put through the Tessari technique) left 
in-situ for 5 or 15 minutes depending on the experiment.  
 Control sections were simultaneously filled with heparinised blood 
(Figure 2.6) to control for pressure and mechanical effects.  
 Test and control sections were simultaneously placed in 2-5mLs of 
patient’s heparinised blood and left in-situ for either 5 or 15 minutes 
depending on the experiment.  
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 After the allotted time the lumens were rinsed with 2 – 3 mLs heparinised 
blood and the centre segments, remote from the clips to prevent 
inclusion of traumatised vein, sectioned for histological fixation (Figure 
2.10).  
Five vein segments were collected per group for each of the products tested. 
This figure was derived from previous research at Leeds Vascular Institute 
which indicated that five vein samples would give an accurate assessment of a 
given product whilst allowing for the large number of products to be tested 
within an appropriate time frame obtaining the high number of patients required 
to enable completion of the complete research project in the allotted research 
period. Previous in-vitro experimentation with foam sclerotherapy undertaken at 
Leeds was based on experiments lasting 2 minutes. However, despite the fact 
that these time frames, especially 15 minutes, are never likely to be achieved 
with in-vivo use of this treatment, it was felt that 5 and more-so 15 minute 
experiments were necessary to discover if prolonged sclerosant foam, vein 
lumen contact, conferred any conceivable benefit to the efficacy of foam 
sclerotherapy. 
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Figure 2.7: Tessari foam made using fully opened 3-way tap without filter. 
Shorthened 20G iv cannula (B Braun) for atraumatic insertion into test 
segment  
 
 
Figure 2.8: Foam made via the Tessari technique being injected into a test 
segment of vein with one end closed with a small artery clip 
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Figure 2.9: control vein segment (containing heparinised blood) and test 
vein segment containing operator “blinded” foam.  
 
 
Figure 2.10: central vein segment (remote from the clips to prevent 
inclusion of traumatised vein) sectioned for histological fixation 
 
Specimens were immediately fixed in 10% buffered formaldehyde (Figure 2.11). 
Each case was allocated a random number (from a computerised random 
number generator) to ensure blinding during histological analysis. 
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Figure 2.11: vein specimens (allotted a random number to maintain 
blinding) immediately fixed in 10% buffered formaldehyde.  
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2.2.4 ASSESSMENT OF EXPERIMENTAL TECHNIQUE: 
EXAMINATION OF THE HISTOLOGICAL EFFECTS OF 
HEPARINISED BLOOD CONTROL VERSUS NORMAL SALINE  
 
In order to assess this experimental technique and the control model, the 
histological effects on the vein wall of heparinised blood controls were 
compared to those of normal saline. However experimentation was performed 
as per all subsequent experiments except that in this case 10 samples (each 
with test [heparinised blood] and control [normal saline]) were tested for the 15 
minute time frame only, as per protocol in section 2.2.2. 
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2.2.5 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
PROPRIETARY FOAM (3% STD AND 3% POLIDOCANOL) 
SCLEROSANTS ON IN-VITRO GSV WALL INTEGRITY 
 
3% STD and 3% polidocanol (Figure 2.12) foams were used on the test 
segments. Experiments were carried out for 5 and 15 minutes each as per 
protocol in section 2.2.2.  
 
 
Figure 2.12: 3% STD as Fibro-vein™ (STD pharmaceutical products Ltd, 
England), 3% polidocanol  as Sclerovein (Resinag Pharmaceutical And 
Health Care Products, Switzerland) 
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2.2.6 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
CONSTITUENT PARTS OF THE PROPRIETARY SCLEROSANT 
FOAMS ON IN-VITRO GSV WALL INTEGRITY, TO ASCERTAIN 
THE MOST ACTIVE INGREDIENT  
 
The constituent parts of proprietary 3% STD foam were applied to the test 
segments. These were buffered 3% STD alone and 2% benzyl alcohol. 
Experiments were carried out for 5 and 15 minutes each as per protocol in 
section 2.2.2. Experimentation was not undertaken on the constituent parts of 
polidocanol as results of vein wall damage showed that polidocanol did not 
damage the vein media.  
 
2.2.7 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
‘LONGER-LASTING’ FOAM SCLEROSANTS ON IN-VITRO GSV 
WALL INTEGRITY, TO ASCERTAIN THAT PRODUCING 
MAXIMAL EFFECT ON THE VEIN WALL 
 
The “longer-lasting” 3% STD foams included STD 3% and pluronic 5%, STD 3% 
and carbomer 0.4%, and STD 3% and xanthum 0.15%. Results revealed that 
STD 3% and xanthum 0.15% caused a greater degree of injury than the other 
two longer-lasting foams hence its constituent parts were assessed individually. 
These were phosphate buffer pH 7.6, normal saline 0.9% and buffered xanthum 
alone 5%. Experiments were carried out for 5 and 15 minutes each as per 
protocol in section 2.2.2. 
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2.2.8 ASSESSMENT OF CUTTING BALLOONS FOR USE AS MONO-
THERAPY OR ADJUVANT TREATMENT WITH FOAM 
SCLEROTHERAPY FOR TREATMENT OF TRUNCAL 
VARICOSE VEINS 
 
Due to cost implications and initially to examine our hypothesis, cutting balloons 
previously used for arterial angioplasty were tested on in-vitro GSV sections 
obtained as per section 2.2.2. Test and control segments were similarly 
separated initially. Balloon sizes over 4mm diameter were used as these have a 
minimum circumference of 12.56mm.  Respective diameters of balloons used 
were: 4mm = 12.56mm circumference; 5mm = 15.7mm circumference; 6 mm = 
18.85mm circumference and 7mm = 21.99 mm circumference. Cutting balloons 
over 4mm also have four atherotomes as opposed to cutting balloons smaller 
than 4mm diameter, which have only three. Atherotomes measure 15mm to 
20mm in length by 0.25mm in height extending 0.127mm from the balloon when 
it is inflated. 
Available balloons (Peripheral Cutting Balloons; Boston Scientific, USA) were 
4.0mm/1.5cm (that is 4mm balloon diameter when inflated to recommended 
pressure)/1.5cm (length of blades running longitudinally on the surface of the 
balloon), 5.0mm/2.0cm (Figure 2.20), 6.0mm/2.0cm and 7.0mm/2.0cm. 
 
Each experiment in this group involved 5 GSV segments (each with test and 
control). The test segments were wrapped inside a saline soaked surgical swab 
held snuggly with finger thumb opposition beside the vein segment/balloon in 
order to mimic resistance of the subcutaneous fat as would be the case in-vitro. 
Other models designed to provide external pressure were assessed but were 
unsuitable. Cutting balloons utilised for these experiments were already used 
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once (on arteries) hence they were used a maximum of twice more to prevent 
significant blunting of their blades. As vein segments are of differing dimension 
and so too are cutting balloons as recorded above, balloons were matched to 
vein segments according to vein diameter.  
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2.2.9 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF CUTTING 
BALLOONS ALONE ON IN-VITRO GSV WALL INTEGRITY 
 
Experiments involved: 
1. Cutting balloon (matched to size of vein) inflated in lumen of test vein 
segment for 10 seconds then deflated and removed. 
Inflation was performed using an Encore™26 Inflation Device (Boston 
Scientific, USA; Figure 2.19) to a pressure of 6.0 Atmospheres (ATM) / 
608 kilo Pascals (kPa) (pressure recommended by the manufacturers for 
each of the balloons) 
2. Cutting balloon (matched to size of vein) inflated to a pressure of 6.0 
ATM / 608 kPa in lumen of test vein segment for 10 seconds. Balloon 
then withdrawn (pulled) from inside the test segment whilst inflated. 
deBakey (non-traumatic forceps) placed at one end of the specimen 
used to anchor the vein to allow withdrawal of the cutting balloon whilst 
inflated.  
 
2.2.10 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
CUTTING BALLOONS IN COMBINATION WITH PROPRIETARY 
FOAM SCLEROTHERAPY ON IN-VITRO GSV WALL INTEGRITY 
  
Experiment: 
1. Cutting balloon inflated to a pressure of 6.0 ATM / 608 kPa in lumen of 
test vein segment for 10 seconds. Balloon then withdrawn (pulled) from 
inside the test segment whilst inflated. deBakey (non-traumatic forceps) 
placed at one end of the specimen used to anchor the vein to allow 
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withdrawal of the cutting balloon whilst inflated. Then 3% STD or 3% 
Polidocanol foam was placed (as per experiments in 2.2.2) into the test 
segment, remaining in the lumen for 5mins. Controls for this experiment 
had the same balloon treatment as test segments and were then filled 
with heparinised blood to control for pressure as per previous 
experiments.  
 
 
Figure 2.13: Encore™26 Inflation Device (Boston Scientific, USA)  
 
Figure 2.14: 5.0mm/2.0cm Peripheral Cutting Balloon (Boston Scientific, 
USA) 
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Figure 2.15: (Experiment 2.2.9.1) cutting balloon placed un-inflated into 
the vein test segment 
 
Figure 2.16: (Experiment 2.2.9.1) vein segment wrapped in normal saline 
soaked surgical swab to mimic resistance of the subcutaneous fat 
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Figure 2.17: (Experiment 2.2.9) balloon inflated for 10 seconds to 6 atm 
with swab held snuggly at side of vein/balloon. Control segments filled 
with heparinised blood 
 
 
Figure 2.18: (experiment 2.2.9.2) as for experiment 1 but balloon inflated 
inside swab then vein segment anchored with deBakey forcep and inflated 
balloon withdrawn. Control segments filled with heparinised blood   
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Figure 2.19: (experiment 2.2.9.2) vein segment anchored with deBakey 
forcep and inflated (6atm) cutting balloon withdrawn 
 
 
Figure 2.20: (experiment 2.2.10) as per experiment 2. Then test segment 
filled with either 3% STD or 3% polidocanol for 5 mins. After the same 
balloon treatment, controls were filled with heparinised blood 
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2.3 IN-VIVO ANIMAL STUDIES 
2.3.1 ASSESSMENT OF A SUITABLE ANIMAL MODEL 
 
Clinical team members at a Home Office accredited animal research facility 
were consulted regarding their knowledge on the matter of choice of animal 
model with the published literature also taken into account. A porcine or sheep 
model was suggested due to their availability, animal husbandry requirements, 
size of animal and their respective veins, limbs and anatomy. Appropriate 
thickness and accessibility through tissue overlying the vein segments was also 
taken into account. This was necessary for USS, experimental treatments and 
dissection. Preliminary visits to the facility by the lead researcher were 
performed in-order to assess the most favourable of the models. It became 
clear that neither animal model would allow pre-procedure USS, preparation of 
the area with shaving, or experimental treatments to be undertaken, only using 
sedation. Hence the requirement for general anaesthetic was agreed which 
impacted upon the accuracy of USS due to the animals being supine. This 
matter was overcome to an extent by occluding the superficial veins proximally 
with hand pressure and subsequently using USS in the distal vein for the 
purpose of vein identification and assessment of competence. 
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2.3.1.1 ASSESSMENT OF A OVINE MODEL  
 
Sheep were initially assessed as a potential model. Beier et alused sheep 
(female merino land sheep, 24-26kg) fore-limb saphenous vein for research into 
tissue engineered vascularised grafts. In accordance with the very few 
anatomical descriptions depicting the medial aspect of the groin in sheep, they 
refer to this neurovascular bundle in the following as saphenous artery, vein(s), 
and nerve (Figure: 2.21).269 They describe its exposure as requiring little 
muscular dissection as it was constantly found in the epifascial soft tissue layer 
beneath the superficial fascia. They report only sparse side branching of the 
saphenous artery and vein(s) with only marginal diminution of vessel diameter 
from proximal to distal noted. They found the saphenous vessels to constantly 
emerge proximally in the groin by passing through a muscular hiatus, formed by 
the tendinous origins of the sartorious muscle anteriorly and the gracilis muscle 
posteriorly (Figure 2.21). For their graft purposes they found dissectible length 
of the saphenous artery and vein was at least 16 cm, reaching from the groin to 
the knee joint with an average arterial and venous calibre of 2.5–3 mm and 2–
2.5 mm, respectively. In seven out of eight sheep, there was just one 
concomitant vein, whereas one sheep had two saphenous veins. This calibre of 
vein though potentially useful for foam studies was deemed likely too small for 
Fogarty and cutting balloon experiments in this research. The sheep available 
for this research project were of a larger size than those used by Beier et 
alhence examinations of sheep as a potential animal model were undertaken.   
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Animals that were being terminated by lethal injection (Sodium pentobarbital 
120mg/mL) for other studies were given analgesia and subsequently general 
anaesthetic via inhaled gas to enable assessment of their fore and hind-limb 
superficial venous systems using both USS and open surgical dissection. The 
appropriate anatomical sites (medial aspect of all four limbs and their junctions 
with the body) were shaved and USS performed. This investigation proved 
difficult due to the relatively low soft tissue mass within the legs of the sheep 
and due to the fact that the animals were supine. Fore-limb veins were 
impossible to delineate on USS in one animal with only arteries seen and the 
other animal died before any useful information could be obtained on USS from 
its fore-limbs. The largest superficial veins seen on USS (2-3mm) (Figure 2.22) 
originated from the hind limbs but they were deep within pre-abdominal tissue 
(Figure 2.23). These deep areas (Figure 2.23) as well as those which would be 
necessary anatomically for experimental purposes were explored surgically and 
this revealed very small vessels (≤2mm) running as paired veins on each side 
of their respective superficial artery on each hind leg (Figure 2.24) becoming 
3mm diameter at maximum deep in pre-abdominal tissue. One hind-limb vein 
was cannulated with great difficulty with a 2.5Ch Fogarty balloon catheter but 
larger catheters required for the purpose of experimentation could not be 
inserted. In the fore limbs the superficial veins were c.2mm for a length of 
>10cm but the majority of this was traversing deep and next to bone (Figure 
2.25).  This procedure was repeated in two other sheep revealing similar 
anatomy in each (Figure 2.26-2.28).  
  
Beyond these anatomical problems, staff at the animal research facility 
highlighted the fact that sheep are more likely to die under general anaesthetic 
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than the majority of other animals they use for research purposes, usually due 
to cardiac arrhythmias. This coupled with the anatomical problem meant that 
sheep were deemed an unsuitable model for this research purpose.  
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Figure 2.21: anatomy of the sheep’s groin and medial thigh with 
sapheneous artery (1) passing between the gracilis muscle (2) and the 
sartorius muscle (3), accompanied by the saphenous nerve (4). From 
Beier et al269 
 
 
 
Figure 2.22: USS pictures from two posterior abdominal wall/upper hind 
limb junctions in a supine sheep under general anaethetic with proximal 
finger pressure to dilate the veins; artery with paired veins alongside 
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Figure 2.23: sheep 1) posterior abdominal wall/upper hind limb junctions 
in a supine sheep under general anaesthetic being prepared (A) for uss 
and surgery (B) revealing a deep running 3mm vein requiring significant 
dissection.  
 
Figure 2.24: sheep 1) inner hind limb thigh level <1mm veins; running 
each side of artery (A) and vein dissected off artery (B) 
 
  
Figure 2.25 : sheep 1) fore limb superficial vein >10cm length available (A), 
and after deeper dissection with 1mm vein deep to tendon and close to 
bone (B) 
 
A 
B A 
B A 
B 
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Figure 2.26: sheep 2) <1mm hind limb veins  
 
Figure 2.27: sheep 2) 1mm forelimb veins running with artery 
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Figure 2.28: sheep 3) <1mm hind limb veins 
 
 
Figure 2.29: H&E stain of section from front leg of sheep 2 right front leg. 
Deemed unsuitable due to paired small veins (arrows) 
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Figure 2.30: H&E stain of section from neurovascular bundle in sheep 2 
left fore- leg 
 
Figure 2.31: H&E stain of section from sheep 2 left hind limb with smaller 
vessels cf fore-limbs. 
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2.3.1.2 ASSESSMENT OF A PORCINE MODEL  
Pigs were then assessed as a potential animal model. Advice given by the 
faculty at the Home Office accredited animal research facility was that porcine 
superficial veins are similar structurally and anatomically to superficial human 
veins though smaller. Animals of c.50kg were likely to be the minimum size 
required to obtain veins in the order of 4-5mm diameter in the knowledge that 
over an intervening 12 week period these animals could triple their body weight 
rendering any follow-up procedures logistically difficult. Fore-limb veins were 
stated likely to be of most use but hind-limbs could be of a useful size. The staff 
felt that it should be possible to treat a 10cm length of superficial vein in each of 
the four limbs without a significant risk of sclerosant entering the deep venous 
system in great volume. Beyond this they stated that porcine superficial veins 
are reasonably easily accessible for treatment and USS assessment and they 
converge with the deep veins in a similar fashion to human superficial lower 
limb veins. In addition they stated that pigs would have more suitable limbs than 
sheep for comparable bandaging post-procedure as would be performed 
following foam sclerotherapy in humans.  
Jones et alreported in their normal porcine controls (weight c.100kg) that the 
superficial venous tributaries of the thigh of the hind-limbs communicated with 
the saphenous veins via a perforating junction approximately six to eight cm 
distal to the junction with the femoral vein (SFJ).267 They state that the 
saphenous venous drainage comprises two venous channels, one usually 
larger than the other, lying on each side of the saphenous artery and 
communicating with each other via a series of bridging veins. These vessels are 
surrounded by a distinct fascial condensation forming the saphenous bundle 
(Figure 2.33). The saphenous veins remained within the saphenous fascia 
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before penetrating the fascia cribrosa and joining the femoral vein separately. 
Each length of saphenous vein consistently contained eight to 10 bicuspid 
valves preventing reflux from the deep system.267  Again a preliminary study 
was carried out on a pig of the size that could be used for this research. This 
was performed on a pig that was being terminated for other research purposes. 
It was again assessed under general anaesthetic with analgesia, in the supine 
position as the experimental animals would be in this study. Shaving was 
unnecessary in the pig model. USS proved difficult but revealed more 
favourably lying and better sized fore-limb veins (c. 4-5mm) in the animal 
examined. Surgical exploration confirmed this and demonstrated that despite 
the fore-limb veins running deep to thick fibrous tissue, they were accessible 
and not as proximal to bone as in sheep (Figure 2.25 A&B). Surgical exploration 
revealed hind limb veins that were slightly larger than those in the sheep 
however they were still small at ≤2mm. The advantage with their hind limb veins 
versus sheep were that they ran a suitably long course superficially before 
entering deep tissue in the abdomen. Veins in the hind legs were again in pairs 
running with the limb’s main superficial artery as per Jones et al267 (Figure 
2.33). A porcine animal model using superficial epigastric veins has been used 
by others in varicose vein treatment research however this was not considered 
in this case due to the altered gravitational and anatomical effects on this vein in 
pigs (Figure 2.34).131 
Hence a porcine model using all four limb superficial veins was chosen as the 
animal model for this research. Due to the costs involved in an animal model 
the study population in the first instance was two animals (4 veins: one per limb) 
studied over 12 weeks to confirm whether the model is feasible. Should this 
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model prove feasible the initial plan was that further animals could be included 
in the study. 
Animals of a suitable size and weight (50-60kg) were selected on the basis that 
they have 4mm diameter fore-limb superficial veins and c. 2-3mm diameter 
hind-limb superficial veins, the latter of which would likely be used for foam 
studies alone if the veins were unsuitable for balloon experiments. The fore-limb 
veins would likely be suitable for all balloon studies. Animals of this size would 
likely be c.150kg 12 weeks later and at that stage still manageable in the 
research facility. Larger animals would have presented logistical problems, 
likely being unmanageable due to their size and weight.  
 
 
Figure 2.32: Superficial venous anatomy of pig limbs
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Figure 2.33: The porcine saphenous bundle from Jones et al.267 
Transverse en bloc preparation of the saphenous bundle and overlying 
skin, mid thigh. Scale bar equals 3 mm. (b) histological section (Verhoeff’s 
elastic stain) of the same block. (c-d) resin vascular cast of the saphenous 
venous network, demonstrating the relationship of both the superficial (sf) 
and deep fascia (df) to the saphenous fascia (arrow heads). Within the 
saphenous compartment, the saphenous artery (sa) is bordered by the 
saphenous veins (sv). Note the numerous valves (arrows) and 
communicating veins within the saphenous network. 
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Figure 2.34: Superficial Epigastric Veins Used For Cyanoacrylate 
Research In A Porcine Model. From Almedia Et Al.131 
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Figure 2.35: fore limb veins in a pig (a) running deep to a thick fascial 
layer (b) 
 
 
Figure 2.36: hind limb pig veins running paired with an artery and 
accessible for a length >10cm  
 
A B 
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Figure 2.37: H&E stain of section from right fore- limb vein of pig 1 
 
Figure 2.38: H&E stain of section from right hind limb of pig 1  
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2.3.2 ASSESSMENT OF THE THERAPEUTIC EFFECTS OF 
PROPRIETARY FOAM SCLEROTHERAPY, “LONG-LASTING” 
FOAM SCLEROTHERAPY AND ENDOVENOUS CATHETER 
BALLOONS (FOGARTY AND CUTTING) IN PORCINE 
SUPERFICIAL VEINS.  
 
The protocol for this stage of the study was established by the research team in 
conjunction with the Home Office accredited animal research clinical team and 
given approval by Home Office officials (Appendix II). This study was 
undertaken in a licensed Home Office facility, with all aspects of the following 
procedures undertaken by licensed staff. 
 
The animals were given anaesthetic pre-medication and were then fully 
anaesthetised in a theatre environment. The animals were given relevant 
prophylactic antibiotics and long-acting analgesic medication. The veins to be 
utilised were initially scanned by USS to ensure patency. Controls for these 
experiments would be vein tissue excised at the initial experimental surgery and 
untreated vein tissue excised at the 12 week stage.  
 
All parts of the procedures were carried out by a licensed animal practitioner 
under the guidance of the lead researcher. 
 
The following procedure was that which was planned: 
Fogarty balloon x5 passes (control); Hind-limb 
Fogarty balloon x5 passes; STD foam; Hind-limb 
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Fogarty balloon x5 passes; cutting balloon x3 passes; Fore-limb  
Fogarty balloon x5 passes; cutting balloon x3 passes; STD foam; Fore-limb 
However, during the procedures it was evident that the neither Fogarty nor 
cutting balloon catheter could be inserted into the hind-limb veins of the two 
animals treated due to the small diameter hind-limb veins veins. Hence to 
maximise use of the animal 3% STD foam (the more potent proprietary foam) 
and 3%STD/0.15% xanthum foam were tested on the hind-limbs of both 
animals.    
Post procedure the limbs were dressed with compression bandaging with 
swabs overlying the superficial vein territory, to apply increased pressure in 
these areas hence mimicking the post-procedure dressing of humans treated 
with foam sclerotherapy for great saphenous varicose veins. 
 
The animals were monitored during their animal husbandry period on the farm 
before returning to the research facility after a 12-week period for surgical 
excision of the treated vein segments for histological analysis. The animals 
were terminated immediately post-operatively whilst still anaesthetised and 
analgised with other organs removed surgically pre-termination for use by other 
research groups to maximise use of the animal.   
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2.3.2.1 ANIMAL 1 (BM 1): OP PROCEDURE; WEIGHT: 55KG; DATE: 
13/06/11  
Pig anaesthetised 
USS all 4 limbs (>10cm length of vein found in all limbs and all patent). 
Tattoo 10cm length in all four limbs 
Open cut down begun distal to distal mark on all limbs to allow access to full 
10cm length. 
1. Right fore-leg (Branch taken as control sample): 
Fogarty Ch3 x5 passes; Cutting balloon 4x1.5cm x1 pass (5cm only); 
STD 3%foam 
(Half of right forelimb treated as catheter would not go any further and 
this size balloon has no guide wire hence weakened catheter allowed 
only one pass. Hole in vein repaired with x3 6-0 sutures 1cm distal to 
catheter entry. More holes present 4cm distal to catheter entry. Entry 
point 1cm distal to tattoo.  
Vein side-branch taken for histology. 
2. Left fore-leg: 
 Fogarty Ch3 x5; Cutting balloon 4x1.5cm x1 pass (c.10cm) 
 Catheter point sealed with 6/0 prolene 
3. Right hind-leg: 
1 mL 0.15% Xanthum and 3% STD foam via lateral branch into more 
proximal half of visible vein (that just lateral to artery), distally no foam 
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4. Left hind-leg: 
1 mL STD 3% foam into more proximal vein (medial to artery) with distal 
half avulsed therefore removed for histology sample; vein tacking suture 
to hold out to length. 
Vein side-branch taken for histology. 
Extra tattoo line placed to mark catheter insertion point. 
All wounds closed with 3-0 silk interrupted horizontal mattress sutures.  
Cicatrin® (Neomycin) antibiotic powder applied to all four wounds. 
Adhesive compression bandages applied to fore-limbs. 
Operation time: 3hr 30min 
 
Post-Op: 
14/6/11: Pig had removed bandages after 24hours.  
15/6/11: Pig seems fine. 
16/6 11: Slight swelling on right hind limb over wound (fluid?). Slight limp? 
17/6/11: Swelling still present, (no inflammation present). Pig is using right hind 
limb a little stiffly – internal bruising? 
20/6/11: Slight swelling still present in right hind limb but pig is no longer 
limping. 
27/6/11: Swelling still present but much reduced. 
12/9/11: All veins harvested at 3 months 
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Figure 2.39: BM1; pre-op tattoos marking 10cm superficial vein in right 
fore-limb 
 
   
Figure 2.40: BM1; pre-op tattoos marking 10cm superficial vein in right 
hind-limb 
   
Figure 2.41: BM1: pre-op tattooing (a) marking 10cm superficial vein in left 
hind-limb; artery easily seen (b; arrows) with paired superficial veins 
 
 
A B 
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Figure 2.42: BM1; exposure of left fore-limb superficial vein  
 
   
Figure 2.43: BM1; left fore-limb experimental rx: fogarty ch3 x5; cutting 
balloon 4mmx1.5cm (x1 pass [10cm]) 
 
   
Figure 2.44: BM1; 4.0mm x 1.5cm peripheral cutting balloon (boston 
scientific, usa) used on forelimbs of bm1 
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Figure 2.45: BM1; right fore-leg experimental rx: fogarty ch3 x5 passes; 
cutting balloon 4mmx1.5 cm (x1 pass (5 cm only)); std 3%foam 3ch 
fogarty balloon trawled through vein (b) 
    
Figure 2.46: Cutting balloon being withdrawn through vein 
    
Figure 2.47: Cutting balloon deflated and removed from vein; small 
venotomy created (a). fascia and skin closed (b) 
 
 
A B 
A B 
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Figure 2.48: BM1; right hind-leg experimental rx: 1 ml 
0.15%xanthum/3%STD foam into vein medial to artery 
      
Figure 2.49 : BM1; left hind-leg experimental rx: 1 ml 3% STD foam into 
vein medial to artery  
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2.3.2.2 ANIMAL 2 (BM 2): OP PROCEDURE; WEIGHT: 50KG; DATE: 
13/06/11  
Pig anaesthetised 
USS all 4 limbs (>10cm length of vein found in all limbs and all patent). 
Tattoo 10cm length in all four limbs 
Open cut down begun distal to distal mark on all limbs to allow access to full 
10cm length. 
1. Right fore-leg (Branch taken as sample): 
Fogarty Ch3 x4 passes and Ch4 x1; Cutting balloon 3mmx1.5cm x1 pass 
(10cm) x3passes (c.8cm); 1.5 mLs STD 3%foam 
Entry point 2.5cm distal to distal tattoo.  
Branch taken as sample 
2. Left fore-leg: 
Fogarty Ch3 x5 passes; Cutting balloon 5mmx2cm x1 pass in 2cm steps 
with deflation between Rxed c.10cm, vein burst and repaired with 
prolene 
Difficulty getting guide wire into vein. 
Caused large holes in the proximal vein x3 repaired with 6/0 prolene 
continuous stitch.  
3. Right hind-leg: 
1 mL Xanthum/3%STD foam via lateral branch into more proximal half of 
visible vein (that just lateral to artery), distally no foam 
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4. Left hind-leg: 
1 mL STD 3% foam via lateral branch crossing over artery into more 
proximal half of visible vein (that just medial to artery), distally no foam 
Extra tattoo line placed to mark catheter insertion point. 
All wounds closed with 3-0 silk interrupted horizontal mattress sutures.  
Cicatrin® (Neomycin) antibiotic powder applied to all four wounds. 
Adhesive compression bandages applied to fore-limbs. 
Operation time: 2hr 35min 
Post-Op 
14/6/11: Pig had removed bandages after 24 hours.  
15/6/11: Pig fine 
16/6/11: Pig fine 
17/6/11: Pig fine 
21/6/11: Right forelimb, swelling under sutured area – seems to be fluid filled 
(~50ml) 
Slight redness. Pig is not limping and the area does not seem to be 
painful. 
Slight swelling also on left fore-limb. 
22/6/11: Swelling on both limbs starting to recede. 
27/6/11:Swelling on left fore-limb receded but there appears to be a single small 
stitch abscess – antibiotics given 
12/9/11: All veins harvested at 3 months 
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Figure 2.50: BM2; left fore-leg experimental rx:fogarty ch3 x5; cutting 
balloon 5mmx2cm (x1 pass in 2cm steps) 
 
 
       
Figure 2.51: 5mmx2cm cutting balloon perforating distal vein on removal  
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Figure 2.52: Vein perforation repaired with 6-0 prolene pre-closure 
    
Figure 2.53: BM2; left hind-leg: 1 ml std 3% foam via branch into vein 
medial to artery 
  
Figure 2.54: BM2; right hind-leg experimetal rx: 1 ml 0.15% 
xanthum/3%STD foam via branch into vein lateral to artery 
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Figure 2.55: All wounds treated with cicatrin® powder and treated region 
of fore-limbs dressed with adhesive compression bandages   
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2.3.3 TERMINATION PROCEDURES 
At the end of the 12 week period the animals were again anaesthetised as 
previously. 
USS was performed on each of the limbs pre-termination to assess their 
patency and ultrasonographic appearance. In both animals all arteries were 
palpable and showed normal flow on USS. All treated veins in both animals 
were occluded but this procedure was difficult due to the size of the vessels and 
the animal being supine.  
Each 10cm length of superficial vein was removed surgically, as atraumatically 
as possible. Dissection proved difficult due to scar tissue. Vascular tissue 
(arteries and vein) were removed en-bloc to prevent damage to the treated 
segments. These tissue segments were then prepared, marked and processed 
in formalin for histopathological processing and analysis. The tissue was tacked 
out to length on histology specimen card and with both mapping and 
photographs of specimens used to note orientation for future analysis. 
Organs were removed from the animals for other research studies. The animals 
were then euthanised in accordance with Home Office regulations. 
A record of the procedures for each animal is recorded below. 
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2.3.3.1 ANIMAL 1 (BM 1): TERMINATION PROCEDURE WEIGHT: 150KG; 
DATE: 12/9/2011 
Pig anaesthetised (Figure 2.56). 
USS all 4 limbs: No venous treated segments patent; arteries palpable with 
normal flow. 
Open cut down between tattoo markings. 
Difficult dissections especially forelegs due to scar tissue hence tissues 
removed en-bloc. 
Vascular tissue removed en-bloc was prepared, marked and immediately fixed 
in 10% buffered formal saline. 
Harvest Time: 4 hours. 
 
 
Figure 2.56: Animal 1 (BM1) being anaesthetised 
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Figure 2.57: BM1; right fore-leg 
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Figure 2.58: BM1; left fore-limb 
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Figure 2.59: BM1; right hind-limb 
 
 
 
Figure 2.60: BM1; left hind-limb 
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2.3.3.2 ANIMAL 2 (BM 2): TERMINATION PROCEDURE: WEIGHT: 150KG; 
DATE: 12/9/2011 
Pig anaesthetised. 
USS all 4 limbs: No venous treated segments patent; arteries palpable with 
normal flow. 
Open cut down between tattoo markings. 
Difficult dissections especially forelegs due to scar tissue hence tissues 
removed en-bloc. 
Vascular tissue removed en-bloc was prepared, marked and immediately fixed 
in 10% buffered formal saline. 
Harvest Time: 3 hours. 
 
Figure 2.61: BM2; right fore-limb 
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Figure 2.62: BM2; left fore-limb 
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Figure 2.63: BM2; right hind-limb 
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Figure 2.64: BM2; left hind-limb 
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2.4 HISTOLOGICAL PROCESSING 
2.4.1 HUMAN TISSUE 
Following immediate fixation in formalin (Figure 2.17: Human tissue) specimens 
were stored at room temperature for at minimum one week. All human tissue 
was processed as per section 2.4.3 
2.4.2 ANIMAL TISSUE 
Following immediate fixation in formalin, animal tissue was sectioned prior to a 
further fixation period. Tissue was cut with a scalpel into 5mm wide blocks by 
the lead researcher. Each was stored in individual numbered containers each 
traceable to that section from which it came. The sections were again stored in 
formalin for an additional week. Due to the abundance of tissue every other 
segment was then processed as per section 2.4.3.   
2.4.3 PROCESSING OF HUMAN AND ANIMAL TISSUE SEGMENTS 
Tissue was processed in the histopathology laboratory as follows and in Table 
2.2: fixed tissue was transferred to a cassette labelled with a unique laboratory 
ID number, and processed into paraffin wax in a Leica ASP2000 tissue 
processing machine (Leica Microsystems,  Milton Keynes, Bucks, UK) using the 
routine overnight programme below: 
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Reagent  Time Temperature 
70% ethanol 30 min 37°C 
80% ethanol 30 min 37°C 
90% ethanol 30 min 37°C 
95% ethanol 30 min 37°C 
100% ethanol 1:00h 37°C 
100% ethanol 1:00h 37°C 
100% ethanol 1:30h 37°C 
Xylene 1:00h 37°C 
Xylene 1:30h 37°C 
Xylene 1:30h 37°C 
Wax 1:00h 65°C 
Wax 1:00h 65°C 
Wax 1:00h 65°C 
Table 2.2: Histopathology processing of vein/tissue segments (sequence 
runs from top to bottom) 
 
Tissue wax embedded on a Leica EG1150C embedding station in Cellwax plus 
wax (Cellpath Ltd, Newtown, Powys, UK). Tissue was sectioned transversely on 
a Leica RM 2235 microtome (Figure 2.27) at 4μm and placed on a glass 
microslide (Solmedia Ltd, Shrewsbury, UK; Figure 2.28). After drying on a hot 
plate for 2 hours at 70°C, slides were de-waxed through 4 changes of xylene 
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(VWR International Ltd, Lutterworth, Leicestershire,  UK) and 4 changes of 
absolute ethanol (Sigma, Poole, Dorset, UK) before then being rehydrated in 
running tap water before staining with Mayers Haematoxylin for 2 minutes and 
Eosin for 2 minutes. Haematoxylin and Eosin was used to demonstrate overall 
vein architecture and had been found in preceding research at Leeds University 
to be the most useful staining method to gain the necessary information on 
damage inflicted chemically and mechanically on vein samples. The previous 
research at Leeds University had also used van Geison and Picrosirus Red 
staining to demonstrate the elastin fibres and collagen respectively, however for 
the purpose of damage assessment these had previously been deemed 
superfluous to requirements. Transmission electron microscopy was deemed 
unnecessary by the pathologist who had taken part in all previous mechano-
chemical vein damage experiments in Leeds. Sections were then dehydrated in 
4 changes of absolute ethanol and three changes of xylene before coverslipping 
in DPX (Solmedia). Analysis was performed on glass slides using light 
microscopy examination. All processed H&E sections were digitally scanned 
using Aperio Scanscope/Imagescope (Version 10.2.2.2319), Aperio 
Technologies, Vista, California) to produce images for subsequent observer 
blinded analysis. These images allowed simultaneous inspection and 
measurement of areas of interest (FIGURES 2.69 and 2.70). 
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Figure 2.65: Tissue was sectioned transversely at 4μm using a Leica RM 
2235 microtome 
 
 
Figure 2.66: 4μM wax embedded sectioned tissue placed on glass 
microslides (Solmedia Ltd, Shrewsbury, UK) 
 
 
Figure 2.67: Sectioned tissue on a glass microslide dried on tissue prior 
to drying on a hot plate for 2 hours at 70°c slides 
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Figure 2.68 : Slides were digitised using an Aperio Scanscope and the 
images stored on a server for quantitative histological analysis using 20x 
magnification sections analysed using Aperio Imagescope v.10.2.2.2319 
(Aperio technologies, Inc. Vista, CA, USA) 
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2.5 HISTOLOGICAL ANALYSIS 
2.5.1 HUMAN TISSUE 
Haematoxylin and Eosin (H&E) staining was performed for identification of the 
intimal, medial and adventitial layers. Interpretation was performed by a 
consultant cardiovascular pathologist blinded to which specimens were the test 
or control segments and to the nature of tests performed. All qualitative analysis 
was performed by the pathologist along with the lead researcher with blinding 
removed after all batches relevant to an experimental category had been 
assessed. Slides from previous research were used prior to commencement of 
these analyses to allow the consultant pathologist to train the lead researcher in 
the assessment of normal, chemically and mechanically damaged vein 
segments both for the purposes of qualitative and quantitative analysis. A 
minimum of two sections were included per slide hence per experiment and two 
were used to determine the results. 30% of quantitative analyses were 
performed in isolation both by the pathologist and the lead researcher. There 
was no evidence of significant inter- or intra-observer variation hence the lead 
researcher performed the remaining 70% of quantitative studies with randomly 
assigned checks or advice on difficult cases performed by the pathologist.  
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2.5.1.1 QUALITATIVE ANALYSIS  
Qualitative analysis was performed on all specimens at 20x magnification using 
the original glass slides and a microscope. For each specimen two transverse 
sections underwent examination. The qualitative outcome measures recorded 
were:  
1. proportion of endothelial cell loss (as a percentage of entire endothelial 
surface on the slide  
2. depth of cell injury (measured in cell depths) 
3. comment on any subendothelial nucleolar vacuolation or opacification of 
nuclei 
4. valve interference with foam activity 
5. other comments 
2.5.1.2 QUANTITATIVE ANALYSIS 
Quantitative data were collated from 20x scanned computerised histology slides 
analysed via Aperio ImageScope v.10.2.2.2319 (histological analysis computer 
programme). For each specimen two transverse sections underwent 
examination. The quantitative outcome measures were endothelial cell loss and 
measurement of the depth of vein wall injury.  
2.5.1.2.1 MEASUREMENT OF ENDOTHELIAL CELL COVERAGE/LOSS 
Endothelial cell loss (Figure 2.69) measurements were performed at 20 x 
magnification (to reduce bias) using the Aperio “Pen Tool” to measure the 
luminal surface and the collective length of endothelial cells remaining in 
micrometres (µm). Where veins were cross-sectioned the luminal surface was 
measured as the complete ring and where vein was displayed as an incomplete 
ring, cut ends of vein were excluded from analysis and the intervening 
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endothelium measured as the “endothelial width”. Endothelial cell loss as a 
proportion of luminal surface present was derived as a percentage figure.  
The extent of endothelial cell coverage was determined by first measuring the 
total luminal circumference. The intima was then closely inspected and intact, 
densely stained endothelial cells that remained in contact with the basement 
were manually marked by the observer and the percentage luminal endothelial 
cell loss calculated.  
The range of measurements between the consultant pathologist and the lead 
researcher was within 10%, demonstrating minimal spread. Comparison of 
paired measurements did not reveal any significant difference (inter-observer 
p=0.821, intra-observer p=0.615). 
 
2.5.1.2.2 MEASUREMENT OF DEPTH OF VEIN WALL INJURY 
Depth of injury (Figure 2.70) measurements were performed at 20 x 
magnification (to reduce bias) using the Aperio “Pen Tool” to measure depth of 
injury and depth of media in micrometres (µm), at the “12 points” of a clock-face 
of in cross-sectional histological images of “tubular” vein at the “12 points” of a 
clock-face of. Where vein was displayed as an incomplete ring, cut ends of vein 
were excluded from the analysis and 12 measurements were taken at evenly 
spaced intervals across the remaining non-mechanically damaged luminal vein 
surface. From these quantitative data, the median and inter-quartile ranges of 
depth of injury were calculated for each specimen tested.  
The depth of vein wall injury was classified in two ways:  
1) the absolute depth of injury, and  
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2) the depth of injury as a proportion of the thickness of the media expressed as 
a percentage. 
The width of the tunica media was measured. This was defined as the point 
from the lumen to the outer layer of smooth muscle. Twelve measurements 
were taken per section, evenly spaced around the circumference of the intima. 
This approach was used as the intima and tunica media are the most constant 
structures, whilst the internal elastic lamina may be absent in places and the 
edge of the adventitia may be partially removed during vein harvesting. The 
percentage depth of injury was then established by measuring the depth that 
sub-endothelial vacuolation extended from the intima (vein lumen). These 
changes are characterised by swollen, pale smooth muscle cells, with an 
unravelling nucleolus, as opposed to the densely stained, small nuclei exhibited 
by normal cells. It is important to quantify the injury sustained by smooth muscle 
cells as this potentially represents collagen damage within that region. At each 
tunica media measurement, the depth of injury was established and a 
measurement taken (the absolute depth of injury) and the median tunica media 
width and median depth of injury was derived for each transverse section. The 
percentage depth of injury was then calculated. The median percentage depth 
of injury and the median absolute depth of injury for each experimental group 
were obtained. 
Reproducibility of the measurement techniques was assessed by comparison of 
inter- and intra-observer measurements. The range of measurements between 
the consultant pathologist and the lead researcher was within 10%, thereby 
again demonstrating minimal spread. Comparison of paired measurements did 
not reveal any significant difference (inter-observer p=0.799, intra-observer 
p=0.589). 
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Figure 2.69: Method of measuring luminal circumference and  endothelial cell 
loss using Aperio Imagescope v.10.2.2.2319 
 
 
Figure 2.70: Method of measuring media depth and depth of injury at 12 
points using Aperio Scanscope v.10.2.2.2319 
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2.5.2 ANIMAL TISSUE  
Haematoxylin and Eosin (H&E) staining was again performed for identification 
of intimal, medial and adventitial layers. Preliminary sections were performed on 
porcine vein tissue during the establishment of the animal vein model, to ensure 
that findings were comparable to those in human tissue. Porcine vein showed 
similar histological findings to human with the same structures highlighted in a 
similar fashion by H&E stain. Interpretation of test sections was performed by a 
consultant cardiovascular pathologist blinded to the nature of tests performed 
however the pathologist was aware that the tissue was from animal studies. 
Similar to experimentation on human tissue each sample had an experiment 
number and was then assigned a laboratory number which was that used 
during histological analysis. These numbers were converted back to the initially 
assigned experimental number only when all analyses had been performed to 
keep both the pathologist and lead researcher blind to the nature of the test. All 
qualitative and quantitative analyses of animal tissue were performed by the 
pathologist along with the lead researcher.  
 
Animal tissue was sectioned every 5mm, and every other section was analysed 
due to the amount of tissue. Initial qualitative results, examined blindly, were 
recorded by the lead researcher and consultant vascular pathologist and then 
in-order to more accurately assess samples the blinding was removed and the 
samples grouped together in the order in which they were both resected and 
hence sectioned. This was necessary to decipher each section’s relation to one 
another by allowing a representation of the full length of the specimen. In order 
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to assess the tissue and treatment and control sections the en-bloc tissue 
sections were orientated correctly in relation to each other to ensure that the 
correct vein was being assessed. This was necessary more so with paired hind-
limb veins with one acting as test and the other control and where veins were 
occluded.  
  
Data were gained from a minimum of six and maximum of eight sections per 
treatment or control with two, of a maximum four cuts, analysed to derive the 
both the qualitative score and quantitative results. 
 
Analysis was performed on all specimens at 20x magnification using the original 
glass slides and a light microscope and from 20x scanned computerised 
histology slides analysed via Aperio Scanscope/Imagescope (Version 
10.2.2.2319), Aperio Technologies, Vista, California) (histological analysis 
computer programme). 
Stereology was considered as a potential method that could be utilised for this 
experimentation. However we felt stereology would add little at this stage but if 
this animal model and experimentation did yield promising results, any further 
animal experiments could be assessed using stereology. Similarly 
immunohistochemistry was considered but having been used in previous vein 
damage research in Leeds to no avail, was deemed an unnecessary 
methodology as well as expense.  
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Fore-limb veins in both animals were treated with a 3Ch Fogarty balloon 
catheter and a cutting balloon with the right fore-limbs additionally treated with 
3% STD foam. The proximally treated segment of vein was compared 
histologically to the distally untreated segment acting as control. This control 
was selected because to remove vein at the initial experimental stage would 
have changed the anatomy and physiology of the limb and to use other veins 
whilst retrieving tissue for final analysis examples would have introduced 
significant variance.  
Hind-limb veins were treated with either 3% STD foam or 0.15% xanthum and 
3% STD foam. The hind-veins are paired hence the paired vein acted as 
control. 
 
2.5.3 QUALITATIVE ANALYSIS  
Details of what was present in the specimen and the nature of damage caused 
were recorded. Two attempts were made at developing qualitative based 
scoring systems. Initially samples were scored using the criteria in table 2.3 with 
a minimum score of 1 and maximum of 20 (TABLE 2.3). Subsequent to 
removing the blinding it was found that using pathology based findings in 
isolation gave little comparable information. Hence this was adjusted to an 
ordinal scale of damage from what we would have liked most to have happened 
to the treated veins, i.e. obliteration/occlusion, through to what would be 
deemed treatment failure i.e. no change or worse still varicose vein formation. 
Thereby a second qualitative scale was formed on this basis with the lowest 
score of 1 delineating the most effective treatment and a score of 7 the least 
effective i.e. the treatment itself resulting in causing varicosities of the treated 
vein (TABLE 2.4).  
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EFFECT SCORE 
Congestion of vessel with blood 1 
Dilated veins with thickened wall 2 
Inflammation (acute and local) 2 
Inflammation (chronic) 3 
Fibrous repair(mature) 2 
Proliferative repair(cellular) 4 
Organisation and recanalisation (per vessel) 3 
Dilated and tortuous vein 3 
Table 2.3:  Animal vein damage qualitative pathology score 1 
 
Effect   Points 
Vein obliteration with no additional effects 1 
Vein obliteration with additional effects 2 
Recanalisation without additional effects  3 
Recanalisation with additional effects 4 
Vein patent without additional effects 5 
Vein patent with additional effects 6 
Vein varicosity  7 
Table 2.4: Animal vein damage qualitative pathology score 2 
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Additional effects included, acute inflammation, chronic inflammation, fibrosis 
and proliferative repair 
 
2.5.4 QUANTITATIVE ANALYSIS 
 
Previous experiments using human GSV allowed measurement of the vein 
circumference and endothelial loss for comparison of test versus control 
segments. Similarly depth of media injury was measurable as an absolute figure 
and as a percentage of the media.   These measures were both obvious due to 
the acute nature of the changes that had been induced by treatments inflicted 
upon the vein segments. It was clear on initial blinded qualitative analysis of 
animal tissue which had been subjected to treatment three months previous, 
that there was no such marked change in the media or endothelial loss per say 
that could be measured. Attempts were made to furnish multiple data points 
including vein wall thickness and vein diameter, however given the nature of the 
treatments these figures could not be obtained with any regularity and were 
therefore not useful for comparison purposes.  The only useful measure that 
could be made was the patent luminal circumference or PLC. The patent 
luminal circumference could be measured whether the vein remained patent, 
occluded, recanalised, expanded or collapsed with an occluded vein having a 
PLC measure of 0.  
Quantitative analysis was carried out by the lead researcher using Aperio 
Imagescope after confirmation of technique with the pathologist.  
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Figure 2.71: x3 Example of forelimb vein experiments with varicosity 
created by cutting balloon and 3%STD treatment   
  
Figure 2.72: X1 Example of patent lumen circumference measurements of 
a distal segment in a hind-limb with patent test and control veins in a limb 
tested with 3% STD foam into more proximal aspect of the vein 
highlighted in green and the control limb vein lumen in red. 
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Figure 2.73: x2 Example of recanalisation of 3% STD treated  test vein on 
left with neo-lumens marked in green. Control vein lumen is marked in 
red. 
 
 
Figure 2.74: x2 Example of test vein obliteration using 3% STD (arrow) 
with patent control vein   
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2.6 STATISTICAL ANALYSIS 
 
Analysis was performed using PASW (SPSS, Statistical Package for Social 
Sciences Inc, Chicago, Illinois, USA) version 18.0. A p value of <0.05 was 
considered significant. 
 
2.6.1.1 PARAMETRIC DATA 
Data was subjected to the Shapiro-Wilk test in order to confirm whether the set 
was normally distributed. If all criteria were met, inter-group comparisons 
between 2 groups were performed using the unpaired or paired t test, where 
appropriate. Data is presented using means and standard deviation. 
 
2.6.1.2 NON-PARAMETRIC DATA 
Inter-group comparisons were performed using the Mann-Whitney U, 
Kolmogorov-Smirnov or Kruskal Wallis test where appropriate.  Data is 
presented using medians and inter-quartile ranges (IQR) 
 
2.6.1.3 REPRODUCIBILITY 
Agreement and variability between inter and intra-observer scores were 
assessed using the Bland-Altman plot and paired t test.  
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3 IN-VITRO FOAM STABILITY STUDIES 
UGFS utilises sclerotherapy in the form of foam to enhance its efficacy by 
increasing the surface area of the treated vein contacted by the sclerosant. A 
previously unanswered question in the literature is how the half-lives of the two 
most commonly used sclerosants compare and how they compare in in-vitro 
testing regarding damage to the vein wall.  This chapter presents the half-life of 
3% STD foam versus that of 3% polidocanol. Chapter four examines the 
damage caused by the respective foams on in-vitro vein segments. 
3.1 IN-VITRO FOAM STABILITY EXPERIMENTS 
For the purposes of the foam stability studies in this research, foam was 
prepared using Tessari’s technique (1:3 ratio of sclerosant : air) with 20 passes 
through a double syringe system and immediately transferred to a preheated 
(37°C) 15ml graduated polyester tube. As stated in the methods section, the 
rate of change in foam volume cannot be used as a measure of foam stability.  
Instead the experimental data was converted to percentage of foam remaining 
against time with the time taken for a 10% (T90) and 50% (T50) decrease in 
volume used as a measure of foam stability. Thus the initial foam volume was 
recorded and subsequent readings were taken every 30 seconds until the 
volume of the foam fell below 25% of its original volume. Experiments were 
conducted at 37oC (Stuart Incubator S16D, Bibby Scientific Ltd, Staffordshire, 
UK). 10 runs were performed for both 3% STD and 3% polidocanol foams. 
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3.1.1 3% STD AND 3% POLIDOCANOL FOAM STABILITY RESULTS  
T90 and T50 values are shown in the Table 3.1 and Figure 3.1. The median T90 
and T50 for 3% polidocanol were significantly higher than those for 3% STD 
(p=0.008 and p=0.004 respectively). Thus 3% polidocanol shows greater 
stability than 3% STD foam. 
 
3% STD  
Run No. 
T90 (sec) T50 (sec)  3% 
Polidocanol  
Run No. 
T90 (sec) T50 (sec) 
1 130 255 1 175.01 412.5 
2 100 204 2 137.26 295.01 
3 115.01 228.76 3 116.25 277.5 
4 77.65 185.99 4 98.5 244.98 
5 104 220 5 110.24 221.25 
6 94.33 206.25 6 244.59 465 
7 90 200 7 190.46 450 
8 106 232.5 8 123 247.5 
9 114 240 9 123.59 255 
10 75 200 10 106.5 210 
Median 
time 
(seconds) 
102.0 
(IQR 91.1 
- 112) 
213.1 
(IQR 201 
- 231.6) 
Median time 
(seconds) 
123.30 
(IQR 
111.7 
- 165.6) 
266.3 
(IQR 245.6 
- 383.1) 
 
Table 3.1: T90 and T50 values forSTD and polidocanol 3% foams 
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Figure 3.1: T90 and T50 (sec) for 3% STD and 3% polidocanol foams 
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3.2 DISCUSSION 
Varying initial volumes of foam were observed during all experiments. This may 
have occurred for multiple reasons. These include that although a graduated 
syringe was used to draw up the liquid to a volume of 1mL for foaming, there 
may have been small volume variation above or below this. This also applies to 
the volume of air drawn up in the second syringe to produce the foam. A smaller 
syringe, with smaller increment markings could have been used to draw up the 
initial volumes and then this transferred to a 10mL syringe. It would however 
have proved difficult to transfer the liquid completely as viscous liquids adhere 
to the syringe wall.    
The results show that 3% polidocanol foam lasts longer than 3% STD foam with 
a median difference of 21.3 s and 53.2 s for T90 and T50 respectively. Similar 
differences between the longevity of the respective foams have been found by 
others using different strengths of these sclerosants.235 This may be related to 
the larger molecular size of polidocanol thus enhancing its surfactant and 
foaming properties. This ought to be beneficial given that foam sclerotherapy is 
considered more efficacious than liquid sclerotherapy because of a longer 
contact time between the sclerosant and the endothelial cells.104 However as 
detailed in chapter four, experiments comparing the damage caused to in-vitro 
sections of human great saphenous vein by these proprietary sclerosants 
revealed that despite its longer foam half-life, polidocanol caused a lesser 
degree of damage to the vein wall than STD foam.  
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4 IN-VITRO HUMAN GREAT SAPHENOUS VEIN 
EXPERIMENTS 
 
4.1 ASSESSMENT OF EXPERIMENTAL TECHNIQUE: 
EXAMINATION OF THE HISTOLOGICAL EFFECTS OF 
HEPARINISED BLOOD CONTROL VERSUS NORMAL 
SALINE 
In order to assess this experimental technique and the control model, the 
histological effects on vein wall of heparinised blood control were compared to 
those of normal saline. 10 samples (each with test [heparinised blood] and 
control [normal saline]) were tested for 15 minutes. 
 
N.Saline  
15 min 
% Endothelial 
 cell loss 
 Heparinised blood  
15 min 
% Endothelial 
 cell loss 
Median 8.04 Median 3.84 
IQR1 2.92 IQR1 1.42 
IQR3 10.83 IQR3 12.56 
 
Table 4.1: Percentage endothelial cell loss at 15 minutes using normal 
saline and heparinised blood  
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Figure 4.1: Percentage endothelial cell loss at 15 minutes using normal 
saline and heparinised blood 
 
Comparison of medians across vein samples treated with normal saline for 15 
minutes versus those treated for the same time span with heparinised blood 
revealed no difference in percentage endothelial loss p=0.45 (Mann Whitney U).  
Injury to the media was not detected in samples treated for 15 minutes with 
either normal saline or heparinised blood with median, IQR1 and IQR3 for all 10 
test segments using both agents, being 0µm and 0% depth of injury 
respectively. 
Heparinised blood was selected as the control agent for all further experiments 
of this type as though there was no difference in its effect on endothelial cells 
versus normal saline. There was in fact a trend toward a lesser median 
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endothelial loss using heparinised blood (3.84%), versus normal saline (8.04%).  
This was not a statistically significant difference. 
4.2 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
PROPRIETARY FOAM (3% STD [FIBROVEIN®] AND 3% 
POLIDOCANOL [SCLEROVEIN®]) SCLEROSANTS ON IN-
VITRO GSV WALL INTEGRITY 
 3% STD and 3% polidocanol foams were used on the test segments. 
Experiments were carried out for 5 and 15 minutes. 
 
Table 4.2: Percentage endothelial cell loss using 3% STD versus 3% 
polidocanol and their respective heparinised blood controls at 5 minutes  
 
Table 4.3: Percentage endothelial cell loss using 3% STD versus 3% 
polidocanol and their respective heparinised blood controls at 15 minutes  
 
3% STD 
5 min  
% 
Endothelial 
Cell loss 
Control 
5 min  
%  
Endothelial 
cell loss 
 3% 
Polidoc. 
5 min 
%  
Endothelial 
 cell loss 
Control 
5 min 
%  
Endothelial 
cell loss 
Median 86.3 Median 7.26 Median 63.48 Median 7.18 
IQR1 84.75 IQR1 3.44 IQR1 62.15 IQR1 3.27 
IQR3 93.73 IQR3 7.97 IQR3 82.81 IQR3 14.38 
3% STD 
15 min  
% 
 
Endothelial  
Cell loss 
Control 
15 min  
%  
Endothelial 
cell loss 
 3% 
Polidoc 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
%  
Endothelial 
cell loss 
Median 97.64 Median 6.71 Median 85.85 Median 5.7 
IQR1 97.25 IQR1 5.7 IQR1 83.83 IQR1 3.1 
IQR3 97.83 IQR3 8.13 IQR3 92.48 IQR3 6.42 
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Figure 4.2: Percentage endothelial cell loss using 3% STD versus 3% 
polidocanol and their respective heparinised blood controls at 5 and 15 
minutes 
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3%  
STD 
5 min 
Median 
depth of 
injury 
(µm) 
Quantitative 
depth of injury 
vs media 
thickness  % 
 3% 
Polidoc. 
5 min 
Median 
depth of 
injury 
(µm) 
Quantitative 
depth of injury 
vs media 
thickness  % 
Median 37.35 3.45 Median 0 0 
IQR1 35.31 3.12 IQR1 0 0 
IQR3 45.76 3.59 IQR3 0 0 
Table 4.4: Vein wall injury data for 3% STD and 3% polidocanol at 5 
minutes 
 
Table 4.5: Comparison of vein wall injury data for 3% STD and 3% 
polidocanol at 5 minutes 
 
 STD 5 min  
 
Polidocanol  
5 min 
p 
Median endothelial cell loss 
(%) 
 
86.3  
(84.8-93.7) 
63.48  
(62.2-82.9) 
= 0.095 
Median depth of injury (µm) 37.4  
(35.3-45.8) 
0 (0-0) < 0.01 
 
Median depth of injury as % 
of 
media thickness  
3.5 (3.1-3.6) 0 (0-0) < 0.01 
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3% 
STD  
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  % 
 
3% 
Polidoc. 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  % 
Median 43.39 5.3 Median 0 0 
IQR1 42.05 3.72 IQR1 0 0 
IQR3 46.68 5.96 IQR3 0 0 
Table 4.6: Vein wall injury data for 3% STD and 3% polidocanol at 15 
minutes 
 
 
Table 4.7: Comparison of vein wall injury data for 3% STD and 3% 
polidocanol at 15 minutes  
 
 
 
 
 
 
 
 
 STD 15 min 
 
Polidocanol  
15 min 
p 
Median endothelial cell loss (%) 
 
97.6 (97.3-97.9) 85.9 
(83.8-92.5) 
< 0.01 
Median depth of injury (µm) 43.4 (42.1-46.7) 0 (0-0) < 0.01 
 
Median depth of injury as % of 
media thickness 
5.3 (3.7-6.0) 0 (0-0) < 0.01 
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Figure 4.3: Depth of media injury (µm) using 3% STD versus 3% 
polidocanol and their respective heparinised blood controls at 5 and 15 
minutes. 
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Figure 4.4: Percentage of media depth injured using 3% STD versus 3% 
polidocanol and their respective heparinised blood controls at 5 and 15 
minutes.  
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Median endothelial cell loss was significantly greater with 3% STD (86.3% 
[84.8-93.7]) versus controls (7.26% [3.44, 7.97]) at 5 mins p=0.008 and at 15 
mins: 3% STD (97.6% [97.3-97.9]) versus controls (6.71% [5.7, 8.13]) p=0.008. 
Similarly 3% polidocanol produced a significantly greater endothelial loss versus 
controls at 5 mins, 63.48% (62.15, 82.81) versus 7.18% (3.27, 14.38) p=0.032 
and at 15 mins (polidocanol 85.85% (83.83, 92.48) versus controls 5.7% (3.1, 
6.42) p=0.008 respectively. Comparison of median endothelial loss at 5 mins 
with 3% STD (86.3% [84.75, 93.73]) vs 3% polidocanol  (63.48% [62.15, 82.81]) 
revealed no significant difference (p=0.095), but at 15 mins there was a 
statistically significant different endothelial loss  p=0.008, with 3% STD having a 
median of 97.64% (97.25, 97.83) endothelial loss versus 85.85% (83.83, 92.48) 
using polidocanol. The enhanced endothelial loss seen with 3% STD between 5 
mins (86.3% [84.75, 93.73]) compared with 15 mins (97.64% [97.25, 97.83]) is 
not statistically significant p=0.151. Similarly the enhanced endothelial loss seen 
with 3% polidocanol between 5 mins (63.48% [62.15, 82.81]) and 15 mins 
(85.85% [83.83, 92.48]) is not statistically significant p=0.095.   
There was no difference found across the range of controls for both the 5 and 
15 minute experiments inclusive (p=0.494: Independent samples median test). 
Hence additional time in-vitro with controls alone did not affect the endothelial 
lining.  
The median depth of media injury and percentage depth of media injured was 
greater with 3% STD (median depth of injury at 5 (37.4µm [35.3-45.8]) and 15 
min (43.4 µm [42.1-46.7]) compared to 3% polidocanol (0 µm [0,0] for 5 and 15 
min experiments) p = 0.008 for both. Similarly percentage depth of media injury 
is greater with 3% STD at 5 (3.5% [3.1-3.6]) and 15 mins (5.3% [3.7-6.0]) 
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compared to 3% polidocanol  (0% [0,0] for 5 and 15 min experiments) p=0.008 
for both.  
Depth of media injury with 3% STD at 5 (37.4µm [35.3-45.8]) versus 3% STD at 
15mins (43.4 µm [42.1-46.7]) showed no difference p=0.841.  There was also 
no difference in the percentage depth of injury with 3% STD at 5 (3.5% [3.1-
3.6]) and 15 mins (5.3% [3.7-6.0]) p=0.310. 
No media injury occurred in controls for any of these experiments hence again 
the additional time 10 minutes between 15 min and 5 min experiments in-vitro 
had no effect on the media.  
 
In summary the significant loss of endothelial lining in test segments compared 
to relatively unaffected controls is similar between 3% STD and 3% polidocanol 
except with longer experiment times where endothelial loss is enhanced with 
3% STD compared to 3% polidocanol (but not compared to itself).  
The depth of media injury in micrometres and as a percentage of the vein media 
is significantly higher for 3% STD as none occurred with 3% polidocanol.   
If these differences also occur in vivo then 3% STD may be more effective in 
causing permanent vein damage than polidocanol  during the treatment of 
varicose veins, 
 
Below are examples of 20x and 40x magnified in-vitro GSV test samples 
stained with H&E. The first (Figure 4.5 A-C) are examples of GSV treated with 
STD for 15 minutes with an arrow pointing to “preserved” foam  and the depths 
of injury clearly marked to the depth of the most superficial viable nucleus, with 
a 40x example of obvious sub-endothelial vacuolation. The second (Figure 4.6) 
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is an example of GSV treated with polidocanol for 15 minutes with large areas 
of intact endothelium (arrows) and no injury to the media. This slide is typical of 
those vein segments treated with polidocanol. 
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 (A) 
 
(B):        (C): 
             
                  
Figure 4.5: Example of in-vitro GSV treated for 15 minutes with 3 % STD 
foam  
(a): arrow pointing to STD foam remaining in contact with damaged media. 
The two measurements of depth of injury are marked reflecting the depth 
of the most superficial viable nuclei (20x)    
(b): close-up of individual “clock-face” measurements (20x)  
(c): sub-endothelial vacuolation highlighting the depth of media injury 
(40x)  
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Figure 4.6: In-vitro GSV treated for 15 minutes with 3% polidocanol foam 
demonstrating intact endothelium with no discernible injury to the media 
(20x) (arrows showing intact endothelium) 
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4.3 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
CONSTITUENT PARTS OF PROPRIETARY SCLEROSANT 
FOAM (3% STD) ON IN-VITRO GSV WALL INTEGRITY, TO 
ASCERTAIN THE MOST ACTIVE INGREDIENT 
The constituent parts of proprietary 3% STD foam were applied to the test 
segments. These are buffered 3% STD alone and 2% benzyl alcohol.   
 
Table 4.8: Percentage endothelial cell loss using buffered non-proprietary 
3% STD versus phosphate buffer pH 7.6 and their respective heparinised 
blood controls at 5 minutes  
 
Table 4.9: Percentage endothelial cell loss using buffered 2% benzyl 
alcohol versus phosphate buffer pH 7.6 and their respective heparinised 
blood controls at 5 minutes  
 
Buffered  
non-proprietary 
3% STD 
5 min 
%  
Endothelial  
cell loss 
Control 
5 min  
% Endothelial 
cell loss 
 Phosphate 
Buffer  
pH 7.6 
5 min 
%  
Endothelial 
cell loss 
Control 
5 min 
%  
Endothelial 
cell loss 
Median 85.28 Median 6.99 Median 1.93 Median 5.62 
IQR1 83.15 IQR1 6.79 IQR1 1.02 IQR1 4.45 
IQR3 87.66 IQR3 7.68 IQR3 8.98 IQR3 7.35 
   p=0.008     p=0.421 
Buffered 
2% Benzyl 
Alcohol  
5 min 
% 
Endothelial  
Cell loss 
Control 
5 min  
% 
Endothelial 
cell loss 
 Phosphate 
Buffer  
pH 7.6 
5 min  
%  
Endothel
ial 
 cell loss 
Control 
5 min 
%  
Endothelial 
cell loss 
Median 13.86 Median 4.94 Median 1.93 Median 5.62 
IQR1 9.32 IQR1 2.93 IQR1 1.02 IQR1 4.45 
IQR3 17.05 IQR3 5.67 IQR3 8.98 IQR3 7.35 
   p=0.095     p=0.421 
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Figure 4.7: Percentage endothelial cell loss using buffered non-
proprietary 3% STD versus buffered 2% benzyl alcohol versus phosphate 
buffer pH 7.6 and their respective heparinised blood controls at 5 minutes  
 
- 199 - 
 
 
 
Table 4.10: Percentage endothelial cell loss using buffered 2% benzyl 
alcohol versus phosphate buffer pH 7.6 and their respective heparinised 
blood controls at 15 minutes  
 
Table 4.11: Percentage endothelial cell loss using buffered non-
proprietary 3% STD versus phosphate buffer pH 7.6 and their respective 
heparinised blood controls at 15 minutes  
 
Buffered 2% Benzyl Alcohol  
15 min 
% 
Endothelial  
Cell loss 
Control 
15 min  
% 
Endothelial 
cell loss 
 
Phosphate 
Buffer 
 pH 7.6 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
% 
Endothelial 
cell loss 
Median 15.67 Median 9.78 Median 4.97 Median 8.91 
IQR1 11.09 IQR1 8.88 IQR1 3.02 IQR1 7.98 
IQR3 18.72 IQR3 12.55 IQR3 8.76 IQR3 12.23 
Buffered  
non-proprietary 
3% STD 
15 min  
%  
Endothelial  
Cell loss 
Control 
15 min  
%  
Endothelial 
cell loss 
 
Phosphate 
Buffer  
pH 7.6 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
% 
Endothelial 
cell loss 
Median 83.12 Median 9.45 Median 4.97 Median 8.91 
IQR1 75.34 IQR1 6.72 IQR1 3.02 IQR1 7.98 
IQR3 94.32 IQR3 10.31 IQR3 8.76 IQR3 12.23 
- 200 - 
 
 
Figure 4.8: Percentage endothelial cell loss using buffered non-
proprietary 3% STD versus buffered 2% benzyl alcohol versus phosphate 
buffer pH 7.6 and their respective heparinised blood controls at 15 
minutes  
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Table 4.12: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using buffered (non-proprietary) 3% STD versus 
phosphate buffer pH 7.6 and their respective heparinised blood controls 
at 5 minutes.  
 
 
Buffered 
 Benzyl  
Alcohol 2% 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
Phosphate  
Buffer  
pH 7.6 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 0 0 Median 0 0 
IQR1 0 0 IQR1 0 0 
IQR3 0 0 IQR3 0 0 
 
Table 4.13: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using buffered benzylalcohol 2% versus phosphate 
buffer pH 7.6 and their respective heparinised blood controls at 5 minutes.  
 
Buffered  
non-proprietary 
3% STD 
5 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
Phosphate  
Buffer  
pH 7.6 
5 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 0 0 Median 0 0 
IQR1 0 0 IQR1 0 0 
IQR3 0 0 IQR3 0 0 
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Buffered  
(non-proprietary) 
3% STD 
15 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
Phosphate  
Buffer  
pH 7.6 
15 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 0 0 Median 0 0 
IQR1 0 0 IQR1 0 0 
IQR3 0 0 IQR3 0 0 
 
Table 4.14: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using buffered (non-proprietary) 3% STD versus 
phosphate buffer pH 7.6 and their respective heparinised blood controls 
at 15 minutes.  
 
 
 
Table 4.15: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using buffered benzylalcohol 2% STD versus 
phosphate buffer pH 7.6 and their respective heparinised blood controls 
at 15 minutes.  
Buffered 
 Benzyl  
Alcohol 2% 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
Phosphate  
Buffer  
pH 7.6 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 0 0 Median 0 0 
IQR1 0 0 IQR1 0 0 
IQR3 0 0 IQR3 0 0 
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5 minute experiments comparing the percentage endothelial loss using buffered 
non-proprietary 3% STD (85.28% [83.15, 87.66]) to its controls (6.99% [6.79, 
7.68]) and to the phosphate buffer (1.93% [1.02,8.98]) displays a significant 
difference for both p=0.008. Comparing percentage endothelial loss using 3% 
STD (85.28% [83.15, 87.66]) to buffered 2% benzyl alcohol (13.86% [9.32, 
17.05]) shows again a statistically significant difference p=0.008. Comparing 
endothelial percentage loss with buffered 2% benzyl alcohol (13.86% [9.32, 
17.05]) to phosphate buffer (1.93% [1.02, 8.98]) also reveals a significant 
difference p=0.032. However this is less marked in comparison to the difference 
between buffered non-proprietary 3% STD and phosphate buffer.  
Comparing endothelial loss across all controls for buffered 3% STD, buffered 
2% benzyl alcohol and phosphate buffer experiments indicates that they are all 
comparatively low p=0.153 (Independent samples median test). 
Therefore 5 minute experiments reveal that during this time frame buffered non-
proprietary 3% STD causes much more endothelial loss (85.28% [83.15, 87.66]) 
than buffered 2% benzyl alcohol (13.86% [9.32, 17.05]) p=0.008 with the later 
causing no more endothelial loss than its controls (4.94% [2.93, 5.67]) p=0.095.  
Similarly for 15 minute experiments, endothelial loss using buffered 3% STD 
(83.12% [75.34, 94.32]) was significantly more compared with buffered 2% 
benzyl alcohol (15.67% [11.09,18.72]) p=0.008 and in comparison to phosphate 
buffer (8.91% [7.98, 12.23]) p=0.008 Mann-Whitney U test. 
Comparison of medians across groups of heparinised blood controls for 
buffered 3% STD, buffered 2% benzyl alcohol and phosphate buffer 15 minute 
experiments again showed no significant difference p=0.343  
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These results suggest that the most active ingredient in proprietary STD is, as 
expected STD. 
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Regarding depth of injury experiments, these results can be summarised by 
stating that neither of the constituent parts of sclerosant foams, buffered 3% 
STD and 2% benzyl alcohol, when used separately, caused any damage to the 
in-vitro vein media for either 5 or 15 minute experiments. 
Comparing the endothelial loss using buffered 3% STD in 5 minute experiments 
(85.28% [83.15, 87.66]) versus 15 min experiments (83.12% [75.34, 94.32]), 
there was no statistical difference p=0.841. Therefore increasing the contact 
time of buffered 3% STD with the in-vitro endothelium did not inflict more 
damage. Similarly buffered 2% benzyl alcohol did not inflict more damage on 
the endothelium with the longer experiments: 5 min (13.86% [9.32, 17.05]) 
versus 15 min (15.67% [11.09, 8.72]) p=0.690. Therefore for either agent 
additional time in contact with the endothelium did not equate to more damage. 
Endothelial loss with proprietary 3% STD at 5 mins is 86.3% (84.8-93.7) versus 
85.28% (83.15, 87.66) with non-proprietary buffered 3% STD p=0.310 and in 15 
min experiments is 97.6% (97.3-97.9) versus 83.12% (75.34, 94.32) p=0.548. 
Therefore when used separately the constituent parts of STD foam damage the 
endothelium but not the media. Additional time in contact with the endothelium 
did not equate to any increase in damage inflicted to the endothelium. Hence 
either the combination of STD and benzyl alcohol in proprietary STD is 
synergistic, or our buffering mechanism was at least interfering with the activity 
of STD against the media.   
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4.4 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
‘LONGER-LASTING’ FOAM SCLEROSANTS ON IN-VITRO 
GSV WALL INTEGRITY, TO ASCERTAIN THAT PRODUCING 
MAXIMAL EFFECT ON THE VEIN WALL 
These are the results for longer lasting STD foams. 
4.4.1 ENDOTHELIAL CELL LOSS WITH LONGER LASTING FOAMS 
 
 
Table 4.16: Percentage endothelial cell loss with 3% STD versus 3% STD + 
5% pluronic and their respective heparinised blood controls at 5 minutes  
 
 
Table 4.17: Percentage endothelial cell loss with 3% STD foam versus 3% 
STD + 5% pluronic foam and their respective heparinised blood controls 
at 15 minutes  
 
The “longer-lasting” 3% STD foams included STD 3% and pluronic 5%, STD 3% 
and carbomer 0.45%, and STD 3% and xanthum 0.15%. Results revealed that 
STD 3%/xanthum 0.15% caused a greater degree of injury than the other two 
longer-lasting foams hence its constituent parts were assessed individually. 
3% STD 
5 min  
% 
 
Endothelial  
Cell loss 
Control 
5 min  
% 
Endothelial 
cell loss 
 3% STD+ 
5% 
Pluronic 
5 min 
%  
Endothelial 
 cell loss 
Control 
5 min 
% 
Endothelial 
cell loss 
Median 86.3 Median 7.26 Median 96.26 Median 12.98 
IQR1 84.75 IQR1 3.44 IQR1 84.16 IQR1 7.18 
IQR3 93.73 IQR3 7.97 IQR3 90.12 IQR3 10.08 
3% STD 
15 min  
% 
 
Endothelial  
Cell loss 
Control 
15 min  
%  
Endothelial 
cell loss 
 3% STD+ 
5% 
Pluronic 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
% 
Endothelial 
cell loss 
Median 97.64 Median 6.71 Median 86.32 Median 6.71 
IQR1 97.25 IQR1 5.7 IQR1 85.52 IQR1 5.7 
IQR3 97.83 IQR3 8.13 IQR3 85.92 IQR3 6.21 
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These were phosphate buffer pH 7.6, normal saline 0.9% and buffered xanthum 
alone 5%.  
 
 
Figure 4.9: Percentage endothelial loss with 3% STD foam versus 3% STD 
+ 5% pluronic foam and their respective heparinised blood controls at 5 
and 15 minutes. 
 
5 minutes experiments comparing endothelial loss with 3% STD versus 
STD/Pluronic revealed no difference (p=1.0). However in the 15 minute 
experiments STD/Pluronic causing less endothelial cell loss than 3% STD 
(p<0.01; Mann Whitney U). . 
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Table 4.18: Percentage endothelial cell loss with 3% STD foam versus 3% 
STD + 0.45% carbomer foam and their respective heparinised blood 
controls at 5 minutes  
 
Table 4.19: Percentage endothelial cell loss with 3% STD foam versus 3% 
STD + 0.45% carbomer foam and their respective heparinised blood 
controls at 15 minutes  
3% STD 
5 min  
% 
 
Endothelial  
Cell loss 
Control 
5 min  
%  
Endothelial 
cell loss 
 
3% STD+ 
0.45% 
Carbomer 
5 min 
%  
Endothelial 
 cell loss 
Control 
5 min 
% Endothelial 
cell loss 
Median 86.3 Median 7.26 Median 84.14 Median 8.56 
IQR1 84.75 IQR1 3.44 IQR1 57.16 IQR1 5.78 
IQR3 93.73 IQR3 7.97 IQR3 85.32 IQR3 10.21 
3% STD 
15 min  
% 
 
Endothelial  
Cell loss 
Control 
15 min  
%  
Endothelial 
cell loss 
 
3% STD+ 
0.45% 
Carbomer 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
% Endothelial 
cell loss 
Median 97.64 Median 6.71 Median 88.64 Median 4.62 
IQR1 97.25 IQR1 5.7 IQR1 86.28 IQR1 3.1 
IQR3 97.83 IQR3 8.13 IQR3 91.72 IQR3 12.39 
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Figure 4.10: Percentage endothelial loss with 3% STD foam versus 3% 
STD + 0.45% carbomer foam and their respective heparinised blood 
controls at 5 and 15 minutes 
 
Neither the 5 nor 15 minute experiments comparing endothelial loss with 3% 
STD versus STD/Carbomer showed a difference between the foams (p=0.222 
and p=0.151 respectively; Mann Whitney U).  
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Table 4.20: Percentage endothelial cell loss with 3% STD versus 3% STD + 
0.15% xanthum and their respective heparinised blood controls at 5 
minutes  
 
 
Table 4.21:  Percentage endothelial cell loss with 3% STD versus 3% STD 
+ 0.15% xanthum and their respective heparinised blood controls at 15 
minutes  
3% STD 
5 min  
% 
 
Endothelial  
Cell loss 
Control 
5 min  
%  
Endothelial cell 
loss 
 
3% STD+ 
0.15% 
Xanthum 
5 min 
%  
Endothelial 
 cell loss 
Control 
5 min 
% Endothelial 
cell loss 
Median 86.3 Median 7.26 Median 98.01 Median 12.98 
IQR1 84.75 IQR1 3.44 IQR1 87.8 IQR1 9.29 
IQR3 93.73 IQR3 7.97 IQR3 98.22 IQR3 15.78 
3% STD 
15 min  
% 
 
Endothelial  
Cell loss 
Control 
15 min  
%  
Endothelial 
cell loss 
 
3% STD+ 
0.15% 
Xanthum 
15 min 
%  
Endothelial 
 cell loss 
Control 
15 min 
% Endothelial 
cell loss 
Median 97.64 Median 6.71 Median 94.71 Median 8.96 
IQR1 97.25 IQR1 5.7 IQR1 91.59 IQR1 6.42 
IQR3 97.83 IQR3 8.13 IQR3 95.21 IQR3 16.35 
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Figure 4.11: Percentage endothelial loss using 3% STD foam versus 3% 
STD + 0.15% xanthum foam and their respective heparinised blood 
controls at 5 and 15 minutes. 
Comparing endothelial loss between 3% STD and STD/Xanthum revealed no 
differences after either 5 (p=0.548) or 15 minutes (p=0.151; Mann Whitney U). 
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Figure 4.12: Summary chart of percentage endothelial cell loss at 5 and 15 
minutes with 3% STD foam, 3% STD + 5% pluronic foam, 3% STD + 0.45% 
carbomer foam and 3% STD + 0.15% xanthum foam. 
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4.4.2 MEDIA INJURY WITH LONGER LASTING FOAMS. 
This chapter displays results for the absolute depth of media injury in µM and 
the percentage depth of the media injured using longer lasting foams. 
 
Table 4.22: Depth of media injury (median [µm] and depth of injury as a % 
of total depth of media [%]) using 3% STD foam versus 3% STD + 5% 
pluronic foam and their respective heparinised blood controls at 15 
minutes.  
 
 
Table 4.23: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using 3% STD foam versus 3% STD + 5% pluronic 
foam and their respective heparinised blood controls at 15 minutes. 
 
3% STD 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
3% STD +  
5% Pluronic 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 37.35 3.45 Median 21.08 3.83 
IQR1 35.31 3.12 IQR1 18.23 3.04 
IQR3 45.76 3.59 IQR3 31.34 4.23 
 
3% STD 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
3% STD +  
5% Pluronic 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 43.39 5.3 Median 25.89 2.97 
IQR1 42.05 3.72 IQR1 24.2 1.94 
IQR3 46.68 5.96 IQR3 26.45 3 
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Figure 4.13: depth of media injury (µm) using 3% STD foam versus 3% 
STD + 5% pluronic foam and their respective heparinised blood controls 
at 5 and 15 minutes 
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Figure 4.14: Depth of media injury (%) using 3% STD foam versus 3% STD 
+ 5% pluronic foam and their respective heparinised blood controls at 5 
and 15 minutes 
 
5 minute experiments comparing depth of injury revealed a significant difference 
between 3% STD versus and STD/Pluronic when comparing absolute depth of 
injury [µm] p=0.016 although there was no difference when comparing the depth 
of injury as a percentage of the media depth (p=1.0; Mann Whitney U). After 15 
minutes there was a significant difference between the two both for absolute 
depth of injury (p=0.016) and for depth of injury as a percentage of the media 
depth (p<0.01) with 3% STD causing greater injury than STD/Pluronic. Thus 
pluronic seems to reduce the effectiveness of STD in inflicting damage in the in-
vitro vein wall media. 
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3% STD 
5 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
3% STD +  
0.45% Carbomer 
5 min 
Median 
depth 
of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 37.35 3.45 Median 32.24 6.91 
IQR1 35.31 3.12 IQR1 0 1.98 
IQR3 45.76 3.59 IQR3 47.03 11.31 
 
Table 4.24: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using 3% STD foam versus 3% STD + 0.45% 
carbomer foam and their respective heparinised blood controls at 5 
minutes.  
 
 
Table 4.25: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using 3% STD foam versus 3% STD + 0.45% 
carbomer foam and their respective heparinised blood controls at 15 
minutes. 
 
3% STD 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  % 
 
3% STD +  
0.45%  
Carbomer 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 43.39 5.3 Median 31.4 7.97 
IQR1 42.05 3.72 IQR1 30.41 3.26 
IQR3 46.68 5.96 IQR3 58.73 12.79 
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Figure 4.15: Depth of injury (µm) using 3% STD foam versus 3% STD + 
0.45% carbomer foam and their respective heparinised blood controls at 5 
and 15 minutes 
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Figure 4.16: Depth of injury (% of total media depth) using 3% STD foam 
versus 3% STD + 0.45% carbomer foam and their respective heparinised 
blood controls at 5 and 15 minutes 
 
5 minute experiments comparing 3% STD with STD/Carbomer revealed no 
difference in the absolute (p=0.421) or percentage depth of injury of the media 
(p=0.841). 15 minute experiments were similar (p=0.421 and p=0.690; Mann 
Whitney U) respectively.  
 
 
- 219 - 
 
 
3% STD 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
 
3% STD +  
0.15% Xanthum 
5 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  
% 
Median 37.35 3.45 Median 57.87 9.51 
IQR1 35.31 3.12 IQR1 36.78 5.44 
IQR3 45.76 3.59 IQR3 58.11 9.58 
Table 4.26: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using 3% STD foam versus 3% STD + 0.15% 
xanthum foam and their respective heparinised blood controls at 5 
minutes.  
 
 
3% STD 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  % 
 
3% STD +  
0.15%  
Xanthum 
15 min 
Median 
depth of 
injury 
(µm) 
Depth of 
injury vs 
media 
thickness  % 
Median 43.39 5.3 Median 32.48 4.32 
IQR1 42.05 3.72 IQR1 25.95 3.79 
IQR3 46.68 5.96 IQR3 38.31 11.25 
Table 4.27: Depth of media injury (median [µm] and depth of injury vs 
media thickness [%]) using 3% STD foam versus 3% STD + 0.15% 
xanthum foam and their respective heparinised blood controls at 15 
minutes. 
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Figure 4.17:  Depth of injury (µm) using 3% STD foam versus 3% STD + 
0.15% xanthum foam and their respective heparinised blood controls at 5 
and 15 minutes 
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Figure 4.18: Depth of injury (%) using 3% STD foam versus 3% STD + 
0.15% xanthum foam and their respective heparinised blood controls at 5 
and 15 minutes 
 
Experiments comparing depth of media injury over 5 (absolute depth p=0.841, 
% depth p=0.222) and 15 minutes (absolute depth p=0.222, % depth p=0.841) 
comparing 3% STD with STD/Xanthum showed no difference.  
 
These results show that STD 3%/xanthum 0.15% caused a greater degree of 
injury than the other two longer-lasting foams hence its constituent parts were 
assessed individually.  
These were phosphate buffer pH 7.6, normal saline 0.9% and buffered xanthum 
alone 5%. These had a minimal effect on the endothelium and none on the 
media. 
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The following are summary charts of the absolute and percentage depth of 
injury caused by longer lasting foams. 
 
 
Figure 4.19: Depth of injury (µm) at 5 and 15 minutes with 3% STD foam, 
3% STD + 5% pluronic foam, 3% STD + 0.45% carbomer foam and  3% STD 
+ 0.15% xanthum foam. 
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Figure 4.20: Depth of injury (%) at 5 and 15 minutes with 3% STD foam, 3% 
STD + 5% pluronic foam, 3% STD + 0.45% carbomer foam and 3% STD + 
0.15% xanthum foam. 
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Compared to proprietary 3% STD foam, longer lasting 3% STD foams did not 
inflict greater injury on either the GSV endothelium or media. Indeed, the 
addition of pluronic had a negative impacted the efficacy of 3% STD in terms of 
both endothelial loss and damage to the vein media. Conversely, STD/Xanthum 
showed a trend towards greater foam efficacy sclerotherapy, at least in 5 
minute experiments, but this still failed to reach significance.  
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CHAPTER V 
ASSESSMENT OF CUTTING BALLOONS 
AS ADJUNCTS TO FOAM SCLEROTHERAPY 
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5 ASSESSMENT OF CUTTING BALLOONS AS ADJUNCTS TO 
FOAM SCLEROTHERAPY  
 
5.1 ASSESSMENT OF CUTTING BALLOONS FOR USE AS 
MONO-THERAPY OR AS ADJUVANT TREATMENT WITH 
FOAM SCLEROTHERAPY FOR TREATMENT OF TRUNCAL 
VARICOSE VEINS 
This chapter presents experiments performed using arterial cutting balloons. 
Their potential as mono-therapy or adjuvant therapy alongside foam 
sclerotherapy for treating truncal varicose veins is examined. 
Each experiment in this group involved 5 GSV segments (each with test and 
control). The test segments were wrapped inside a saline soaked surgical swab 
held snuggly with finger thumb opposition beside the vein segment/balloon in 
order to mimic resistance of the subcutaneous fat as would be the case in-vitro. 
Cutting balloons utilised for these experiments had been previously used once 
in arterial treatments, hence they were used a maximum of twice more to 
prevent significant blunting of their blades. As vein segments are of differing 
dimension and so too are cutting balloons as recorded above, balloons were 
matched to vein segments according to vein diameter.  
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5.1.1 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF CUTTING 
BALLOONS ALONE ON IN-VITRO GSV WALL INTEGRITY 
The first experiments here involved cutting balloons (matched to size of vein) 
inflated in the lumen of the test vein segment for 10 seconds then deflated and 
removed. Inflation was performed using an Encore™26 Inflation Device (Boston 
Scientific, USA; Figure 2.19) to a pressure of 6.0 Atmospheres (ATM) / 608 kilo 
Pascals (kPa) (pressure recommended by the manufacturers for each of the 
balloons). 
The second batch of experiments involved cutting balloons (matched to size of 
vein) being inflated to a pressure of 6.0 ATM / 608 kPa in lumen of test vein 
segment for 10 seconds and then withdrawn (pulled out) from the test segment 
whilst inflated. deBakey (non-traumatic forceps) placed at one end of the 
specimen were used to anchor the vein to allow withdrawal of the cutting 
balloon whilst inflated.  
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Figure 5.1: Number of cuts visible on histological analysis of GSV 
segments after cutting balloon inflated for 10 seconds versus cutting 
balloon inflated for 10 seconds then pulled out of vein segment whilst 
inflated.  
 
These experiments revealed that cuts were only identified in vein segments 
where the cutting balloons were removed from the vein segment whilst fully 
inflated (number of incisions 1(1-4) versus 0(0-0); p=0.032; Mann-Whitney U) 
This is at variance to arterial work were the balloons are designed to be inflated 
and deflated without being pulled through the vessel lumen. This necessity to 
drag the exposed blade through the lumen in order to make it cut the luminal 
surface is likely due to high vein wall compliance compared to arteries. 
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FIGURE  5.2: x1 cross-sectional image of in-vitro GSV damaged by 
withdrawing a cutting balloon through the vein lumen whilst fully inflated. 
Arrows highlight the damage caused by each of the four atherotomes. 
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Figure 5.3: x1 cross-sectional image of in-vitro GSV damaged by 
withdrawing a cutting balloon through the vein lumen whilst fully inflated. 
Arrows highlight the damage caused by each of the four atherotomes and 
the measurements taken using Aperio Imagescope.  
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Figure 5.4: Magnified view of damaged caused to GSV media by an 
atherotome on a cutting balloon withdrawn whilst fully inflated. Injury is 
almost the full depth of the media 
 
 
Figure 5.5: Further close-up of damaged caused to GSV media by an 
atherotome on a cutting balloon withdrawn whilst fully inflated. Injury is 
again almost the full depth of the media. 
 
- 232 - 
 
 
Figure 5.6: x1 cross-sectional image of in-vitro GSV. Cutting balloon was 
inflated and deflated prior to removal with no resultant atherotome blade 
cuts. 
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Figure 5.7: Cutting balloon size category versus number of atherotome 
cuts visible. 
 
Balloon sizes available were 4mm diameter with a balloon circumference (circ.) 
12.56mm, 5mm diameter and 15.7mm circumference, 6mm diameter and 
18.85mm circumference, and 7mm diameter and 21.99mm circumference.. 
Balloons were matched 1:1 with vein diameter. Experiments revealed that there 
was a significant difference between the number of atherotome blade cuts 
made with smaller (4-5mm diameter) 0 (0-1) vs larger 6-7mm diameter cutting 
balloons 0 (0-0), p=0.03. Therefore despite attempts to match veins to balloon 
size, only the 4-5mm diameter cutting balloons created any cuts in the luminal 
surface of the vein. No-matter the presumed greater force created by larger 
balloons they appear to have been restricted in the deployment of their 
atherotomes. Hence where it may have been expected that in relatively 
compliant venous versus arterial tissue larger balloons would create more 
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luminal cuts, it appears that smaller cutting balloons are needed to allow 
atherotome deployment.  
5.1.2 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF CUTTING 
BALLOONS IN COMBINATION WITH PROPRIETARY FOAM 
SCLEROTHERAPY ON IN-VITRO GSV WALL INTEGRITY 
Experiments in this case involved cutting balloons being inflated as above, 
again to a pressure of 6.0 ATM / 608kPa in lumen of test vein segment for 10 
seconds, with the balloon then withdrawn (pulled) from the test segment whilst 
inflated. Subsequently either 3% STD or 3% Polidocanol foam was placed (as 
per experiments in 2.2.2) into the vein segments for 5mins. Controls for this 
experiment had the same balloon treatment as test segments and were then 
filled with heparinised blood to control for pressure as per previous experiments.  
 
Figure 5.8: Depth of media injury caused by 3% STD with atherotome 
blade cuts versus no atherotome blade cuts. 
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Presence of atherotome cuts did not increase the depth of media injury caused 
by 3% STD. Controls treated with 3% STD had a median depth of injury of 
76.57µm (45.1, 108.05) versus those with atherotome blade cuts 85.07µm 
(79.13, 88.4) p=1.00 Mann-Whitney U.  
 
 
Figure 5.9: Vein segment demonstrating atherotome blade cuts with 
concurrent use of 3% STD. Measurements of luminal circumference, 
media depth and depth of injury by 3%STD (Aperio Imagescope) are 
displayed. 
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Figure 5.10: Effect of atherotome blade cuts on media damage caused by 
3% STD: depth of injury perpendicular to atherotome blade cuts compared 
to depth of injury in non-cut luminal surface of vein. 
 
Depth of injury perpendicular to atherotome blade cuts was no deeper than that 
created by 3% STD at the luminal surface of the same vein segments being 
77.93µm (61.35, 94.09) vs 80.32µm (49.59, 104.63) respectively, p=0.837 
Mann-Whitney U. Hence inflicting cuts on the vein lumen did not augment the 
media injury caused by STD alone.  
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Figure 5.11: Depth of injury at atherotome blade cut sites, perpendicular 
to luminal surface versus elsewhere on same vein segments. 
 
 
The depth of injury inflicted into the media perpendicular to the luminal surface 
was significantly deeper at the sites of atherotome blade cuts, 241.4µm (195.65, 
410.60) compared to elsewhere on the vein luminal surface, 77.93µm (61.35, 
94.09) p=0.001 Mann-Whitney U. 
Hence it appears that though 3% STD damages the same depth of vein tissue 
no-matter it’s surface of entry, luminal or cut media, the additional aid of a 
deeper starting point afforded by the atherotome blade cut allows for a 
significant enhancement of STD’s depth of penetration into the media relative to 
the luminal surface.  
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Figure 5.12: Media thickness compared to depth of mechanocemical 
injury.  
 
Vein wall media had a median thickness of 640µm (516-833). Depth of injury 
inflicted upon it circumferentially by 3% STD was median 77.93µm (61.35-
94.09), by atherotome blades 202.6µm (188.9-298.95) and the deepest level of 
damage at atherotome blade cut sites with additional 3% STD damage was 
241.4µm (207.8-403.6) p<0.01. 
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Figure 5.13: Percentage depth of injury seen in samples treated with 
cutting balloons and 3% STD.  
 
With STD alone the median percentage depth of media injury circumferentially 
was 13.32% (10.21, 13.8), at atherotome blade cut sites 25.56% (24.3, 38.8) 
and at the deepest level of damage at atherotome blade cut sites from the 
effects of 3% STD 48.42% (38.04, 51.48). Comparing the percentage depth of 
media injury with 3% STD alone versus 3% STD with prior use of an 
atherotome cutting blade there was a significant increase in the percentage 
depth of media injured (13.32% to 48.42% p=0.01; Mann-Whitney U). 
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Figure 5.14: x20 example of nuclear vacuolation caused by deeper 
penetration of 3% STD into the vein wall media at the site of an 
atherotome blade cut. 3% STD foam is seen in-situ on the luminal surface. 
 
 
Figure 5.15: Example of measurements made at the site of an atherotome 
blade cut (green boxes) with addition of 3% STD showing depth of cut and 
the enhanced  depth of penetration of 3% STD at this point (purple boxes: 
Aperio Imagescope)  
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Figure 5.16: Further example of measurements made at the site of an 
atherotome blade cut with addition of 3% STD showing depth of cut and 
the enhanced depth of penetration of 3% STD at this point (Aperio 
Imagescope)  
 
 
Figure 5.17: Example of an atherotome cut with concurrent 3% 
polidocanol foam. The media is not damaged at either the luminal surface 
nor at the deeper starting point afforded by the atherotome blade cut. 
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CHAPTER VI 
IN-VIVO ANIMAL STUDIES 
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6 IN-VIVO ANIMAL STUDIES 
6.1 ASSESSMENT OF THE THERAPEUTIC EFFECTS OF 
PROPRIETARY FOAM SCLEROTHERAPY, “LONGER-
LASTING” FOAM SCLEROTHERAPY AND ENDOVENOUS 
CATHETER BALLOONS (FOGARTY AND CUTTING) IN 
PORCINE VEINS 
 
This chapter presents the results from all animal experiments. All of the 
procedures were carried out by a licensed animal practitioner under the 
guidance of the lead researcher with details of experiments as per chapter two. 
 
Fore-limb veins in both animals were treated with a 3Ch Fogarty balloon 
catheter and a cutting balloon with the right fore-limbs additionally treated with 
3% STD foam. The proximally treated segment of vein was compared 
histologically to the distally untreated segment acting as control.  
Hind-limb veins were treated with either 3% STD foam or 0.15% xanthum and 
3% STD foam. The hind-veins are paired hence the paired vein acted as 
control. 
The in-vivo tissue was harvested at three months during animal termination and 
processed as per chapter two. 
Animal tissue was sectioned every 5mm, and every other section analysed. 
Initial qualitative results, examined blindly, were recorded by the lead 
researcher and consultant vascular pathologist and then in-order to more 
accurately assess samples the blinding was removed and the samples grouped 
together in the order in which they were both resected and hence sectioned. 
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This was necessary to decipher each section’s relation to one another by 
allowing a representation of the full length of the specimen. The en-bloc nature 
of the tissue specimens allowed orientation and thereby assessment of the 
effects of each treatment.  
Data were gained from a minimum of six and maximum of eight sections per 
treatment or control with two, of a maximum four cuts, analysed to derive both 
the qualitative score and quantitative results. Hence there are twelve to sixteen 
data points per treated segment for both qualitative and quantitative results. 
Due to these experiments involving only two animals, statistical analysis is 
limited to examination of the differences within each animal individually.   
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6.1.1 QUALITATIVE DATA ANALYSIS 
A scale of damage was developed according to what the desired outcome of 
the treatment on the veins would be i.e. obliteration/occlusion without damage 
to neighbouring tissue, through to what would be deemed treatment failure i.e. 
no change or worse still varicose vein formation. Thereby a qualitative scale 
was formed on this basis with the lowest score of 1 delineating the most 
effective treatment causing obliteration/occlusion, with a score of 7 for the least 
effective i.e. the treatment itself resulting in varicosities of the treated vein 
(TABLE 6.1). A score was given for each section with a minimum of two 
sections used per slide for every 5mm of tissue. The initial blindly gathered 
qualitative data for all samples was compared to the animal vein qualitative 
pathology score 2 showing no significant variance. 
 
Effect   Points 
Vein obliteration with no additional effects 1 
Vein obliteration with additional effects 2 
Recanalisation without additional effects  3 
Recanalisation with additional effects 4 
Vein patent without additional effects 5 
Vein patent with additional effects 6 
Vein varicosity  7 
 
Table 6.1: Animal vein qualitative pathology score 2 
 
Additional effects included acute inflammation, chronic inflammation, fibrosis 
and proliferative repair. 
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6.1.2 QUANTITATIVE DATA ANALYSIS 
It was clear on initial blinded qualitative analysis of animal tissue which had 
been subjected to treatment three months previous, that as per preceding 
human vein experiments measuring the acute changes of endothelial loss and 
depth of media injury, that there was no such marked change in the media or 
endothelial loss that could be measured. The only useful measure that could be 
made was the patent luminal circumference or PLC in micrometres (µm). This 
was done by ensuring that the sections of vein in question were orientated 
correctly in relation to each other to ensure that the correct vein was being 
assessed. This was necessary more so with paired hind-limb veins with one 
acting as test and the other control. The PLC could be measured for both fully 
patent and partly occluded vein segments with fully occluded segments having 
a PLC measure of 0. PLC measurements were made using Aperio imagescope 
as per chapter two.
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6.2 3% STD AND CUTTING BALLOON VERSUS CUTTING 
BALLOON ALONE  
6.2.1 QUALITATIVE RESULTS: 3% STD AND CUTTING BALLOON 
VERSUS CUTTING BALLOON ALONE  
 
Qualitative analysis of slides from both animals right fore-limb veins treated with 
Fogarty Ch3/Cutting Balloon/3%STD foam revealed widely patent veins with the 
majority of analysed sections being varicose. None of the test vein segments 
were occluded. Controls in animal 1, being distal parts of the same vein, were 
mostly normal vein segments but in animal 2 it appeared that there may have 
been some thrombosis with evidence of recanalisation.  
  3% STD with 
Cutting 
balloon and 
fogarty pre-
treatment 
Cutting 
balloon and 
fogarty 
 
Animal 1 Test  6 (5,7) 7 (7,7) p=0.101 
Control 6 (5,6) 5 (5,5)  
 p=0.639   p=0.01  
 
Animal 2 Test  7 (7,7) 7 (7,7) p=0.730 
Control 4 (3.25,4) 5 (5,5)  
 p=0.036 p=0.029  
P values derived from Mann-Whitney U test 
Table 6.2: Animal vein qualitative pathology score 2 results for 3% STD 
and cutting balloon treatment versus cutting balloon alone. 
 
Qualitative scores for animal 1 (Fogarty Ch3/Cutting Balloon/3%STD foam) 
were 6(5,7) and its control segment, 6(5,6), p=0.639  Mann Whitney U revealing 
no difference, yet those for animal 2, 7(7,7) and its control, 4 (3.25,4) p=0.036 
reached significance. It is difficult to draw any conclusions regarding the non-
significant difference between this treatment and its control in animal 1 and the 
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significant difference in animal 2. This could be explained by a thrombus 
propagating in a retrograde fashion in animal 2.  
Veins treated with Fogarty Ch3/Cutting Balloon alone in both animals were 
found to be varicose and their respective controls showed normal vein. 
Treatment with Fogarty and cutting balloons therefore appears to have altered 
the treated section of vein compared to control segments, but unfortunately to 
become varicose. 
Comparing the two treatments, Fogarty Ch3/Cutting Balloon/3% STD foam 
versus Fogarty Ch3/Cutting Balloon alone within animal 1 [6(5,7) versus 7 (7,7)] 
showed no difference, p=0.101 with both causing varicosities. Similarly in 
animal 2 comparison of the same treatments [7 (7,7) versus 7 (7,7)] p=0.730 
showed no difference. Hence it appears that the addition of 3% STD to the 
cutting balloon treatments made no difference.  
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Figure 6.1: Animal vein qualitative pathology score 2 results for 3% STD 
and cutting balloon treatment versus cutting balloon alone (Animal 1 and 
2 scores combined for graphical purposes only). 
 
 
 
 
 
 
- 251 - 
 
6.2.2 QUANTITATIVE RESULTS: % STD and cutting balloon versus 
cutting balloon alone 
 
  3% STD with 
Cutting 
balloon and 
fogarty pre-
treatment 
Cutting 
balloon and 
fogarty 
 
Animal 1 Test  2654µm  
(2517, 3611) 
3424µm 
(3105, 5164) 
p=0.138 
Control 1481µm  
(1481, 1843) 
1047µm  
(974, 1110) 
 
 p=0.01  p=0.01  
 
Animal 2 Test  4864µm 
(3438, 5844) 
5802µm 
(5387, 6037) 
p=0.730 
Control 1217µm  
(793, 2317) 
432µm  
(424, 439) 
 
 p=0.016 p=0.029  
P values derived from Mann-Whitney U test 
Table 6.3: Patent luminal circumference/PLC (µm) for Fogarty Ch3/cutting 
balloon/3%STD foam versus Fogarty Ch3/cutting balloon. 
 
There was a statistically significant difference between all test segments PLC 
and their respective control segments highlighting that the treatment had indeed 
altered the vein. Overall however no difference was noted between the two 
therapies resultant PLC’s when compared to each other within both animals. 
These quantitative results reflect the qualitative results, showing that dilated or 
varicose veins resulted from treatment involving balloons, with control segments 
being of a smaller calibre.  
- 252 - 
 
Figure 6.2: Patent luminal circumference (PLC) (µm) for 3% STD and 
cutting balloon treatment versus cutting balloon alone (Animal 1 and 2 
results combined for graphical purposes only). 
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Figure 6.3: x3 Example of forelimb vein experiments with varicosity 
created by cutting balloon and 3%STD treatment   
 
  
 
Figure 6.4: x1 Example of varicosity created by cutting balloon treatment 
and 3% STD treatment     
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Figure 6.5:x4 Example varicosity created by 3% STD and cutting balloon 
treatment 
- 255 - 
 
6.3 0.15% XANTHUM AND 3% STD VERSUS 3% STD ALONE 
6.3.1 QUALITATIVE RESULTS: 0.15% XANTHUM AND 3% STD 
VERSUS 3% STD ALONE 
Qualitative analysis of hind-limb veins in animal 1 revealed that vein treated with 
0.15% xanthum and 3% STD was obliterated with some sections having fibrosis 
and others with at worst some evidence of recanalisation. The qualitative 
pathological vein score was median 2(1,3) with paired vein control score being 
5(5,5) i.e. normal vein. Analysis of animal 2’s hind-limb vein similarly treated 
with  0.15% xanthum and 3% STD foam revealed similar changes to animal 1 in 
that the vein was obliterated with occasional areas of fibrosis and a qualitative 
pathological vein score of 1 (1,1.5) with paired vein control score again being 
5(5,5) i.e. normal vein. 
Animal 1’s vein treated with 3% STD foam had recanalised with the additional 
effects of fibrosis noted. The qualitative pathological vein score using 3% STD 
in animal 1 was median 4 (3.5,4). Animal 2’s vein treated with 3% STD was 3% 
STD again recanalised with an area of obliteration surrounding fibrosis with a 
qualitative pathological vein score of 4 (4.5,5.75). Qualitative pathological vein 
score for paired vein control segments for both animal’s hind-limb vein 3% STD 
experiments were 5(5,5) i.e. normal vein. 
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  0.15% 
Xanthum & 3% 
STD 
3% STD  
Animal 1 Test  2 (1,3) 4 (3.5,4) p=0.035 
Control 5 (5,5) 5 (5,5)  
 p=0.01 p=0.365  
 
Animal 2 Test  1 (1,1.5) 4 (4.5,5.75) p=0.01 
Control 5 (5,5) 5 (5,5)  
 p=0.01 p=0.485  
P values derived from Mann-Whitney U test 
Table 6.4: Animal vein qualitative pathology score 2 results for 0.15% 
xanthum and 3% STD versus 3% STD alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence there was a significant difference between Xanthum/3%STD’s test 
segment scores versus its respective controls in both animals, but not for 
scores with 3 % STD versus its controls. In both animals a significant difference 
is found when results from Xanthum/3%STD are compared with those from 3 % 
STD with more favourable results in terms of vein occlusion at three months 
occurring with Xanthum/3%STD than with 3% STD. 
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Figure 6.6: Animal vein qualitative pathology score 2 for 0.15% xanthum 
and 3% STD versus 3% STD alone (Animal 1 and 2 results combined for 
graphical purposes only) 
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Figure 6.7: x2.4 Example of hind-limb experiments with control vein on left 
patent (lumen highlighted in red) and test vein on right (arrow) obliterated 
post treatment with 0.15% xanthum and 3% STD    
 
 
 
Figure 6.8: x2 Example of patent control vein and test vein (arrow) 
obliterated using with 0.15% xanthum and 3% STD    
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Figure 6.9: X1 Example of distal segment in hind-limb with patent test and 
control veins in limb tested with 3% STD foam into more proximal aspect 
of vein with lumen circled in red. 
 
 
 
Figure 6.10: x2 Example of recanalisation of 3% STD treated test vein on 
left with neovascularised lumens marked in green. Control vein lumen is 
marked in red. 
 
 
- 260 - 
  
Figure 6.11: x6 Example of recanalisation of 3% STD treated test vein 
 
 
Figure 6.12: x2 Example of test vein obliteration using 3% STD (arrow) 
with patent control vein   
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6.3.2 QUANTITATIVE RESULTS: 0.15% XANTHUM AND 3% STD 
VERSUS 3% STD ALONE 
 
  0.15% 
xanthum & 3% 
STD 
3% STD  
Animal 1 Test PLC 268µm  
(0, 540) 
1926µm  
(1495, 3102) 
p=0.01 
Control PLC 1013µm  
(913, 1436) 
1857µm  
(1160, 2510) 
 
 p=0.026  p=0.694  
 
Animal 2 Test PLC 0µm  
(0, 609) 
1070µm 
(975, 1183) 
p=0.023 
Control PLC 1367µm  
(919, 1701) 
1704µm  
(1063, 2765) 
 
 p=0.035 p=0.24  
 
Table 6.5: Patent luminal circumference/PLC (µm) for Xanthum/3%STD 
foam versus 3%STD foam 
 
Hence Xanthum/3%STD significantly reduced the patent luminal circumference 
of the treated veins in comparison to its controls in both animals whereas 
3%STD did not. Moreover Xanthum/3%STD significantly reduced the patent 
luminal circumference in comparison to veins treated with 3% STD alone across 
both animals.  
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Figure 6.13: Patent luminal circumference/PLC (µm) for Xanthum/3%STD 
foam versus 3%STD foam (Animal 1 and 2 results combined for graphical 
purposes only) 
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6.4 CONCLUSIONS  
6.4.1 3% STD AND CUTTING BALLOON VERSUS CUTTING 
BALLOON ALONE  
Qualitative and quantitative results showed that in both animals the two cutting 
balloon related treatments resulted in making the veins varicose as opposed to 
occluding them. Regarding these varicose changes to test segments, it appears 
that the balloon treatments have in fact stretched the vein walls and made it 
less likely that they will occlude with or without subsequent use of 3% STD 
foam. All experiments involved trawling an inflated cutting balloon within the 
lumen after trawling with a Fogarty Ch3 balloon. The cutting balloon size was 
matched to the treated vein although the pig veins were narrower calibre than in 
previous human experiments. It is likely from analysis of veins in the human 
cutting balloon experiments that in instances where the vein diameter is too 
small in relation to the cutting balloon that in fact the atherotomes may not have 
deployed. However in this partially open experiment with part of the treated vein 
exposed, it was possible to see that the atherotomes were at least partially, if 
not fully deployed.  
In summary Fogarty and cutting balloon treatment with or without 3% STD 
caused varicose changes in the treated vein instead of the desired obliteration/ 
occlusion. It appears that the addition of 3% STD to the cutting balloon 
treatments made no difference.  
It would appear that either the balloons were too large compared to the treated 
veins and caused a significant structural deformity by overstretching the vein 
wall resulting in varicosities or the atherotomes rather than cause venous 
scarring and fibrotic occlusion heightened by an increased influx of sclerosant 
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into the vein wall, actually weakened the vein wall such that it was rendered 
structurally deficient therefore caused varicosities.  
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6.4.2 0.15% XANTHUM AND 3% STD VERSUS 3% STD ALONE 
Xanthum/3%STD treated segments had a significantly lower qualitative score 
and PLC, both markers of treatment success, versus its respective controls in 
both animals, but this was not the case for 3 % STD versus its controls. 
Moreover Xanthum/3%STD had significantly lower qualitative scores and 
reduced the patent luminal circumference in comparison to veins treated with 
3% STD alone across both animals.  
From these preliminary animal tests it appears that Xanthum/3%STD shows 
promise as a treatment for varicose veins with more favourable results in terms 
of vein occlusion at three months occurring with Xanthum/3%STD than with 3% 
STD. 
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CHAPTER VII 
DISCUSSION AND CONCLUSIONS 
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7 DISCUSSION AND CONCLUSIONS 
Primary varicose veins are a common problem with a multitude of treatments 
which suggests that the search continues for the optimal treatment. Minimally 
invasive treatments show the most promise as they at least appear to match the 
recurrence rates of surgery but with lower morbidity. Minimally invasive 
treatments that have shown most success thus far are those that damage the 
GSV with thermal related injury. However, the device purchase and 
consumables and the requirement for tumescence all increase the cost. In 
contrast sclerotherapy is less expensive and requires little in the way of 
specialist equipment. Further, success rates may be greater when foam 
sclerotherapy is used. UGFS can be repeated but this increases the cost 
financially and in terms of time and man-power. It also relies on significant 
patient compliance. Despite 150 years of unregulated human experimentation 
the “perfect sclerosant,” free from complications and causing permanent vein 
occlusion has not been found. The desired functions of sclerosing solutions are 
the destruction of venous endothelial cells, exposure of subendothelial collagen 
fibres, and ultimately fibrotic occlusion of the treated vein13. Endothelial damage 
is enhanced by greater concentrations of sclerosant although side effects, 
particularly pigmentation are more common with stronger solutions of the 
commonly used sclerosants. The use of foam increases the surface area of vein 
wall that is treated and prolongs the contact time of the sclerosants. This ought 
to amplify the effect of the agent.  
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The hypothesis of this thesis is that current foam sclerotherapy can be modified 
or assisted via other means to improve its efficacy.  
As a starting point this thesis examines current primary varicose veins 
treatments at the outset of this research. STD and polidocanol foams, which 
appear to have the best proven efficacy and are the most widely used 
worldwide, are examined in chapter three regarding their foam half-lives and in 
chapter four regarding their activity against a novel in-vitro GSV model to assist 
in answering the question, is foam longevity the most important factor in 
determining the efficacy of UGFS and which of the most widely used scleroant 
foams is most potent? In chapter three, the half-life of 3% polidocanol foam is 
shown to be much longer than that of 3% STD. In chapter four experiments 
show that 3% STD is the most active sclerosant agent in terms of damage to 
the vein wall compared with polidocanol. It therefore appears from the results 
obtained that the active ingredient is the most important factor and not the foam 
half-life.  
The next set of experiments in chapter four again pose the question, is the 
longevity of foam a factor in its efficacy? This question is answered by 
examining the damage inflicted on vein wall by STD foams with prolonged half-
lives. There are few studies detailing the pathological changes induced by 
sclerotherapy on varicose veins. An in-vitro GSV model was used for this 
research to allow testing of multiple agents in order to gain answers to the 
questions of this thesis.  This model is used firstly to assess the constituent 
parts of proprietary STD to ensure that, as is proven the case, STD itself is in 
fact the most active agent against the vein wall. Experiments appear to show 
that the ingredients included in proprietary STD are synergistic in that the 
combination causes more damage compared with its separate parts. This 
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however could be due to a fault of experimental methodology e.g. the buffer 
used with STD. One of the key questions of this research is does prolonging 
foam longevity improve foam efficacy? Results in chapter four have shown that 
longer lasting STD foams do not enhance its activity against the vein wall, at 
least acutely. Therefore, it appears that the active agent in its current 
proprietary form is optimal, at least according to these in-vitro results. 
The further question of whether adjuncts can improve the efficacy of STD foam 
is examined. Ikponmwosa et al formerly investigated this question in terms of 
Fogarty catheters used prior to foam sclerotherapy, which did not appear to 
improve its efficacy against the vein media. In this research cutting balloons are 
tested as a potential pre-treatment prior to the use of foam sclerotherapy. They 
appear to increase the depth of penetration of sclerosant foam into the vein wall 
media by affording the sclerosant a deeper starting point. If intermittent 
increased depth of penetration of sclerosant foam and resultant enhanced 
depth of STD vein wall injury were to translate to improved efficacy of foam 
sclerotherapy through subsequent fibrosis, then this adjunct does show 
promise. In order to ascertain whether cutting balloons used prior to foam does 
translate to improvement of foam sclerotherapy using STD alone, preliminary 
animal studies were carried out on a porcine model. Animal studies were 
performed on two pigs with test experiments performed and the vein samples 
collected and analysed three months later. These preliminary studies of cutting 
balloons used as adjuncts to foam sclerotherapy show that rather than assist in 
the occlusion/obliteration of the treated vein, the balloons appear to have 
damaged the structure of the vein wall leaving them varicose which is in effect 
the opposite of the desired treatment effect. 3% STD foam and the most 
promising of the longer lasting foams were also tested and results show that 
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counter to those of the in-vitro studies that in fact 0.15% xanthum and 3% STD 
actually outperformed proprietary 3% STD in causing vein occlusion.  
Discussion of each chapter is included below. 
 
7.1 FOAM HALF-LIVES  
Chapter three shows that 3% polidocanol foam lasts longer than 3% STD foam 
with a median difference of 21.3sec and 53.2sec for T90 and T50 respectively. 
Similar differences between the longevity of the respective foams have been 
found by others using different strengths of these sclerosants35. This may be 
related to the larger molecular size of polidocanol thus enhancing its surfactant 
and foaming properties. This ought to be beneficial given that foam 
sclerotherapy is considered more efficacious than liquid sclerotherapy because 
of a longer contact time between the sclerosant and the endothelial cells13 
however subsequent results refute that. 
Areas for improvement in these experiments include that varying initial volumes 
of foam were observed during these experiments. Although a graduated syringe 
was used to draw up the liquid to a volume of 2mL for foaming, there may have 
been small volume variation above or below this. This also applies to the 
volume of air drawn up in the second syringe to produce the foam. A smaller 
syringe, with smaller increment markings could have been used to draw up the 
initial volumes and then this transferred to a 10mL syringe. It would however 
have proved difficult to transfer the liquid completely as viscous liquids adhere 
to the syringe wall.   The results however were reproducible.  
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7.2 ASSESSMENT OF THE HISTOLOGICAL EFFECTS OF 
TESTED FOAMS 
Experiments in chapter four involve a novel in-vitro model for the assessment of 
foam sclerosants on human GSV samples from patients with primary varicose 
veins. Firstly the model was tested using normal saline compared with 
heparinised blood from the patient which acted as the control for future foam 
related experiments. The model proved effective in that endothelial loss was 
minimal and there was no media damage inflicted by normal saline or 
heparinised blood. Though this model is relatively simple and could be criticised 
mainly on the basis of being in-vitro, it gave consistent results over the whole 
period of this research and allowed multiple experiments to be carried out due 
to the high patient number, based on the simplicity of the model.   In-vivo testing 
in humans though the ideal, is not realistic in this country from an ethical 
perspective and many of the questions from this chapter could be answered to 
an appropriate degree using in-vitro experimentation. Examining the most 
widely used proprietary foams revealed that though endothelial loss was similar 
using STD and polidocanol, the median depth of injury and the percentage of 
media injured were significantly higher with STD. Although there are no other 
histological studies with which to compare these findings they would support the 
clinical view that STD is a more potent sclerosant than polidocanol with higher 
concentrations of the latter necessary to produce the same effect3-5, 35, 36. Our 
model has shown that in fact the same effect clinically is possibly derived from 
very different effects at the cellular level, as it would seem unlikely that 
polidocanol has any propensity to damage the vein media in-vivo if it does not 
do so in-vitro. Of the two proprietary foams this research appears to show that 
STD foam is the only sclerosant likely to damage the media in-vivo, however, 
we cannot prove this. 
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The constituent parts of proprietary STD were examined in the same way 
showing as expected that STD is the most active ingredient as opposed to 
benzyl alcohol which is included in the proprietary product for its preservative 
function. Of note when broken down into its constituent parts STD foam did not 
damage the vein media as opposed to proprietary STD foam. This indicates that 
either the combination of STD and benzyl alcohol in proprietary STD is 
synergistic, or our buffering mechanism was at least interfering with the activity 
of STD against the media. This question could be answered by working in 
conjunction with the manufacturers of STD and using a more appropriate 
buffering agent simply extracting the benzylalcohol from proprietary STD foam.  
Compared to proprietary 3% STD foam, longer lasting 3% STD foams did not 
inflict greater injury on either the GSV endothelium or media. Indeed, the 
addition of pluronic had a negative impact on the efficacy of 3% STD in terms of 
both endothelial loss and damage to the vein media. Conversely, 3% STD and 
xanthum showed a trend towards enhanced media damage compared to 3% 
STD at least in 5 minute experiments, but this still failed to reach statistical 
significance.  
Combining results from chapters three and four it is evident that although 
polidocanol foam shows greater stability than STD foam and may thus remain in 
the treated segment of vein for longer (in-vivo), damage to the media is 
significantly greater with STD. Similarly it appears that modifying proprietary 
STD to increase the foam half-life does not improve its efficacy in damaging the 
vein wall. Parsi et alfound that the therapeutic effect of a sclerosant appears to 
occur in the first few seconds after injection19. Thus it is possible that as long as 
the active drug is distributed to the target area, longer exposure may not 
significantly increase its efficacy. Certainly our results suggest that the longevity 
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of the foam matters less than the active ingredient. A question that arises from 
this is that, if the active ingredients damage a certain depth of media and this is 
all done upon the first contact between treated surface and sclerosant, is there 
a possibility that an immediate or planned early but delayed repeat treatment 
with foam could inflict a greater degree of damage on vein wall?  
Furthermore on the basis this work it seems likely that the initial success of 
sclerotherapy is associated with simple thrombotic occlusion and that 
recanalisation is promoted by persisting islands of endothelial cells and the 
absence of significant fibrosis due to the failure to inflict a significant injury to 
the media. Although this hypothesis seems logical this study only assesses the 
immediate impact of sclerotherapy in an in vitro model. It is possible that these 
sclerosants may cause greater tissue damage in vivo.  
 
Although the findings of this section of results appear robust in their being 
repeatable, it has a number of shortcomings. These include the previously 
discussed in-vivo versus in-vitro issue but also the relatively small number of 
veins tested per experiment. This research demanded a method that allowed 
throughput of a significant number of patients to allow the relevant questions to 
be answered, yet the defined research period coupled with the competing 
relative lack of patients having open surgical procedures during this age of 
minimally invasive therapies meant that this number of five patients per test was 
deemed an appropriate balance between these factors.  
Furthermore whilst animal models could be used as the next best thing to in-
vivo human studies, animal research expense would preclude large numbers. In 
addition there is no established animal model with SFJ and GSV incompetence. 
The advantage of the human in-vitro GSV model used in this research is that it 
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can easily be used in the initial assessment of longer lasting foams and novel 
sclerosants.  
 
7.3 CUTTING BALLOONS AS ADJUNCTS TO FOAM 
SCLEROTHERAPY 
Experiments assessing cutting balloons as a potential adjunct for foam 
sclerotherapy certainly showed promise for improving its efficacy by affording 
the foam a deeper starting point for sclerosant to damage the vein wall. The 
depth of injury inflicted into the media, perpendicular to the luminal surface, was 
significantly deeper at the sites of atherotome blade cuts, 241.4µm (195.65, 
410.60) compared to elsewhere on the vein luminal surface, 77.93µm (61.35, 
94.09) p<0.01 Mann-Whitney U. This translates to 13.32% (10.21, 13.8) depth 
of media injured using 3% STD alone versus 48.42% (38.04, 51.48) at 
atherotome blade cut sites, with the combined effects of a cutting balloon used 
prior to application of 3% STD foam p<0.01 Mann-Whitney U.  
Potential problems with the experimental methods in these human GSV in-vitro 
cutting balloon studies include that firstly the balloons are designed for arterial 
work and not vein specific. This could not be overcome during the timeframe of 
this research as no such device exists and there is no precedent, therefore this 
was the most appropriate device in the circumstance. Secondly due to the 
expense of arterial cutting balloons those used were second hand and were 
used (maximally) twice further in these experiments. These cutting balloons 
were used despite these obvious issues as the experiments were designed to 
make initial assessments of the potential of these devices as adjuncts for foam 
sclerotherapy. The expense of new balloons for each experiment was not a 
viable alternative at this stage of research into such adjuncts. Notwithstanding 
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the above problems, results show that larger balloon sizes did not inflict 
atherotome blade cuts in the vein media. Matching the balloon to vein sizes was 
necessary to attempt to optimise the use of each balloon and not cause 
significant mechanical stretch of the vein wall. This was done as much as 
possible however matching was limited by the range of balloons available and 
occasionally by the range available at a given time. This limitation has however 
inadvertently allowed the question of the most appropriate arterial cutting 
balloon size required to cause atherotome blade damage to vein tissue to be 
answered. Smaller balloons inflict more atherotome blade cuts as the blade 
delivery mechanism of larger balloons is restricted in larger balloons, despite 
the increased compliance of veins over arteries. Thirdly, the moist swab held 
closed with finger pressure, used to mimic the extrinsic pressure of the 
subcutaneous component of the average upper thigh was basic. However other 
models considered were more expensive without any significant improvement in 
function.   
Experiments in chapters four and five reveal that 3% STD damages the same 
depth of vein no-matter its surface of entry. Pre-treatment with a cutting balloon 
allows for a significant enhancement of STD’s depth of penetration at the site of 
atherotome blade cut sites. Whether this translates to improved efficacy of 3% 
STD requires in-vivo studies which are conducted in preliminary animal studies 
in chapter six. 
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7.4 ANIMAL STUDIES 
Results of animal fore-limb vein experiments revealed that Fogarty and cutting 
balloon treatment with or without 3% STD caused varicose changes in the 
treated vein instead of the desired obliteration/ occlusion. It appears that the 
addition of 3% STD to the cutting balloon treatments made no difference. It 
would appear that either the balloons were too large compared to the treated 
veins and caused a significant structural deformity by overstretching the vein 
wall resulting in varicosities or the atherotomes rather than cause venous 
scarring and fibrotic occlusion enhanced by an increased influx of sclerosant 
into the vein wall, rather weakened the vein wall such that it was rendered 
structurally deficient therefore caused varicosities. In hind-limb experiments 
Xanthum/3%STD had significantly lower qualitative histopathology animal vein 
scores and reduced the patent luminal circumference, both markers of 
treatment success, in comparison to veins treated with 3% STD alone within 
both animals.  Results from these studies would suggest that Xanthum/3%STD 
has promise as a treatment for varicose veins with more favourable vein 
occlusion results at three months compared with 3% STD.  
 
No other animal suffers from varicose veins hence the difficulties in obtaining a 
suitable model. Other animal models were researched and assessed and the 
advice of experts in the field was sought before the decision was made to use 
pigs as the test model. These preliminary experiments performed on a pig 
model presented difficulty due to the different anatomy and sizes of vessel.  At 
the time of the experiments it was obvious that the hind-limb veins were not 
usable for catheter related experiments and the experiments could not be 
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conducted as planned.  In order to utilise the animal to its fullest extent, hind 
limb vein experiments were adjusted to compare proprietary 3% STD foam to 
the best of the longer lasting foams. This resulted in no whole single leg vein 
acting as a control but this was felt justifiable on the basis of maximising use of 
the animals and the number of experiments performed. Beyond this difficulties 
with fore-limb vein experiments were encountered largely in the placement of 
balloon catheters into what were smaller veins compared to human GSV. 
Unfortunately the result was that the number of passes of respective balloon 
catheters was not uniform however was kept so as much as possible.  Attempts 
to use the smallest available cutting balloon catheter (3mm) were thwarted by 
the fact that it is not usable with a guidewire and therefore would not advance 
with ease. A 4mm catheter was the smallest available that was passable with 
relative ease but was less well matched to the treated vein size. These practical 
issues were only raised when experimentation had begun and though 
adaptations were made they do lead to differences in the planned experimental 
methods hence affect interpretation of the results. Beyond this other issues 
such as the partial open nature of the procedures and resultant wound healing 
over the vein, the unlicensed use of xanthum with STD in the same animal, the 
lack of ability to place dressings on the hind legs and other variations and 
anomalies do effect interpretation of the results. As a preliminary model there 
are certainly positives to take from these learning points and the results which 
were achieved. The results highlight the need for any further research into 
mechanical adjuncts for foam sclerotherapy in the form of cutting balloons, to be 
conducted with balloons of a smaller maximal diameter than the treated vein. In 
fact it is likely for venous use that any such adjunct should not include a balloon 
at all, as it appears from both human and animal studies in this research and by 
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Ikponmwosa et al that balloons do not add mechanical benefit  on their own and 
unless very small likely hinder the object of the treatment. Cutting balloons in 
their current form are very expensive, which would in itself, render them 
impossible to justify as an adjunct to foam sclerotherapy. The mechanisms 
involved in deploying the atherotomes in cutting balloons as well as the 
atherotomes themselves are the cause of their great expense and  both 
faculties in relation to mechanically damaging the media of veins are likely 
unnecessary. It would appear from this research that an adjunct to foam 
sclerotherapy should be something more in keeping with a valvulotome with 
retractable blades.  Experimentation with foams on hind-limb veins had the 
advantage of an inherent though not perfect control of the paired vein. The 
disadvantage with these veins is the transfer value of results to human GSV, in 
that the vein calibre was extremely small in comparison. Vein obliteration 
occurred significantly more with the use of 0.15% xanthum and 3% STD but it 
did occur with 3% STD alone. It is difficult to establish whether this is in fact as 
a result of the “strength” of the treatments or the “weaknesses” of the veins 
which were very thin walled. Results need to be interpreted with this in mind, 
though there is certainly more activity against the vein wall using the longer 
lasting STD foam in these preliminary animal experiments, which is certainly 
promising.    
Occasional vein segments treated with either 0.15% xanthum and 3% STD as 
well as 3% STD alone showed evidence of recanalisation which is a marker for 
potential treatment failure. Of particular interest is that results here show that 
segments above and below obliterated segments are recanalised. It is known 
that even when complete endothelial loss is achieved re-endothelialisation may 
still occur via circulating endothelial progenitor cells. It would be thought much 
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less likely when the vein is obliterated but these results show that in this pig 
model where obliteration is segmental recanalization can occur even in a three 
month time frame. This certainly would prove ominous for any varicose vein 
treatment and is likely the downfall somewhere along their course for all 
treatments for this condition. 
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LIST OF ABBREVIATIONS 
AOR Adjusted odds ratio 
CEAP Clinical Etiological Anatomical Pathophysiological  
CI Confidence intervals 
CLASS Comparison of LAser, Surgery and foam Sclerotherapy  
CVD Chronic venous disease 
EVLT  Endovenous laser therapy 
GSV  Great Saphenous vein 
H&E Haematoxylin and eosin  
HES Hospital episode statistics 
ICER Incremental cost-effectiveness ratio 
Min  Minute 
µm Micrometre 
NICE National Institute for Clinical Excellence 
RCT Randomised control trial 
RFA Radiofrequency ablation 
Sec  Second 
SFJ Sapheno-femoral junction 
SPJ  Sapheno-popliteal junction 
SSV  Short saphenous vein 
STD  Sodium tetradecyl sulphate 
SVT Superficial venous thrombosis 
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APPENDIX I 
PATIENT INFORMATION SHEET (VERSION 3) 12/01/2008 
 
Study: “Development of an ideal model for foam sclerotherapy in the 
treatment of primary varicose veins” 
  
Investigation of a new method in the treatment of varicose veins 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done. We will explain what it would 
involve for you. Please take time to read the information carefully.   
 
Ask us if anything is unclear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Purpose of the study 
 
Varicose veins are very common and new ways of treating the condition are 
being looked at. We would like to look at ways of improving methods for treating 
varicose veins. In the future it may mean that treatment can be done as an 
outpatient. 
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It is completely up to you to decide to take part. We will describe the study and 
go through this information sheet, which we will then give to you. We will then 
ask you to sign a consent form to show you have agreed to take part.  
 
You are free to withdraw at any time, without giving a reason. 
 
This would not affect the standard of care you will be given. 
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If I decide to take part? 
 
You have been offered surgery for varicose veins. This involves tying off the vein 
(faulty blood vessel) at the main link in the groin. Two small cuts (about 5mm long) are 
made. One in the groin at the top of the main faulty vein and one near your knee. The 
top end of the vein in your groin is tied. Then a flexible wire is passed through the vein. 
The wire, along with the vein, is carefully pulled out of the leg through the cut near your 
knee (see figure 1).  
                        
Figure 1.Inside view of right leg. 
 
To perform the research:  
We would like to do an experiment on the vein after collection. We will be adding a 
treatment called foam sclerotherapy. This is to see if it can be used to close veins. This 
could prevent an operation for varicose veins in the future. For the experiment to work, 
we need to wash the vein before we can look at the effects of the foam. We therefore 
need a small blood sample (5ml) to wash the vein. This can be taken when your drip 
line is placed before your anaesthetic or form the vein itself. You will not need any extra 
needles to take the blood 
Vein removed through cut near knee 
Varicose vein  
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Are there are any risks? 
No, there is no increase in the risk of the operation. You will have the same 
treatment and there will not be any extra cuts on your leg. You will not need any 
extra needles to take the blood sample. 
You will not have any more pain or discomfort because of this extra procedure. Your 
operation will be longer by 2-3 minutes. 
The information we get from this study will potentially help other people with varicose 
veins and provide a range of options for treatment of this condition. 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. All information which is collected about you during the research 
will be kept strictly confidential. All tissue samples will have your name removed. 
 
 
What will happen to my samples? 
 
Once we have analysed data from the samples they will be destroyed. We will 
not store any samples after they have been used for this study.  
 
- 285 - 
 
What will happen if I don’t want to carry on with the study? 
 
If you withdraw from the study, we will destroy all your identifiable samples, but 
we will need to use the data collected up to your withdrawal. 
 
Complaints 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (Dr Barry McAree or Mr M 
J Gough 0113 2432799). If you remain unhappy and wish to complain formally, you 
can do this through the NHS Complaints Procedure. Details can be obtained from the 
Leeds General Infirmary. 
 
Further Information 
For further information about the project please contact: Mr Barry McAree 
01132432799. For independent advice regarding taking part please contact: Research 
and Development, Leeds General Infirmary 01132432799. 
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12/01/2008 
Consent Form (Version 3) 
 
 
Research study: Investigation of a new method in the treatment of 
varicose veins 
 
 
 
Researcher: Barry McAree 
 
 
I have read and understand the information sheet for the study. I have had the chance 
to think about the information and ask questions.    YES/NO 
 
 
I agree that left over tissue samples removed during my treatment may be  
used for research. The tissue samples will be discarded after research.  
          YES/NO  
 
I agree that a blood sample can be taken. This will be discarded after research 
          YES/NO
       
 
I agree to my GP being told of my taking part in the study   YES/NO  
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I agree to take part. This is voluntary and I am free to leave at any time without giving a 
reason. This will not affect my medical care or legal rights.     
         YES/NO 
 
 
 
 
 
_______________ ________________ _________________  
Name of Patient         Date                         Signature  
 
 
 
 
_________________ ________________ ___________________  
 
Name of Researcher  Date    Signature  
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APPENDIX II 
ANIMAL RESEARCH PROTOCOL 
Optimisation of medical/minimally invasive treatment of primary varicose 
veins: establishment of an animal (porcine) model to assess the 
therapeutic effects of current marketed foam sclerotherapy, optimised 
foam sclerotherapy and endovenous catheters versus control. 
Version 4; 31/05/2011 
SUMMARY 
Title: Optimisation of medical/minimally invasive treatment of primary varicose 
veins: establishment of an animal model to assess the therapeutic effects of 
licensed foam sclerotherapy, optimised (unlicensed for human use) foam 
sclerotherapy and endovenous catheter therapy (unlicensed for human use), 
versus control on porcine superficial veins. 
Objectives: to ascertain the haemodynamic, ultrasonographic and 
histopathological changes of superficial porcine veins treated with licensed 
foam sclerotherapy, optimised (unlicensed for human use) foam sclerotherapy 
and endovenous catheter therapy (unlicensed for human use), versus control. 
Design 
Study endpoints:  
 Haemodynamic changes: patency, reflux and ultrasonographic changes  
 Histopathological analysis -  degree and  extent of tunica intima and 
media damage  
 
INTRODUCTION 
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Sclerotherapy has been used for several decades in the treatment of smaller 
varicose veins either alone or in combination with conventional ligation of the 
saphenofemoral junction (SFJ). Ultrasound-guided foam sclerotherapy involves 
a sclerosant solution forcibly mixed with air or another gas (CO2) to produce 
foam. Compared with liquid, foam displaces blood from the vein lumen and thus 
has greater contact (both duration and extent) with the venous endothelium with 
the intention of increasing the efficacy of the procedure. This technique has 
further enabled the use of sclerotherapy in the treatment of great (GSV) 1,2 and 
small (SSV) saphenous vein incompetence. In man the procedure performed 
either without anaesthesia or after administration of local anaesthesia. The 
foam mixture is injected into the superficial vein and its distribution monitored 
with ultrasound. The upper end of the vein may be compressed to prevent the 
foam entering the deeper veins. Subsequent vein occlusion is initially the result 
of thrombosis following widespread disruption/destruction of the endothelium. 
However there is no evidence that significant injury is inflicted to the tunica 
media (in particular the collagen bundles) which is a dominant feature of the 
thermal minimally invasive techniques that are currently employed in the 
treatment of superficial venous incompetence.3,4 The latter is believed to be 
central to promoting permanent venous occlusion and elimination of superficial 
venous incompetence. Further, evidence from our own laboratory has shown 
that with conventional foam sclerotherapy islands of endothelial cells persist 
and this may explain the relatively high incidence of re-canalisation (up to 30% 
at 3 years) with this treatment.5   
Various sclerosants and aeration methods may be used to produce the foam for 
this procedure. However the most widely used technique in the UK is that 
described by Tessari 6,7using air and sodium tetradecyl sulphate (STD) at a 
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ratio of 3:1.  Early results of a randomised trial comparing foam sclerotherapy to 
conventional surgery have demonstrated quicker return to normal activities and 
similar short term occlusion rates, although as indicated above medium term 
recurrence rates (for superficial reflux) are disappointing.1,2  
Although our previous studies have highlighted some of the reasons why foam 
sclerotherapy may have limited medium term success it is possible that if the 
foam was in contact with the vein for longer that deeper vessel injury may occur 
thus achieving denaturation and contraction of the collagen bundles in the 
tunica media.. To that end a method has been developed that increases the 
half-life of foam from around 160 seconds to greater than 15 minutes. As an 
alternative to chemical destruction of the endothelium and tunica media, 
mechanical (balloon) denudation of the endothelium and injury to the tunica 
media with an additional specialised catheter might prove effective on the basis 
that a combination of these two events appears important in achieving 
permanent vein ablation.  Endovenous catheter balloon therapy might provide a 
possible alternative minimally invasive therapy for the treatment of varicose 
veins either alone or in combination with foam sclerotherapy. This hypothesis is 
currently being assessed in a series of ex-vivo experiments using GSV 
harvested from patients with GSV incompetence undergoing conventional 
surgery for their varicose veins.  
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STUDY AIM 
The aim of this study is to ascertain the haemodynamic, ultrasonographic and 
histopathological changes in porcine superficial veins treated with licensed foam 
sclerotherapy, optimised (unlicensed for human use) foam sclerotherapy and  
endovenous catheter therapy (unlicensed for human use), versus controls (no 
intervention). 
STUDY POPULATION/SAMPLE SIZE/RANDOMISATION  
In the first instance two animals (4 veins: one per limb) will be studied over 12 
weeks to confirm that the model is feasible. On the assumption this proves to be 
the case it is likely that further animals will be studied. 
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STUDY PROCEDURE 
Porcine superficial veins are similar to superficial human veins in that they are 
of comparable size both before and after proximal occlusion. It should be 
possible to treat a 10cm length of superficial vein in each of the four limbs 
without a significant risk of sclerosant entering the deep venous in great 
volume. Porcine superficial veins are reasonably easily accessible for treatment 
and ultrasound assessment and they converge with the deep veins in a similar 
fashion to human superficial lower limb veins. In addition pigs have suitable 
limbs for comparable bandaging post-procedure as would be performed 
following foam sclerotherapy in humans.  
This study will be undertaken in a licensed Home Office facility, with all aspects 
of the following procedures undertaken by licensed staff.  
Animals of a suitable size and weight (50-60kg) will be selected on the basis 
that they  have 3mm diameter foreleg superficial veins and c. 4mm diameter 
hind leg superficial veins. The animals will be given anaesthetic pre-medication 
and will then be fully anaesthetised in a theatre environment. The animal will be 
given relevant prophylactic antibiotics and long-acting analgesic medication. 
The veins will be scanned by ultrasound to ensure they are patent.   
The following procedure will then be carried out by a licensed animal 
practitioner under the guidance of research staff: 
1. Fogarty balloon x5 passes (control)  
2. Fogarty balloon x5 passes; STD foam 
3. Fogarty balloon x5 passes; cutting balloon x3 passes  
4. Fogarty balloon x5 passes; cutting balloon x3 passes; STD foam  
The length of vein treated will be measured by ultrasound (aiming to treat 10cm 
segments in all limbs) and the proximal and distal points of treatment marked on 
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the skin by tattooing with Indian Ink to facilitate the subsequent harvesting of the 
relevant segment of vein. Post procedure the limbs will be dressed with 
compression bandaging and swabs overlying the superficial veins to apply 
increased pressure in these areas hence mimicking the post-procedure 
dressing of humans treated with foam sclerotherapy for great saphenous 
varicose veins;  
The veins will be scanned by ultrasound at pre-termination to assess their 
patency and ultrasonographic appearance. The ultrasound assessment of the 
pre-and post-treated veins will be recorded as - compressibility of the superficial 
veins will be assessed and classified as compressible (implies vein is patent) or 
non-compressible (implies occlusion), iso-echoic (no longer visible) or hypo-
echoic (consistent with patency).  
At the end of the 12 week period the animal would again be anaesthetised as 
previously and each 10cm length of superficial vein removed surgically, as 
atraumatically as possible. The segments will then be labelled and processed in 
formalin to allow histopathological preparation and analysis in an appropriate 
laboratory facility. The animal will then be slaughtered in accordance with Home 
Office regulations. 
DATA RECORDING 
Data will be recorded by study doctors and will be the responsibility of the chief 
investigator. 
STATISTICAL CONSIDERATIONS 
The sample size was chosen to prove concept and usefulness of an animal 
model. 
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SOURCE DATA/ DOCUMENTS/ CONFIDENTIALITY 
Data will be recorded on encrypted files on NHS computers in concordance with 
the Data Protection Act 1998. Data will be accessible to study doctors and 
research nurses.  
QUALITY CONTROL 
Quality control/assurance will be maintained by the Home Office. 
PUBLICATION POLICY 
Upon completion of the study results and conclusions will be published in 
relevant peer reviewed vascular surgical journals. 
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